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Sewage epidemiology is increasingly becoming an alternative method of estimating drug 
usage and consumption patterns for a given population.  With the constant emergence of 
new psychoactive substances such as cathinones and piperazines, versatile, reliable, 
specific and sensitive analytical methods are needed for their detection in complex 
matrices such as waste water.  This thesis reports the development of an analytical 
method based on solid phase extraction, derivatization with pentafluoropropionic 
anhydride and analysis by gas chromatography-mass spectrometry for the simultaneous 
analysis of 29 illicit and therapeutic drugs of abuse. 
All 29 drugs could be reliably identified in spiked waste water samples using selected ion 
monitoring and splitless injection. Recoveries for the majority of the drugs were above 70 
%. Linearity varied based on the analyte but was assessed in the range 2.0 x 10-4 to 1.4 
µg/mL. Intra-assay and intermediate precision of the instrument was determined at 
0.005, 0.1 and 1.0 µg/mL, with the majority of relative standard deviations less than 10 %. 
Limits of detection and quantification for drugs such as amphetamine and 
methamphetamine were better than reported values for liquid chromatography-tandem 
mass spectrometry, a more commonly used technique. 
Untreated 72 h composite waste water samples from Cambridge, UK, were analysed 
using a six-point standard addition curve.  Eleven drugs of abuse were detected, including 
amphetamine, methamphetamine, butylone and 4-fluoromethamphetamine. The latter 
two having been detected for the very first time in waste water.  Using the validated 
method, the consumption of heroin, ketamine, cocaine, methamphetamine and 
amphetamine, in Cambridge, UK, was estimated to be 399.4 ± 90.8, 2463.5 ± 182.5, 195.5 
± 95.4, 84.3 ± 59.1 and 38.9 ± 24.8 mg/day per 1000 inhabitants. 
This is the first reported validated method for the detection of both classic drugs of abuse 
and new psychoactive substances in waste water using gas chromatography-mass 
spectrometry and derivatization with pentafluoropropionic anhydride. 
Keywords: Drugs of abuse, gas chromatography-mass spectrometry, waste water, 
pentafluoropropionic anhydride, selected ion monitoring 
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CHAPTER ONE 
THEORETICAL BACKGROUND TO THE RESEARCH 
The aim of this chapter is to present the research topic underpinning this study in the 
perspective of the wider area of water pollution and the global priorities in this field as 
well as the sample collection, pre-treatment, preparation and analytical techniques used. 
A background to waste water treatment in line with the regulations that govern it and the 
challenges due to emerging organic contaminants is also discussed. 
 
1.1   WATER POLLUTANTS 
The varied and thriving chemical industry has led to the increased production of 
pharmaceutical, petrochemical, agrochemical, industrial and consumer chemicals to meet 
growing demand (Deblonde, et al., 2011; Harrison, 2013). However, despite most of these 
compounds making a positive contribution to our daily lives, they have not been without 
controversy. The presence of these compounds, their by-products during manufacture 
and their degradation products in water has led to increasing public awareness as well as 
scientific interest and concern about their effects on aquatic life and the environment as a 
whole (Caliman and Gavrilescu, 2009; Wille, et al., 2012; Loos, et al., 2013). Key 
compounds of concern have traditionally included pesticides, polycyclic aromatic 
hydrocarbons, industrial chemicals and endocrine-disrupting compounds (EDCs) which 
are widely acknowledged as water pollutants (Mol, et al., 2000; Verenitech, et al., 2006; 
Boleda, et al., 2011; Tomsikova, et al., 2012; Luo, et al., 2014; Wilson, et al., 2014). EDCs 
have been associated with the disruption of hormonal activity, sexual development and 
reproductive function in aquatic organisms (Bayen, et al., 2013; Ribeiro, et al., 2014a). 
However, over the past two decades scientific interest in pharmaceutical and personal 
care products (PPCPs), including drugs of abuse, as emerging pollutants has steadily 
increased as evidenced by the increasing number of publications (Jjemba, 2008; 
Hogenboom, et al., 2009; Kummerer, 2009; Deblonde, et al., 2011; Bayen, et al., 2013; 
Petrie, et al., 2013; Luo, et al., 2014; Verlicchi, et al., 2012 & 2014; Zhang, et al., 2014).  
PPCPs consist of a wide variety of organic compounds emanating from human and 
veterinary pharmaceuticals, drugs of abuse and consumer products (Luo, et al., 2014). 
These are discussed further in section 1.3.4. 
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It is worth noting the definition of the terms ‘contaminant’ and ‘pollutant’, which are 
often used interchangeably. When a chemical is present in the environment with no 
evidence of harm it can be regarded as a contaminant.  Where evidence of harm exists, 
the chemical can be regarded as a pollutant (Harrison, 2013). At a particular 
concentration relevant to the chemical activity, any chemical can cross over from 
‘contaminant’ to ‘pollutant’ status (ibid).  The effects of pollution on water include 
aesthetic (e.g. litter and smells), deoxygenation, disturbance of the pH balance and 
toxicity to aquatic and terrestrial organisms (Escher, et al., 2011).  In various literature 
sources, PPCPs have interchangeably been referred to as emerging organic contaminants 
(EOCs) (Jurado, et al., 2012; Gilart, et al., 2014), emerging environmental pollutants 
(Kasprzyk-Hordern, et al., 2009c) and micropollutants (Jiang, et al., 2013; Luo, et al., 
2014). 
 
1.2   SUSTAINABLE WATER MANAGEMENT 
With greater demand on water from domestic, agricultural and industrial use, fuelled by 
an unprecedented population growth, sustainable water management has become a key 
focus area among scientists and others. There is global consensus that better water 
management systems need to be put in place to ensure that water remains of good 
quality for human needs as well as for aquatic and terrestrial animals which rely on it 
(Royal Society of Chemistry, 2007).  In the Royal Society of Chemistry’s (RSC) summary 
report on sustainable water (RSC, 2007), chemistry has been shown to play an 
increasingly important role in helping to address some of the key challenges being faced 
in the management of water. This is because understanding the chemical nature and 
behaviour of pollutants in water can help bring about appropriate solutions into their 
management (ibid). The chemical sciences have always played an important role in the 
treatment of water for consumption as well as in removing pollutants from waste water 
and industrial effluent. However, in order for solutions to be relevant, the ever changing 
nature and levels of pollutants in waste water need to be determined as well as their 
chemical and synergistic behaviour in the presence of other substances in water 
(Kummerer, 2009; Lopez-Serna, et al., 2010; Escher, et al., 2011; Bayen, et al., 2013). 
While there have been great advances in developing life cycle assessments for 
conventional man-made pollutants that pose a risk to aquatic systems, such as pesticides 
and EDCs, similar research into emerging contaminants, such as PPCPs, still has a long way 
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to go (Kasprzyk-Hordern, et al., 2007; Lopez-Serna, et al., 2010; Deblonde, et al., 2011; 
Bayen, et al., 2013).  This is one of the key chemical science challenges as identified by the 
RSC (2007) report. One of the recommendations arising from this challenge is for funding 
bodies to prioritise research that seeks to identify and understand the behaviour of such 
emerging contaminants.  Since the RSC report, there has been an accelerated emergence 
of funded research into emerging contaminants in various water sources (Jurado, et al., 
2012) and in different parts of the world (van Nuijs, et al., 2011a; Thomas, et al., 2012; 
Luo, et al., 2014). 
 
1.2.1   Policies Governing Sustainable Water Management 
In Europe, sustainable water management is a concern for member countries of the 
European Union (EU). Hence the Water Framework Directive (WFD) (2000/60/EC) of the 
EU governs the quality of surface water through the Environmental Quality Standards 
Directive (EQSD) (2008/105/EC).  The EQSD (2008) acknowledges the threat to the aquatic 
environment that chemical pollution poses as this ultimately affects ecosystems and 
human health.  In this regard the EQSD identifies various priority substances that need to 
be regulated with regards to their discharge into surface water.  These substances include 
chemicals such as anthracene and mercury and its compounds, which are toxic even at 
low concentrations and are carcinogens (EQSD, 2008; Harrison, 2013).  The EQSD is 
focused on preventive action and lays the cost and responsibility of rectifying pollution on 
the ‘polluter’. Another EU legislation complimenting the WFD is called Registration, 
Evaluation, Authorization and Restriction of Chemicals (REACH) (EC 1907/2006). REACH 
(2006) requires that all chemical manufacturers and importers present evidence of the 
environmental risk assessment of the chemical before it can be marketed.  This is 
implemented through a registration system.  Pharmaceutical products are not included 
under the REACH legislation as they are covered by separate registration procedures, 
such as the Medicines and Healthcare Regulatory Agency (MHRA) in the UK (MHRA, 
2014). 
 
In the UK, the waste water treatment processes are regulated by different agencies. 
England and Wales are managed by the Environment Agency (EA) (EA, 1994), the Scottish 
Environment Protection Agency (SEPA) is responsible for Scotland (SEPA, 1994), while 
Northern Ireland is managed by the Northern Ireland Environment Agency (NIEA) (NIEA, 
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2007). These agencies stipulate the quality of waste water from a waste water treatment 
plant (WWTP) before it is discharged into surface and ground water, based on regulations 
defined by the European Commission Council Directive concerning waste water 
treatment (91/271/EEC). In addition, a Chemical Investigations Program (CIP) was set up 
in 2009 by the UK Water Industry Research (UKWIR) and EA to investigate how efficient 
the current treatment processes are in removing some of the priority substances as 
stipulated by the EQSD.  These priority substances have recently been expanded to 
include a few pharmaceutically active compounds (PhACs) such as steroid oestrogens and 
ibuprofen, which have traditionally not been targeted for analysis (Petrie, et al., 2013; 
UKWIR, 2013; Zenker, et al., 2014).  However, the majority of PPCPs, including illicit drugs, 
are still not being routinely monitored in waste water and surface water and their effects 
on the aquatic and terrestrial ecosystems are not widely understood (Dong, et al., 2013; 
Zenker, et al., 2014). 
 
1.3   WATER TREATMENT 
One cannot mention sustainable water management without referring to water 
treatment plants.  Water treatment plants cater for the treatment and purification of 
water for domestic use, treatment for industrial use or treatment of waste water 
emanating from these and other sources for discharge or reuse (Binnie & Kimber, 2009; 
Manahan, 2010).  As samples for this research are sourced from a WWTP, more emphasis 
will be placed on this.  However, treatment of water for domestic use will be briefly 
mentioned due to the link between the two. 
 
1.3.1   Domestic Water Treatment 
Sources of water for domestic use include rivers, lakes, streams, reservoirs, and 
groundwater (Gerba, et al., 2006; Harrison, 2013). Sources of contamination of these 
water bodies include natural organic and inorganic substances from the environment as 
well as man-made contaminants from industrial, waste water and run-off (Harrison, 
2013). The main aim of treatment of water for domestic use is to remove microorganisms 
and chemical contaminants when present so as to produce water that is safe for human 
consumption (Binnie & Kimber, 2009).  The treatment varies depending on the water 
source and supply needs but generally includes coagulation, flocculation, filtration and 
disinfection (Manahan, 2010).  While treatment is effective in minimising the presence of 
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microorganisms and chemicals, studies have shown the presence of various drugs of 
abuse in domestic water (Boleda, et al., 2011).  The main source of PhACs found in 
potable water is thought to be due to contamination from waste water effluent (Lopez-
Serna, et al., 2010; Metcalfe, et al., 2010). 
 
1.3.2   Waste Water and its Composition 
Water from domestic use ultimately ends up at a WWTP where it undergoes various 
treatment processes.  Historically, the aim of waste water treatment was to minimise 
disease and odour and protect potable water (Harrison, 2013). In present times, this aim 
has expanded to include the reduction in the concentration of organic matter and certain 
pollutants so as to produce an effluent that will pose minimal harm to human and animal 
health and the natural environment (Gerba & Pepper, 2006; Gomes, 2009).  Over 11 
billion litres of waste water, comprising mainly domestic and industrial waste, is treated 
in around 9000 WWTPs in the UK on a daily basis [Department for Environment, Food and 
Rural Affairs (DEFRA) 2012; Harrison, 2013].  Once waste water is treated, it is mainly 
discharged to surface waters such as rivers, streams, estuaries, the sea or ground water 
(EA, 1994; DEFRA, 2002; DEFRA, 2012). As water from these sources is ultimately re-used 
in one way or the other, the management of WWTPs forms part of sustainable water 
management (RSC, 2007). In this thesis and various other publications waste water 
flowing into a WWTP is interchangeably referred to as influent, raw and untreated waste 
water (van Nuijs, et al., 2011a; Castiglioni, et al., 2013 & 2014; Nefau, et al., 2013). 
 
The composition of waste water varies widely depending on the source e.g. domestic, 
industrial, medical facilities, agricultural and run-off (Peirce, et al., 1998; Gerba & Pepper, 
2006; Escher, et al., 2011; Lin, et al., 2014). The majority of WWTPs servicing large towns 
and cities treat combined waste water from these and other sources (Harrison, 2013).  In 
this regard, the main constituents of waste water, aside from water itself, are nitrogenous 
compounds (e.g. proteins and urea), carbohydrates (e.g. sugars and starch), fats (e.g. 
cooking oil and soap), PPCPs, agricultural chemicals, metallic salts, heavy metals, grit and 
rocks (Manahan, 2010; Harrison, 2013). 
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1.3.3   Waste Water Treatment 
Waste water treatment processes were originally developed to remove pollutants such as 
pathogens, nutrients, heavy metals, herbicides and pesticides (Jjemba, 2008).  However, 
due to the ever changing composition of pollutants in waste water, treatment processes 
will need to be improved on to cater not only for traditional pollutants but also emerging 
ones such as pharmaceuticals (Caliman & Gavrilescu, 2009; Kummerer, 2009). 
 
Generally waste water undergoes four main stages of treatment comprised of physical, 
chemical, and biological processes (Gomes, 2009).  These are referred to as preliminary, 
primary, secondary and tertiary treatment in reference to increasing treatment levels 
(Gerba & Pepper, 2006). The intensity of treatment that waste water is subjected to 
mainly depends on the source, desired quality of the effluent and the capabilities of the 
sewage treatment plant (EA, 1995; RSC, 2007; Manahan, 2010).  While the basic aims of 
each treatment level remains the same, the process of achieving this may vary from plant 
to plant depending on the technology used (Gomes, 2009). 
 
1.3.3.1   Preliminary Treatment 
The main aim of preliminary treatment is to remove large suspended solids such as rags, 
wood, glass and rocks as well as coarse solids such as grit (Jjemba, 2008). If not removed 
prior to secondary treatment, these items can cause damage and blockage to the network 
of pipes and pumps used to move waste water from one section to the other.  Screens 
are typically employed to remove the larger solid objects while graters may also be used 
to reduce the size of some larger objects and facilitate their removal through subsequent 
treatment processes (Gomes, 2009). The objects removed during preliminary treatment 
are ultimately incinerated or disposed of at a landfill (Jjemba, 2008).  Preliminary 
treatment is sometimes incorporated into the primary treatment stage (Gerba & Pepper, 
2006; Manahan, 2010). 
 
1.3.3.2    Primary Treatment 
During the primary treatment stage, organic and inorganic suspended solids are removed 
by sedimentation while floating material is removed by skimming.  A large portion of oil 
and grease is also removed during primary treatment (Jjemba, 2008; Gomes, 2009).  Large 
sedimentation tanks are used and the settled solids, referred to as primary sludge, are 
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removed for further treatment.  The primary sludge is subjected to digestion by anaerobic 
bacteria which help reduce its volume before disposal as solid waste (Jjemba, 2008). 
 
1.3.3.3   Secondary Treatment 
The main aim of the secondary treatment stage is the removal of dissolved organic 
components and colloidal constituents (Pepper, et al., 2006).  Microorganisms found in 
waste water rely on oxygen to degrade the organic matter and this results in the 
reduction of the oxygen content in water which can have detrimental effects to aquatic 
life that rely on oxygen for various biological processes (Manahan, 2010). This is referred 
to as the biochemical oxygen demand (BOD). The key focus during secondary treatment is 
therefore to reduce the BOD by limiting the organic components that are available for 
decomposition by microorganisms in waste water.  This is achieved mainly by using 
aerobic microorganisms (mainly bacteria) in the presence of added oxygen (Gomes, 
2009).  The microorganisms oxidize the organic matter until the BOD is within acceptable 
levels (Manahan, 2010).  Sedimentation tanks are also used during secondary treatment 
but the ‘sediment’ comprises of microorganisms and is referred to as biological sludge.  
The biological sludge is normally processed further in combination with primary sludge 
(Gomes, 2009).  Additional suspended solids, not removed during primary treatment, are 
also removed during secondary treatment (Gerba & Pepper, 2006). 
 
1.3.3.4   Tertiary Treatment 
Waste water normally undergoes tertiary treatment when more specific components 
need to be removed to meet specific criteria such as for drinking water (Pepper, et al., 
2006; Manahan, 2010).  During this stage, components such as nitrogen, phosphorus, 
heavy metals and pathogens are removed.  Although mentioned separately, tertiary 
treatment processes are sometimes incorporated into primary or secondary treatment 
processes or used instead of secondary treatment (Gomes, 2009).  A combination of 
biological and chemical processes are used to remove the components as well as improve 
the aesthetic aspects such as odour and colour before the effluent is released into surface 
and ground water or reused (EA, 1994; Manahan, 2010).  Advanced filtration using 
granular or membrane filters, oxidation using chlorination or ozonation, 
photodegradation using ultraviolet (UV) radiation, electrolysis and aeration are some of 
the processes employed during tertiary treatment (Jjemba, 2008: Binnie & Kimber, 2009). 
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Waste water that has undergone primary, secondary or tertiary treatment is referred to 
as effluent or treated waste water (Hedgespeth, et al., 2012; Loos, et al., 2013; Nefau, et 
al., 2013). 
 
1.3.4   Pharmaceuticals and Personal Care Products (PPCPs) in Waste Water 
Although only a few PPCPs are being monitored in waste water effluent (section 1.2.1), 
this appears to be a step in the right direction in recognising the changing nature of 
emerging pollutants.  PhACs being detected in waste water and surface water are from 
diverse therapeutic classes such as antibiotics, analgesics, hormones, beta-blockers, and 
antidepressants (Dong, et al., 2013; Zenker, et al., 2014). Table 1.1 lists the PhACs 
monitored by the CIP (section 1.2.1) due to their high levels being detected in waste 
water and surface water and potential ecotoxicological effects (Petrie, et al., 2013; 
Zenker, et al., 2014). 
 
Table 1.1: Pharmaceutical compounds and quality criteria as monitored by  
the Chemical Investigations Program, UK (UKWIR, 2013). 
 
 
PhACs, by definition, include drugs legally manufactured for therapeutic purposes (e.g. 
Ibuprofen), drugs with no known legal therapeutic use (i.e. illicit drugs such as ecstasy) as 
well as legally manufactured drugs which are being abused (e.g. diazepam) [Moffat, et al., 
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2011b; United Nations Office on Drugs and Crime (UNODC), 2014]. The latter two 
categories are collectively referred to as drugs of abuse in this thesis to distinguish from 
drugs being used solely for therapeutic purposes. The term ‘abuse’ in the phrase ‘drugs of 
abuse’ refers to the deliberate use of a substance for non-medicinal purposes to produce 
psychoactive effects (altering of alertness, mood, perception or behaviour) or intoxication 
(King, et al., 2013).  Sources of PhACs found in waste water include manufacturers, 
hospitals, and households (Kummerer, 2009; Philips, et al., 2010; Behera, et al., 2011; 
Luo, et al., 2013). 
 
Although not the focus of this research, personal care products (PCPs) are normally 
grouped and investigated together with PhACs (Hedgespeth, et al., 2012; de Garcia, et al., 
2013; Zhang, et al., 2014). Categories of PCPs include parabens, antiseptics, surfactants, 
UV filters and polycyclic musks (Stuart, et al., 2012; Loos, et al., 2013; Luo, et al., 2013). 
Table 1.2 lists some PPCPs and their concentrations as detected in untreated and treated 
waste water from urban areas. 
 
Table 1.2: Concentrations of pharmaceuticals and personal care products reported in 
urban waste water. 
 
1.3.4.1   Pharmaceutically Active Compounds (PhACs) 
The focus of this research is on PhACs and more emphasis will be placed on them from 
this point on. Compared with pesticides and EDCs, the environmental risk assessments 
and toxicological profiles in the aquatic and terrestrial environment are not fully 
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established for the majority of PhACs (Deblonde, et al., 2011; Zenker, et al., 2014). 
However, some research groups suggest low ecotoxicological risk to aquatic and 
terrestrial organisms due to the dilution factor of waste water effluent entering surface 
water or as a result of photodegradation (Gros, et al., 2010; Wang & Lin, 2014) while 
others report an associated ecotoxicological risk (Escher, et al., 2011; Stuart, et al., 2012; 
Zhang, et al., 2014). These risks can reportedly lead to development of antimicrobial 
resistance, reduction in plankton diversity, an impact on human embryonic development, 
feminization of certain aquatic organisms and possible bioaccumulation of certain 
pharmaceuticals (Kumirska, et al., 2011; Stuart, et al., 2012; Loos, et al., 2013; Zenker, et 
al., 2014; Zhang, et al., 2014).  In this regard, the ecotoxicological effects on aquatic 
organisms such as algae, daphnia and certain fish have been reported (Zenker, et al., 
2014; Zhang, et al., 2014). There are also published reports on the ecotoxicological effects 
of non-steroidal anti-inflammatory drugs (NSAIDS) on terrestrial animals e.g. diclofenac 
and its effect on the declining vulture populations in Pakistan (Oaks, et al., 2004) and the 
detection of flunixin in sheep’s wool which also has possible ecotoxicological effects 
(Richards, et al., 2011).  However, as ecotoxicological data is available for less than 10 % 
of the prescribed PhACs, it is thus evident that more work still needs to be done to fully 
understand their potential risk to the environment (Bayen, et al., 2013; Zhang, et al., 
2014).  This incorporates developing analytical methods to enable the detection of these 
PhACs in the environment, such as in waste water, and developing toxicological risk 
assessments to determine concentration levels that pose a risk (Escher, et al., 2011).  
Although a PhAC may be present at a low concentration and not exhibit any toxicological 
effects individually, its unknown synergistic effect in the presence of other compounds in 
a complex mixture, such as waste water, is still cause for concern (Loos, et al., 2013; 
Wang & Lin, 2014). In addition, concentration levels that may not be harmful to terrestrial 
life may be harmful to aquatic organisms and hence any toxicological risk assessments 
need to account for the effects on different types of organisms. PhACs are also known to 
undergo degradation and transformation processes within the sewage system, which may 
have different ecotoxicological effects to the parent drug. These processes are described 
in the next section. 
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1.3.4.2   In-Sewer Degradation and Transformation of Pharmaceuticals 
There are various factors that affect the presence and levels of PhACs within the  
sewerage system between their points of excretion and sampling.  Some factors are 
linked to the characteristics of a particular WWTP and these include the treatment 
processes (section 1.3.3), hydraulic retention time (HRT), pH, temperature and 
composition of the waste water.  The HRT is the time allowed for biodegradation and 
sorption and varies depending on the compound and loading rate at the WWTP (Luo, et 
al., 2014). Other factors, such as the chemical structure, polarity, half-life, pKa (acidity) 
and pKow (hydrophobicity) are based on the physico-chemical properties of the drug.  
Collectively, all these factors affect the natural attenuation of a compound in waste water 
and surface water (Luo, et al., 2014; Zenker, et al., 2014). Natural attenuation processes 
include physical processes (e.g. dispersion, dilution and sorption), biological processes 
(e.g. biodegradation and biotransformation) and chemical reactions (e.g. 
photodegradation, interchange between different enantiomeric forms, interaction with 
other compounds within the matrix (Baker & Kasprzyk-Hordern, 2013; Wang & Lin, 2014; 
Zhang, et al., 2014). 
 
These transformation and degradation processes can affect both quantitative and 
qualitative aspects of the compounds, such as a reduction in the concentrations of 
compounds below their limits of detection or potential transformation of one compound 
that is already present in the waste water into the target analyte e.g. methamphetamine 
into amphetamine (Reid, et al., 2014a; Thai, et al., 2014).  Therefore, in-sewer 
transformation and degradation of compounds forms a major limitation of the sewage 
epidemiological approach since the final detected concentration may be an under- or 
over estimation of the original concentration present in the matrix before the 
degradation processes (Zuccato, et al., 2008; Lai, et al., 2011; van Nuijs, et al., 2011b; 
Castiglioni, et al., 2013).   In this regard, various studies have been conducted to try and 
understand these attenuation processes, including the stability of drugs of abuse during 
various storage conditions (van Nuijs, et al., 2012; Bijlsma, et al., 2013a; Senta, et al., 
2014). 
 
However, it should be noted that the longer the compound is exposed to the conditions 
in the WWTP, especially during the treatment process, the higher the possibility of it 
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undergoing the various attenuation processes.  This in turn affects the efficiency of 
removal of the PhACs from waste water before it is discharged into surface water (Stuart, 
et al., 2012; Zhang, et al., 2014). For instance, samples collected at the inlet of the WWTP 
would have spent less time exposed to the natural attenuation processes than those 
which have been collected after completion of the treatment process. Therefore, 
concentrations of some PhACs will be found at higher levels in untreated waste water 
than in treated waste water or surface water (Hernandez, et al., 2011; Baker & Kasprzyk-
Hordern, 2013; Nefau, et al., 2013).  This is discussed further in section 1.3.4.3. This also 
implies that as a result of attenuation processes, the parent drug may not be detected in 
waste water (treated and untreated) or surface water, but its degradation products may 
be present and more stable and hence may also be used for quantification. In this regard, 
some research groups have investigated degradation products of PhACs in the aquatic 
environment with the aim of determining their environmental fate (Bijlsma, et al., 2013a; 
Rodayan, et al., 2014). On the other hand, the degradation products could also have 
negative ecotoxicological effects different from that of the parent compound and hence 
may need to be included in any ecotoxicological risk assessments (Wang & Lin, 2014). 
 
1.3.4.3   Removal of Pharmaceuticals during Waste Water Treatment 
Although not specifically targeted during waste water treatment, published studies have 
shown that a reasonable amount of these PhACs are removed from waste water as a 
result of current treatment processes (Postigo, et al., 2010; Behera, et al, 2011; Luo, et al., 
2014; Sun, et al., 2014).  However, the various attenuation processes discussed in section 
1.3.4.2 affect the removal of PhACs from a WWTP leading to a wide variation in removal 
rates between different compounds and also within the same compound (Postigo, et al., 
2010; Hedgespeth, et al., 2012; Luo, et al., 2014). The type of treatment processes at the 
WWTP also plays a crucial role in the efficiency of removal of PhACs (Hedgespeth, et al., 
2012; Bayen, et al., 2013; Kumirska, et al., 2013).  This has led to various published 
investigations into the efficiency of the treatment processes in removing PhACs and 
results vary widely depending mainly on the physico-chemical properties of the PhAC and 
the waste water treatment process used (Gros, et al., 2010; Postigo, et al., 2010; Behera, 
et al., 2011; Baker & Kasprzyk-Hordern, 2013; Gilart, et al., 2014; Luo, et al., 2014).  
Therefore, removal rates can range from 20 % to 100 % (Table 1.3), which still constitutes 
only partial removal, and these drugs persist in treated waste water which ultimately gets 
13 
 
discharged into surface water (Huerta-Fontela, et al., 2008; Boleda, et al., 2009; Kasprzyk-
Hordern, et al., 2009c; Postigo, et al., 2010; Bayen, et al., 2013; Pal, et al., 2013; 
Patrolecco, et al., 2013; Zhang, et al., 2014). 
 
Table 1.3: Removal efficiency of pharmaceuticals at waste water treatment plants. 
 
More specifically, drugs of abuse have been shown to persist in treated waste water and 
hence their detection in surface water can mainly be attributed to discharge of treated 
waste water and untreated influent into surface waters (Jones-Lepp, et al., 2004; Postigo, 
et al., 2008a; Boles & Wells, 2014).  Drugs of abuse can also be directly disposed into the 
aquatic system leading to a minimal or major contribution to the final concentration 
(Postigo, et al., 2008a; Kasprzyk-Hordern, & Baker, 2012; Emke, et al., 2014). Although 
concentrations of drugs of abuse detected in surface waters are low (ng/L), their potential 
risk to human and environmental health cannot be dismissed (Postigo, et al., 2010; 
Jurado, et al., 2012; Repice, et al., 2013).  Some of the surface water these drugs are 
present in is ultimately treated for drinking water (potable water) and if the drugs are not 
efficiently removed, they can persist in the potable water (Boleda, et al., 2009 & 2011; 
Baker & Kasprzyk-Hordern, 2013; Luo, et al., 2014). It is worth mentioning here that in 
Boleda’s (2009 & 2011) findings, the majority of drugs of abuse and their metabolites 
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studied were completely eliminated from the potable water by the more stringent 
treatment processes with some only occurring at ultratrace levels (below 3 ng/L).   
 
However, the long term effects of unwitting consumers drinking low level drug 
concentrations are still unknown, especially when multiple drugs are present in the 
potable water (Vazquez-Roig, et al., 2013). Since they are increasingly being regarded as 
emerging pollutants, it is therefore necessary to not only determine the levels of these 
drugs in waste water but to also understand their behaviour.  Individual behaviour may 
differ from synergistic behaviour when combined with other chemicals in waste water 
(Repice, et al., 2013; Wang & Lin, 2014).  Although determining the full life-cycle 
assessment on these drugs of abuse and their potential harm to aquatic and terrestrial 
life is out of the scope of this study, it is hoped that the findings presented will make a 
positive contribution to overall research in this field.  Detecting their levels in waste water 
and determining any potential adverse effects will need a wide variety of analytical 
methods, including those presented in this research, to suit different applications and 
budgets. 
 
1.3.4.4   Drugs of Abuse and Sewage Epidemiology 
Although some PhACs were recognised as environmental contaminants in the 1970s, 
widespread scientific interest in them occurred mainly from the mid-1990s coinciding 
with development of more sensitive analytical techniques (Jones-Lepp, et al., 2004; Farre, 
et al., 2012). On the other hand, drugs of abuse have only recently been targeted for 
investigation as environmental contaminants post 2000 (Postigo, et al., 2010; Daughton, 
2011; Repice, et al., 2013). As mentioned in section 1.3.4.3, PhACs have been detected in 
waste water influent and effluent as well as surface water.  The rationale behind this is 
that once drugs are consumed, they are processed by the body and released as parent 
drug and metabolites, mainly through urine and faeces, into the sewage system (Repice, 
et al., 2013).  Once at the WWTP, they are subjected to various treatment processes as 
discussed in section 1.3.3.  However, as already inferred, these treatment processes are 
not always 100 % efficient when it comes to removing PhACs and hence these substances 
persist even in treated waste water. Several studies have been conducted around the 
globe to detect the levels of pharmaceutical substances in waste water and surface water 
(Berset, et al., 2010; Metcalfe, et al., 2010; Irvine, et al., 2011; de García, et al., 2013; 
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Boles & Wells, 2014). Although initially suggested by Daughton (2001b), investigations 
into the presence of PhACs in treated and untreated waste water was taken a step further 
in 2005 (Zuccato, et al., 2005) when measured levels of cocaine and its metabolites were 
used to estimate its consumption by a population serviced by a particular WWTP.  Since 
then various research groups from different countries (e.g. Australia, Belgium, Canada, 
Finland, Italy, Spain, Switzerland, UK, USA) have investigated drugs of abuse in waste 
water and surface water (Gheorghe, et al., 2008; Loganathan, et al., 2009; Metcalfe, et al., 
2010; Zuccato, et al., 2011; Hernandez, et al., 2011; Irvine, et al., 2011; Baker & Kasprzyk-
Hordern,  2013; Burgard, et al., 2013; Emke, et al., 2014; Ort, et al., 2014; Vuori, et al., 
2014). The main difference between these groups has been the classes of drugs of abuse 
investigated, the approaches to sampling and sample preparation, the type of validation 
carried out and the interpretation of results. With such data gathered from different 
countries or at different times of the year, comparisons can be made regarding usage 
patterns of drugs of abuse in different locations, at different days, months or seasons 
(Reid, et al., 2011; van Nuijs, et al., 2011a; Zuccato, et al., 2011; Thomas, et al., 2012; 
Burgard, et al., 2013). Hence, the phrase ‘sewage epidemiology’ was developed to refer 
to the process of using analytical tools to extract targeted biological indicators from waste 
water in order to gather specific epidemiological information (Daughton, 2011). Drugs of 
abuse were the first substances to be analysed in this manner. 
 
Sewage epidemiology, as a means of estimating the consumption of drugs of abuse, 
compliments other forms of data such as criminal and medical records, drug monitoring, 
drug seizures, consumer interviews and population surveys (González-Mariño, et al., 
2010; van Nuijs, et al., 2009d; Castiglioni, et al., 2014).  In many cases, the drug 
consumption figures obtained from sewage epidemiology closely match figures obtained 
from social-epidemiological studies (Reid, et al., 2011; Lai, et al., 2013b; Ort, et al., 2014). 
Hence, comparisons between the different forms of data can be made in order to obtain 
a better understanding of the trends in the use of drugs of abuse (Reid, et al., 2012). One 
major advantage of the sewage epidemiology approach over socio-epidemiological 
methods is the production of real-time data since results from sewage can be obtained 
within hours or days while socio-epidemiological studies take longer (González-Mariño, et 
al., 2010; Khan & Nicell, 2011; Prichard, et al., 2014). The sewage epidemiological 
approach has even been adopted by the European Monitoring Centre for Drugs and Drug 
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Addiction (EMCDDA) as a feasible method for estimating community drug consumption 
(EMCDDA, 2008 & 2014b). Although sewage epidemiology is anonymous and generalised, 
it can also be applied to more localised situations such as a waste water stream from a 
prison (Postigo, et al., 2011), a college (Burgard, et al., 2013), a music festival (Lai, et al., 
2013c), a neighbourhood (Boles & Wells, 2014) or even after a major sporting event 
(Berset, et al., 2010; Gerrity, et al., 2011) or holiday period (van Nuijs, et al., 2011b; Lai, et 
al., 2013a) to determine any spatial and/or temporal trends in drug usage.  However, 
ethical and legal aspects of localised sampling needs to be carefully considered and 
addressed prior to any research work being undertaken (Boles & Wells, 2014; Castiglioni, 
et al., 2014; EMCDDA, 2008 & 2014b; Prichard, et al., 2014). 
There are increasing collaborations between research groups in the area of sewage 
epidemiology to better understand the behaviour of these drugs in waste water 
individually (stability), collectively (drug-drug interactions) and their effect on aquatic 
wildlife.  Further research into separating chiral compounds, thereby enabling the better 
estimation of illicit drug consumption versus therapeutic use of amphetamine type 
stimulants (ATS), as well as between consumption versus direct disposal into the sewer 
system, has also been investigated (Kasprzyk-Hordern & Baker, 2012; Emke, et al., 2014; 
Ribeiro, et al., 2014b).  Illicit drugs in sewage sludge have also been investigated but not 
to a large extent (Kaleta, et al., 2006).  As treated sludge is increasingly used for 
agricultural purposes, it could be worth investigating for the presence of PhACs and their 
potential effect on the environment. The presence of PhACs in groundwater has also 
been investigated due to the reliance on groundwater as a potable water source in some 
areas (Juradao, et al., 2012; Stuart, et al., 2012). 
The most commonly abused drugs in the UK and the selection of drugs for this research 
are discussed in the next section. 
 
1.4   DRUGS OF ABUSE  
As mentioned in section 1.3.4, PhACs can be considered to comprise therapeutic drugs as 
well as drugs of abuse.  Most drugs of abuse are restricted in use, possession or supply, by 
law, due to the potential harmful effects on the user and others.  They are, therefore, 
referred to as controlled substances. The majority of drugs of abuse are either illegally 
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manufactured in clandestine laboratories or diverted from legitimate sources (Cole, 2003; 
White, 2005; King, et al., 2013; EMCDDA, 2014a). 
 
In the UK, drugs are primarily controlled by the Misuse of Drugs Act 1971 (MDA, 1971) 
and the Misuse of Drugs Regulations 2001 (MDR, 2001).  The MDA, 1971 controls the 
unauthorized possession and supply of drugs and stipulates penalties for their misuse 
while the MDR, 2001, controls the legitimate use, distribution and sale of drugs (MDR, 
2001; Cole, 2003).  However, in spite of restrictions on their possession, supply, 
manufacture and use, the abuse of drugs has not abated.  Instead, the use of drugs of 
abuse has been increasingly fuelled by an enterprising and prevalent illegal drug 
manufacturing industry (King, et al., 2013; EMCDDA, 2014; UNODC, 2014). The most 
commonly abused drugs are derived from plants (e.g. cannabis, cocaine) but synthetic 
drugs (e.g. cathinones, synthetic cannabinoids and synthetic opioids) and semi-synthetic 
drugs (e.g. heroin) pose just as much of a social problem (Dickson, et al., 2010b; EMCDDA, 
2014a; Reid, et al., 2014b).  These are contextualised with regard to usage in North 
America and Europe in the following section. 
 
1.4.1   Commonly Abused Drugs 
As discussed in section 1.4, the regulation of drugs of abuse has not stopped their ever 
increasing recreational use. According to the UNODC (2014) report, the worldwide 
estimate of people aged 15-64 years who used drugs of abuse in 2012 lies between 162 
and 324 million. In Europe, cannabis is the most widely abused drug followed by cocaine 
and drugs in the opioid and ATS groups (EMCDDA, 2014a).  According to the Crime Survey 
for England and Wales (CSEW, 2014), the most commonly abused drugs in England & 
Wales among 16-59 year olds in the 2013/2014 period, in decreasing order of 
consumption, are cannabis, cocaine, and ecstasy. This equates to 8.8 % of the population 
(i.e. 2.7 million people) in this age range having taken an illicit drug. In terms of amounts 
of drugs seized in Europe, cannabis is the most prevalent (81 %), followed by cocaine       
(9 %), heroin (4 %), amphetamine (3 %), ecstasy (2 %), with methamphetamine and 
lysergic acid diethylamide both at 1 % each (EMCDDA, 2014a). The majority of these 
seizures occurred in Spain and the UK (ibid). Consistent or declining trends in heroin and 
cocaine use in the major markets (North America & Europe) are negated by increasing 
and/or consistent misuse of new psychoactive substances (NPS) and prescription drugs 
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such as benzodiazepines and barbiturates, a noticeably growing health and social 
problem in a number of developed and developing countries (UNODC, 2013). 
 
1.4.2   Selection of Drugs for this Research  
The selection of target drugs and metabolites included in this research was, therefore, 
based on a) the most commonly abused drugs in Europe and England and Wales 
according to the CSEW (2014) and EMCDDA (2014a) reports, respectively, b) published 
findings from toxicological and sewage epidemiological studies (van Nuijs, et al., 2011a; 
Helander, et al., 2014; Pal, et al., 2013; Baker, et al., 2014), and c) emerging drugs of 
abuse (i.e. NPS) as indicated in the UNODC (2013 & 2014) and EMCDDA (2014) reports.  
Most data obtained from published sewage epidemiological studies has been on classic 
drugs of abuse such as cocaine, amphetamine, and ecstasy and therapeutic drugs such as 
morphine, diazepam, ibuprofen (Reid.,  et al.,2011; van Nuijs., et al., 2011; Thomas., et al., 
2012). Although classic drugs of abuse were also included in this research,  the emphasis 
was on NPS such as piperazines, cathinones and ketamine, since they are increasingly 
being abused and little sewage epidemiological data is available for them (Meyer, et al., 
2010; Corkery, et al., 2012; Chen, et al., 2014; Helander, et al., 2014; Reid, et al., 2014a; 
UNODC, 2014). Classic illicit drugs of abuse such as cocaine, amphetamine, 
methylenedioxymethamphetamine (MDMA) and therapeutic drugs of abuse such as 
morphine and diazepam were added for comparative purposes and to determine if their 
levels would be much higher than the NPS due to their historically more prevalent use 
(CSEW, 2014; EMCDDA, 2014; UNODC, 2014). 
 
Table 1.4 lists the drugs and metabolites investigated in this research and internal 
standards used. The compounds belong to a wide range of chemical classes, namely 
cocainics, phenylethylamines, piperazines, cathinones, opiates, benzodiazepines, tricyclic 
antidepressants and dissociatives.  For purposes of this thesis, classification of the drugs is 
based on the system adopted by the UNODC (2013) report.  In addition, some drugs are 
referred to using their more commonly used terms, such as heroin for diacetylmorphine 
and MDMA or ecstasy for methylenedioxymethamphetamine (Cole, 2003; Baker & 
Kasprzyk-Hordern, 2013; Nefau, et al., 2013; Ostman, et al., 2014).  However, as a note, 
the common terms normally refers to illegally manufactured drugs which may contain 
other drugs and additives while the structural name denotes the drug standard as 
19 
 
obtained from licensed suppliers. Further background to the drug classes investigated in 
this research is provided in Appendix II. 
 
Table 1.4: Drug and internal standard structure, empirical formula and molar mass 
(g/mol). 
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Table 1.4 cont’d: Drug and internal standard structure, empirical formula and molar 
mass (g/mol). 
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Table 1.4 cont’d: Drug and internal standard structure, empirical formula and molar 
mass (g/mol). 
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Table 1.4 cont’d: Drug and internal standard structure, empirical formula and molar 
mass (g/mol). 
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1.4.2.1   New Psychoactive Substances (NPS) 
NPS, incorporating ‘designer drugs’, became prevalent in the late 1980s and are based on 
various adaptations of the phenylethylamine backbone (Figure 1.1).  These include 
addition of a methylenedioxy ring moiety (e.g. MDMA), addition of fluorine (e.g.               
4-fluoromethamphetamine) and addition of a ketone group (e.g. methcathinone) (Shulgin 
& Shulgin, 1991; Julien, 2005; Santali, et al., 2011; UNODC, 2013). 
 
 
Figure 1.1:  Structure of phenylethylamine. 
 
NPS have been marketed as ‘legal highs’ to mislead the general public into thinking that 
they are safe and legitimate to consume, and as ‘bath salts’, ‘research chemicals’ or ‘plant 
food’ to mislead the authorities (Measham, et al., 2010; Corkery, et al., 2012; Khreit, et 
al., 2013; UNODC, 2013; EMCDDA, 2014a).  However, since NPS tend to be based on 
pharmacological or structural properties of classic illicit drugs such as amphetamine or 
ecstasy, they are proving to be just as harmful as the legislated drugs on which they are 
based (Corkery, et al., 2012; UNODC, 2013).  Aryl substituted piperazines (e.g. 
benzylpiperazine), cathinones (e.g. mephedrone) and ketamine have increasingly become 
key members of this group of NPS (UNODC, 2013; Chen, et al., 2014).  The majority of 
illegal production of NPS (except ketamine) occurs in clandestine laboratories in Europe 
and Asia and since the slight modification in chemical structure makes the drugs 
‘unlegislated’ on an international basis, they keep one step ahead of the legalisation that 
more commonly abused drugs are subjected to (Zuba, 2012; UNODC, 2013).  Ketamine 
used illegally is mainly diverted from legitimate sources. While many NPS are now 
legislated, new drugs with slight chemical modifications (to circumvent the legislation) are 
being reported weekly, making it difficult for the relevant authorities to take the 
necessary social intervention or legal measures (Favretto, et al., 2013; EMCDDA, 2014a; 
UNODC 2013 & 2014). 
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Table 1.5 lists some NPS (mainly cathinones and piperazines) that have been investigated 
in published sewage epidemiological studies. Other NPS investigated include synthetic  
cannabinoids and ATS analogues (Reid, et al., 2014b). 
 
Table 1.5: New psychoactive substances investigated in waste water. 
 
 
The number of identified NPS in the European Union rose from 166 in 2009 to 251 by the 
end of 2012 and 348 in 2013 (UNODC 2014). These included synthetic cannabinoids, 
substituted phenylethylamines and those outside the common chemical groups 
(EMCDDA, 2014a). According to the CSJ (2013) report, NPS are entering the UK market at 
a rate of one drug per week and are used more often than classic drugs of abuse.  In 
addition, the misuse of ketamine has doubled since 2006.  Therefore, due to their 
increasing usage, NPS have recently started to be included in sewage epidemiological 
studies as shown in Table 1.5. However, the NPS listed in Table 1.5 were analysed using 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) and not all studies 
detected the target NPS in waste water.  To the author’s knowledge, NPS have not been 
analysed by gas chromatography–mass spectrometry (GC-MS) for sewage epidemiological 
purposes. 
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1.4.3   Linking Drug Metabolism and Sewage Epidemiology 
In order to link the amount of target drugs detected in waste water with their 
consumption, it is important to understand their fate once administered into the human 
body. Drugs of abuse are mainly administered into the body through oral or intravenous 
means, or by inhalation (Julien, 2005; Levine, 2006; Drummer, 2011). Once administered, 
the drug is absorbed and distributed to different sites around the body through the 
vascular system in order to have an effect (Jjemba, 2008). Some of these sites include 
organs that help with its elimination from the body such as the kidneys, liver and lungs 
(Drummer, 2011). Most drugs undergo metabolism in the liver and are ultimately 
excreted from the body mainly by the kidneys into urine (Drummer & Wong, 2013). Other 
metabolic processes also result in excretion from the body by other means such as sweat, 
faeces and exhalation.  Some of the excreted fractions are referred to as metabolites 
(Drummer, 2011).  Therefore, the majority of the administered dosage of a drug is 
eliminated in metabolite form. However, the parent drug can also be excreted at various 
rates depending on the drug (Jjemba, 2008). 
 
Whilst the main aim of metabolism is to facilitate the excretion of the drug, it can also 
alter the pharmacological action of the drug thereby resulting in pharmaceutically active 
or inactive metabolites (Drummer, 2011; Drummer & Wong, 2013). The metabolic 
process in the body is mainly conducted through two phases referred to as phase I and 
phase II metabolism (Levine, 2006; Drummer, 2011).  During phase I metabolism the drug 
is chemically modified through processes such as oxidation, hydroxylation, hydrolysis, 
dealkylation or reduction (Levine, 2006; Drummer & Wong, 2013).  Some drugs only 
become pharmacologically active after phase I metabolism.  For example, the tricyclic 
antidepressant amitriptyline only becomes active once converted to nortriptyline as a 
result of phase I metabolism (Drummer, 2011). 
 
The metabolites formed in phase I are further modified by conjugation reactions during 
phase II metabolism.  These phase II metabolites are more water-soluble than the phase I 
metabolites and hence more amenable to elimination from the body. Common 
conjugation reactions include glucuronidation and sulphation but due to the prevalence 
of glucose in biological systems, glucuronidation is the most prevalent phase II process 
(Levine, 2006; Drummer, 2011). One advantage of the glucuronidation process is that it 
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reduces the pharmacological and biological activity of a drug and hence potentially 
minimises the harmful effects these metabolites could cause to aquatic systems (Jjemba, 
2008). There are a few exceptions to this, such as morphine-6-glucuronide which is more 
active as an analgesic than morphine (Levine, 2006; Drummer & Wong, 2013).  However, 
it is reported that glucuronide conjugates are deconjugated in waste water back to the 
parent drug due to the activity of glucuronidase enzymes present in faecal bacteria 
(Melis, et al., 2011; van Nuijs, et al., 2011a; Senta, et al., 2014).   This releases the more 
pharmacologically active form of the metabolite which poses potential risk factors to the 
aquatic system and hence the concern regarding these emerging pollutants (section 
1.3.4.2). 
 
By the direct measurement of the metabolites or parent drug excreted in urine or faeces 
through the sampling of waste water from a WWTP, an estimate of the consumption of 
the parent drug can be made (Daughton, 2011). However, it is preferable to measure the 
metabolites where possible since measurement of the parent drug alone does not 
necessarily indicate consumption, and in some cases the parent drug may not survive the 
metabolic process (e.g. heroin).  The parent drug may also be present as a result of illegal 
dumping or direct discharge from a manufacturing facility (Fick, et al., 2009; Phillips, et 
al., 2010; Baker, et al., 2014).  For instance, cocaine detected in waste water could be 
from direct disposal through the sewer system, while detection of one of its main 
metabolites, benzoylecgonine (BZE) or ecgonine methyl ester (EME), would indicate 
consumption (Zuccato, et al., 2005; van Nuijs, et al., 2009b). As a number of metabolites 
can be produced by a single drug due to the various mechanisms involved in metabolism, 
only one or two key metabolites need to be targeted for analysis (Drummer & Wong, 
2013).  The choice of metabolite selected for analysis depends on the aim of the analysis, 
its stability in the matrix and during analysis, the type of analytical method and the 
intended application of the results (forensic, work-place testing, and statistics).  For waste 
water analysis, it makes sense to target the major metabolites which are eliminated at 
relatively high excretion rates. Since the drugs occur at trace levels in waste water, these 
major metabolites would have a higher chance of detection compared to metabolites 
eliminated only at very low excretion rates. 
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1.4.4   Linking Drug Detection Levels with Consumption 
In order to estimate the consumption of the target drug (mg/day) from the concentration 
(ng/L) detected in waste water, a knowledge of the percentage of the dosage of the 
target drug excreted as the main metabolite is required. Using cocaine as an example, the 
following information is required (van Nuijs, et al., 2009a; Castiglioni, et al., 2014): 
 
a) The flow rate of the waste water at the WWTP (L/day).  This is used to convert 
concentrations (ng/L) of one of the main metabolites of cocaine i.e. ecgonine methyl 
ester (EME) into daily mass loads (mg/day). 
b) The relative amount of cocaine excreted as its main metabolite EME.  This is required 
to back-calculate from mass loads into a total amount of cocaine consumed (mg). 
c) The relative molar mass of cocaine and EME. 
d) The population served by a particular WWTP. 
 
Equation 1.1 is then used to obtain drug consumption data in mg per day; 
 
 
The conversion factor (CF) is obtained from the ratios of the molar masses of cocaine and 
EME, taking into account the percentage dose of cocaine excreted as the metabolite i.e. 
45 % (Equation 1.2).  The choice of the excretion rate used is explained on the following 
page. 
 
The calculated amount, mg/day, is then normalized for the number of people served by a 
particular WWTP (expressed in mg/day per 1000 people).  A worked example from the 
analysis of a real waste water sample is provided in sections 5.31 & 5.3.2 (pages 168-170) 
 
For drugs where metabolite standards are not commercially available, especially 
cathinones and piperazines, excretion rates of the parent drug can be used if known 
28 
 
(Castiglioni, et al., 2013; Reid, et al., 2014a). In the case of unavailability of excretion rates 
of the parent drugs or metabolites, quantification of levels in waste water can be made 
without linking to consumption (Chen, et al., 2014). 
 
Although outside the scope of this research, the area of pharmacogenomics (the study of 
how genetic make-up affects an individual’s response to drugs) is worth mentioning here 
since it affects the percentage drug excreted as a metabolite between individuals and 
ethnic groups (Edenberg, 2007; Baik, et al., 2011; Wang, et al., 2011).  Therefore, average 
values of human urinary excretion rates have been used in this thesis and various 
published literature in sewage epidemiology to calculate drug consumption and do not 
account for variations between individuals and ethnic groups (Lai, et al., 2013a).  Other 
factors that affect the urinary excretion rate in individuals include the sex, age, co-
administration of other drugs, route of administration, amount of dose and pH of urine 
(Oyler, et al., 2002; van Nuijs, et al., 2011b; Kasprzyk-Hordern, & Baker, 2012; Castiglioni, 
et al., 2013; Lai, et al., 2013a).  In this regard, different percentages of human urinary 
excretion rates have been reported for the same drug in sewage epidemiological 
calculations (van Nuijs, et al., 2011a).  For instance, the excretion rate for cocaine is 
reported as 1.45 % by Baker (2013) while Moffat (2011b) reports it as 9 % while that for 
BZE ranges from 6.5 to 55 % (Castiglioni, et al., 2013). For calculations in this research, 
urinary excretion rates based on published articles in sewage epidemiology and as 
reported in Moffat (2011b) were used (Table 5.3, page 169). 
 
In order for the target drugs to be detected, they require to be effectively extracted from 
the relevant sample matrix and analysed.  The following sections cover the analytical 
process used in this research from sample collection through to instrumental analysis.  
Extraction techniques based on SPE and LLE, gas chromatography, as well as the chemical 
derivatization process are also discussed. 
 
1.5   SAMPLE COLLECTION, PRE-TREATMENT AND ANALYSIS 
A number of comprehensive review articles have been written on sample collection, 
preservation, storage, preparation and analysis in relation to sewage epidemiology 
(Postigo, et al., 2008a; Boles & Wells, 2010; van Nuijs, et al., 2011a; Baker & Kasprzyk-
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Hordern, 2011b; Wille, et al., 2012; Pal, et al., 2013).   Key aspects relevant to this 
research are discussed below. 
 
1.5.1   Water Sources and Sampling 
The variety of water sources used by researchers in this field include, surface water (e.g. 
rivers, streams), groundwater and waste water influent and effluent (Jurado, et al., 2012; 
Pal, et al., 2013; Racamonde, et al., 2013). The choice has been governed by the aim of 
the research (e.g. comparative studies, detection and/or quantification), the expected 
concentration of the target analyte, and accessibility to the water source. In this research, 
untreated waste water was used for quantification as this have been noted to have higher 
concentrations of PhACs than treated waste water or surface water (section 1.3.4.2) 
(Chen, et al., 2014; Gilart, et al., 2014). 
 
Sampling methods used in sewage epidemiological studies have been varied and include 
grab, composite and passive sampling.  Although useful information can still be obtained 
from grab samples, they don’t provide time-weighted average (TWA) concentrations over 
an extended sampling period (Vrana, et al., 2010).  Composite samples, on the other 
hand, provide TWA concentrations since discrete aliquots of samples are collected at 
specific time intervals over a certain period e.g. 12-99 h and pooled into one sample at 
the end of the collection period (van Nuijs, et al., 2009c; Boles & Wells, 2010 & 2014).  
Composite samples are therefore considered a better representation of possible analytes 
passing through a WWTP over a specified timeframe. Passive sampling is an alternative to 
composite sampling as it also provides TWA concentrations over a specific and continuous 
time period ranging from a few hours up to 60 days (Mills, et al., 2007; Yargeau, et al., 
2014).  Reported passive samplers used for measuring pharmaceutical compounds in 
waste water include polar organic chemical integrative samplers (POCIS) and 
Chemcatcher® passive samplers (Bartelt-Hunt, et al., 2009; Greenwood, et al., 2009; 
Wille, et al., 2012; Yargeau, et al., 2014).  Both consist of a sorbent contained between 
two microporous membranes which allow free-flowing water with dissolved compounds 
to pass through to the receiving phase where they are trapped. Passive samplers can 
sample much larger volumes of water (0.05 - 0.35 L/day) and the receiving phase can be 
tailored for the target analytes thereby increasing the ability to detect compounds 
present even at utlratrace levels (Mills, et al., 2007). 
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Sampling has either been conducted using amber glass bottles or plastic containers 
(Hernandez, et al., 2011; Castiglioni, et al., 2013; Racamonde, et al., 2013).  The latter, 
based on polyethylene terephthalate (PET), polypropylene (PP) and high-density 
polyethylene (HDPE), were used during this research.  Sample volumes quoted in 
literature range from 500 mL to 2500 mL and volumes extracted ranged from 5 mL to 
1500 mL (van Nuijs, et al., 2011a; Racamonde, et al., 2013). 
 
Therefore, the sampling technique chosen depends on the aim of the research, the water 
source to be sampled, the nature and expected concentration of the target analytes as 
well as the analytical technique to be used. 
 
1.5.2   Sample Pre-treatment and Storage 
Once the sample has been collected, it needs to be transported to the laboratory (if off-
site) for pre-treatment and storage. Therefore, preserving the sample during 
transportation and storage is important in ensuring the reliability of the data obtained.  
According to published literature, samples were sometimes transported to the laboratory 
in cooled dark containers and immediately extracted or stored in the dark at 4 - 5 °C and 
extracted within 7 days to prevent degradation of analytes (Lacina, et al., 2013). 
Alternatively, samples were stored at -20 °C for extraction at a later date (Postigo, et al., 
2008b; Lai, et al., 2013a).  In a further step to preserve analytes and minimise 
decomposition within the matrix due to microbiological activity, some research groups 
acidified the samples to pH 2-3 at the sampling site or in the laboratory (Vazquez-Roig,   
et al., 2013) or dosed them with sodium azide (Gerrity, et al., 2011), sodium thiosulphate 
(Boleda, et al., 2011) or mercury chloride (Senta, et al., 2014) before cold storage.  
Whatever the sample preservation method used, the aim should be to get the samples as 
quickly as possible to the laboratory for cold storage or extraction.  Cold transport may be 
necessary to prevent decomposition of the analytes especially if the sampling site is 
located far from the laboratory or if collection and analysis occur in different countries 
(Fick, et al., 2009; Baker, et al., 2012; Bayen, et al., 2013). 
 
Before the sample is extracted or stored, it is taken through a filtration step.  Sample 
filtration is normally conducted immediately after arrival at the laboratory and before 
storage or immediately before extraction, after storage. Different types of filters with 
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various pore sizes (0.2 - 0.7 µm) have been used in sewage epidemiology. These include 
nylon membrane, nitrocellulose, and glass microfiber filters (González-Mariño, et al., 
2010; Pedrouzo, et al., 2011; Chen, et al., 2014). The aim with filtration is to remove as 
much of the particulate matter as possible which can clog up the solid phase extraction 
(SPE) cartridges, gas chromatography (GC) and liquid chromatography (LC) columns as 
well as  injection needles and liners (for GC) if not effectively removed.  Throughout this 
research waste water samples were vacuum filtered through a disposable 1000 mL 
capacity polystyrene stericup funnel and receiver system with a 0.22 µm GP Millipore 
Express® Plus membrane (Millipore, UK).  As far as the author is aware, this type of filter 
has not been used before in waste water analysis but it is very convenient and effective at 
filtering sample volumes ranging from 150 to 1000 mL.  Due to the high surface area of 
the filter (40 cm2), it did not easily clog up during filtration and the SPE cartridges on 
which the filtrate was loaded also did not clog up. Tap and deionized water samples were 
not filtered before extraction due to the high clarity of the samples and a lack of visible 
suspended solids. 
 
Once the sample is filtered, it is taken through an extraction process with the aim of 
separating the target analytes from the sample matrix.  Commonly used extraction 
methods are discussed in the following section. 
 
1.5.3   Sample Extraction 
Prior to instrumental analysis, target compounds require extraction from the relevant 
matrix. Commonly applied extraction techniques for emerging contaminants in aqueous 
environmental samples mainly utilize SPE and to a much less extent LLE (Pedrouzo, et al., 
2011; Ademollo, et al., 2012; Rabii, et al., 2014). In particular, automated on-line SPE and 
solid-phase microextraction (SPME) are increasing in popularity due to their time-saving 
advantages (Mills & Walker, 2000; Racamonde, et al., 2013; Östman, et al., 2014).  LLE is 
more commonly used in clinical and toxicological settings (Liu, et al., 2010; Couchman & 
Morgan, 2011; Peters, 2011) and has rarely been used in the extraction of PPCPs from 
waste water (Mol, et al., 2000; Jimenez, 2013; Loos, et al., 2013; Robles-Molina, et al., 
2014).  Since LLE is a solvent-based extraction process, any improvements in the recovery 
of analytes from a sample matrix mainly rely on the solvent(s) selected (Couchman & 
Morgan, 2011). On the other hand, SPE relies on the use of extraction sorbents with 
32 
 
varying properties and selectivities for analytes and hence optimisation of the extraction 
process not only relies on the solvents used but also on the sorbents selected (section 
3.4.2). 
 
Alternatives to SPE & LLE that are increasingly being used include SPME & liquid-phase 
microextraction (LPME) (Farre, et al., 2012; Spietelun, et al., 2013).  SPME & LPME are 
techniques whereby sample extraction and concentration are simultaneously conducted 
(Willie, et al., 2012).  When coupled with GC-MS or LC-MS, SPME & LPME techniques are 
quick, cost effective, result in low LODs and LOQs and adhere to the priniciples of ‘green 
chemistry’ (section 1.5.3.2) by requiring low to no volumes of solvents (Racamonde, et al., 
2013; Spietelun, et al., 2013 & 2014).  Sample volumes used range from 0.5 mL to 100 mL 
and on-line derivatization methods can be incorporated into the method to further cut 
down on sample preparation time (Mills & Walker, 2000; Hyotylainen, 2009; Racamonde, 
et al., 2013).  Other advantages of SPME and LPME include reduction in matrix effects 
compared with SPE and LLE. 
 
In this research, LLE was used in comparative studies with SPE during the preliminary 
method development stages but subsequent extraction was based on SPE.  Therefore, 
more emphasis is given to the SPE process. 
 
1.5.3.1   Solid Phase Extraction (SPE)  
SPE is a sample preparation technique used to separate and concentrate target analytes 
from various sample matrices.  The desired analytes are systematically retained onto a 
solid-phase sorbent and subsequently extracted with a suitable solvent (Thurman & Mills, 
1998). This enables analytes to be isolated from one solution (the sample matrix) and re-
dissolved in a different solvent (elution solvent).  Most sample matrices comprise a 
mixture of target analytes and undesired and possibly interfering compounds. Therefore, 
the more the target analytes are selectively separated from the other matrix components, 
the cleaner the extract will be with a reduction in interfering compounds (Couchman & 
Morgan, 2011).  The entire SPE process is typically achieved with the use of small volumes 
of suitable solvent during the conditioning, rinsing and elution steps.  Typical sample 
volumes extracted during waste water analysis of drugs of abuse range from 50 mL to 
over 1500 mL (van Nuijs, et al., 2011a; Vazquez-Roig, et al., 2013).  It stands to reason 
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that the larger the initial sample volume used, the higher the chances of detecting and 
quantifying compounds which normally occur in trace amounts (ng/L or pg/L) 
(Racamonde, et al., 2013; Wilson, et al., 2014).  However, as SPE is not exclusively 
selective, this may also concentrate suspended solids and interferents within the matrix 
which could result in clogging of the column and signal suppression or enhancement 
(Hyotylainen, 2009; Baker & Kasprzyk-Hordern, 2011a; Gilart, et al., 2014). The target 
analytes are then eluted into 4 - 10 mL of a suitable solvent and concentrated further for 
analysis (Thurman & Mills, 1998). 
 
Sorbents used in SPE processes occur in many different formats such as disks, cartridges 
and syringe barrels (Thurman & Mills, 1998; Poole, 2003).  The sorbent format used for a 
particular extraction mainly depends on the nature of the sample matrix, the volume of 
sample, the expected concentration of the target analytes, and the analytical technique 
used to separate and identify the components (Hennion, 1999; Poole, 2003; 
Chromacademy).  Syringe barrels were used in this research. The majority of single use 
syringe barrels are made from polypropylene and are packed with sorbent material with 
different chemical properties. The main sorbent packing materials are either silica-based 
or polymer-based and have reversed phase, normal phase, ion exchange and mixed-mode 
(Thurman & Mills, 1998). Polymeric Oasis® mixed-mode reverse phase and ion exchange 
sorbents supplied by Waters, UK, were used in this research and are described in the 
following section. 
 
1.5.3.1.1   Oasis® Mixed Mode Sorbents 
Oasis MCX and HLB sorbents have been the most widely reported in sewage 
epidemiology for multianalyte extraction of acidic, basic and neutral pharmaceutical 
compounds (Boles & Wells, 2010; Baker & Kasprzyk-Hordern, 2011b; van Nuijs, et al., 
2011a; Wille, et al., 2012; Burgard, et al., 2013; Gilart, et al., 2014; Lopes, et al., 2014).  
Depending on the extraction protocol and pharmaceuticals under analysis, on comparison 
with other sorbent types, either the Oasis MCX or HLB sorbent were found to be more 
suitable (Gheorghe, et al., 2008; Gracia-Lor, et al., 2010; Vazquez-Roig, et al., 2013). MCX 
has strong cationic exchange properties suitable for bases while HLB is a universal reverse 
phase sorbent that can retain polar acids and bases and neutral analytes. 
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The Oasis® SPE sorbents used in this research are depicted in Figure 1.2. The backbone of 
all Oasis products is based on the reverse phase HLB (hydrophilic-lipophilic balanced). 
 
 
Figure 1.2: Chemical properties of Oasis HLB and MCX SPE sorbents used during analysis 
(used with permission from Waters, UK). 
 
Although it can be used on its own for its reverse phase properties, the HLB sorbent also 
forms the backbone of all the other Oasis mixed mode sorbents.  It comprises a lipophilic 
divinylbenzene and hydrophilic N-vinylpyrrolidone copolymer and was first introduced in 
1996 as a polymeric sorbent that could be wetted, yet still retain its hydrophobic 
reversed-phase properties. The HLB sorbent is suitable for the recovery of acidic, basic 
and neutral compounds. The Oasis MCX (mixed-mode strong cation exchange) is as a 
result of the sulphonation of the Oasis HLB sorbent and is most suitable for basic 
compounds with a pKa range of 2-10 (Waters, 2006b).  Due to the presence of the 
divinylbenzene and hydrophilic N-vinylpyrrolidone copolymer, it can also retain acidic and 
neutral drugs. 
 
As an alternative to silica-based products, the divinylbenzene and hydrophilic N-
vinylpyrrolidone copolymer offers advantages such as water wettability, polar retention, 
stability across pH 1-14, absence of unreacted silanol interactions with analytes which can 
lead to irreversible bonding (Sigma-Aldrich, 1998), and does not affect recoveries even if 
it dries out (Waters, 2006a).  The last point is important especially with manual 
simultaneous extractions which could lead to some sorbents without sample/solvent for 
short periods of time. In addition, Oasis mixed-mode SPE sorbents do not require the 
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conditioning step and could thereby save time on the extraction process. These 
advantages have led to numerous references in literature, especially with regard to 
analysis of various types of water samples for PhACs, including illicit drugs (Kostopoulous 
& Nikolaou, 2008; van Nuijis, et al., 2009; Gerrity, et al., 2011). 
 
Retention of analytes by mixed-mode SPE is by a number of interactions including 
electrostatic interactions, hydrogen bonding, dipole-dipole, van der Waals forces and ion 
exchange.  These complement each other with regards to retention of analytes with 
varying polarities and chemistries, leading to more effective sample clean-up (Telepchak, 
et al., 2004; Waters, 2006a). The decision to use the Oasis SPE products for this research 
was mainly due to two factors. Firstly, the majority of studies relevant to the research of 
this thesis have utilized Oasis cartridges for the extraction of pharmaceutical compounds 
from various water samples (Pal, et al., 2013; Gilart, et al., 2014). Secondly, the ability of a 
single type of mixed-mode SPE sorbent to retain acids, bases and neutral compounds 
without the need for using different sorbent types for each group of analytes was 
regarded as an advantage for the multianalyte method under development (Waters, 2006 
a&b).  The majority of the target analytes during this research were basic with only 
morphine being amphoteric. Therefore SPE sorbents used for preliminary studies were 
MCX and HLB.  All were of 3 mL capacity with 30 µm particle size packed to a mass of     
60 mg. 
 
SPE protocols for extracting various types of compounds (acidic, basic, amphoteric and 
neutral), including recommendations for selecting the most suitable sorbent material and 
solvents depending on the nature of the target analytes, are readily available in the 
literature or from the supplier (Telepchak, et al., 2004; Levine, 2006; Waters, 2006a&b). 
Therefore once the target analytes have been decided on it may be necessary to compare 
various types of syringe barrels containing packing material with different chemical 
properties to determine the most suitable protocol for the analytical method under 
development (sections 3.4.2.1). All preliminary SPE investigations and the final protocol 
were applied through an SPE vacuum manifold using a manual set-up. 
 
Whilst SPE is an effective technique for sample extraction, concentration and clean-up, an 
alternative (or complimentary) technique is the more traditional LLE which is discussed 
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further in section 1.5.3.2. Prior to the development of SPE, LLE was more commonly used 
in extracting analytes from one liquid phase into another (Hennion, 1999). While there 
has been an increase in the use of SPE since its development, LLE is still used in many 
laboratories (Levine, 2006; Hendriks, et al., 2007; Raikos, et al., 2009; Namera, et al., 
2011; Jiménez, et al., 2013; Farajzadeh, et al., 2014). 
 
1.5.3.2   Liquid-Liquid Extraction (LLE) 
In LLE, target analytes are isolated from complex matrices (e.g. urine, blood, waste water) 
through their ability to partition between two immiscible solvents.  The polarity of the 
solvents used in respect to the polarity of the target analytes, the pH of the sample with 
respect to the pKa of the target analytes and the volume of extraction solvent and number 
of repeat extractions all play a role in improving the recovery of the target analytes from 
the matrix (Levine, 2006).  The effectiveness of a given solvent in extracting a particular 
analyte is chiefly determined by how miscible with water the solvent is and its polarity, 
i.e. dielectric constant, as well as its hydrogen bonding ability (Flanagan, et al., 2007).   
 
Almost all common drug substances have some degree of polarity and hence will be 
extracted into a polar solvent (Levine, 2006).  Some common solvents used in SPE and LLE 
and their properties are listed in Table 1.6.  
 
Table 1.6: Common solvents and their extraction-related properties. 
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The polarity of a solvent is expressed as its dielectric constant. The higher the dielectric 
constant, the higher the polarity and vice versa. In most instances a mixture of two 
miscible solvents are used to optimise the extraction ability of analytes from aqueous 
solutions.  The solvents complement each other with regards to hydrogen bonding ability 
(Stimpfl, 2011). The ability of an analyte to form hydrogen bonds with a given solvent 
affects it solubility and subsequent extraction into the solvent (Levine, 2006). Other 
factors to consider for the solvent are low toxicity, volatility and flammability and it 
should be able to extract the analytes from the matrix without the interferents as well as 
not react with the analytes (Couchman & Morgan, 2011).  Examples of solvents used in 
the extraction of PPCPs from various water samples include acetone, ethyl acetate,          
n-hexane and toluene (Mols, et al., 2000; Jimenez, 2013; Loos, et al., 2013; Robles-
Molina, et al., 2014). It is worth mentioning the concept of ‘green chemistry’ which has, 
as one of its aims, the reduction of the use of toxic and/or hazardous solvents or their 
substitution with more health and environmentally friendly alternatives as well as 
eliminating the toxic waste generated (Sheldon, 2005). 
 
Examples of solvents that have become undesirable for use due to health and 
environmental concerns include chloroform, carbon tetrachloride and pentane. These can 
be substituted with more environmentally friendly solvents such as dichloromethane, 
ethyl acetate, and heptane, respectively (Doble & Kruthiventi, 2007; Alfonsi, et al., 2008). 
After selection of a solvent, the pH of the aqueous sample matrix requires adjustment in 
order to convert the target drugs to unionized forms, which enable them to be readily 
extracted into the polar solvent. This is at least 2 pH units above the pKa for basic drugs 
and 2 pH units below the pKa for acidic drugs (Appendix III). Ideally, it is more effective to 
extract acidic, basic and neutral drugs in separate fractions but this adds multiple steps to 
the extraction process thereby prolonging the method.  Multianalyte extraction protocols 
therefore set out to find optimum conditions for the simultaneous extraction of acidic, 
basic and neutral drugs in as few steps as possible. This presents a challenge due to the 
analytes containing different physicochemical properties (e.g. pKa and polarity) (Levine, 
2006; Kasprzyk-Hordern, et al., 2007). As mentioned in section 1.5.3.1.1, the majority of 
drugs investigated in this research were basic with pKa values ranging from 7.5 to 9.9, 
with diazepam having a pKa of 3.3. As with SPE, LLE is also not exclusively selective for the                     
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target analytes and hence can also lead to co-extraction of other unwanted matrix  
components (Gilart, et al., 2014). 
 
1.5.3.3   Comparison between SPE and LLE  
Some of the key factors which influence the choice on whether to use SPE or LLE include 
the chemical properties of the analytes, the complexity of the sample matrix and 
subsequent analytical technique to be used.  Each sample extraction technique has 
advantages and disadvantages which need to be considered based on the aim of the 
analysis.  These are listed in Table 1.7 below. 
 
Both SPE and LLE, although helping to clean up the sample and concentrate the analytes, 
add extra time to the analytical process and may lead to loss of some of the analytes as 
recoveries are rarely 100 % for all compounds (Frenich, et al., 2009).  However, sample 
clean-up also protects instrumental components from excessive clogging or getting dirty 
(columns, ionisation source, injection liners for GC-MS, injection needles) thereby 
reducing maintenance costs.  Both SPE & LLE are also applicable for a wide range of 
compounds. Overall, SPE has a higher enrichment factor thereby leading to increased 
selectivity and sensitivity (Farajzadeh, et al., 2014; Wilson, et al., 2014).  This is even more 
important with matrices where analytes are present in trace amounts such as waste 
water and surface water. SPE has, therefore, increasingly found widespread use in the 
preparation of environmental samples for emerging organic contaminants (van Nuijs, et 
al., 2010; Pal, et al., 2013; Gilart, et al., 2014; Ribeiro, et al., 2014b; Wilson, et al., 2014). 
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    Table 1.7: Advantages and drawbacks of SPE and LLE. 
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How effectively a drug is extracted from its matrix depends on a number of factors, 
including its chemical structure and pKa. Most drugs will ionise in solution based on their 
pKa and the pH of the solution in which they are dissolved (Levine, 2006; Stimpfl, 2011).  
Therefore, the pH of the sample matrix relative to the pKa of the analytes plays an 
important role in the effective reproducible and quantitative isolation of analytes from 
the sample matrix. However this poses a challenge when developing a single multianalyte 
method containing analytes with varying pKa values (sections 3.4.1 and 3.4.2). Table 1.8 
lists the known pKa values of the analytes investigated in this research.  
 
Table 1.8: pKa values of target drugs. 
 
 
Most had one pKa value ranging from 7.1 (methcathinone) to 9.9 (amphetamine and 
methamphetamine). The exceptions were diazepam (pKa 3.3) and morphine which is 
amphoteric (pKa 8.0 and 9.0). Amphoteric compounds have the ability to act as either an 
acid or a base and hence will have different recoveries at various pH values (Levine, 2006; 
Stimpfl, 2011).   At the time of writing of this thesis, pKa values of a number of cathinones 
and piperazines were not readily available.  However, based on the pKa of methcathinone 
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and benzylpiperazine (9.6), their pKa values can be estimated to be in the range 7 - 10.  
Unless otherwise stated, pKa values are from Moffat (2011b). 
 
Therefore by taking advantage of the physico-chemical properties of the analytes (e.g. 
pKa) a suitable sample preparation procedure can be developed.  For SPE and LLE, this has 
a number of benefits such as, adding selectivity to the process, optimising recovery from 
the sample matrix and ensuring reproducible sample consistency (Couchman & Morgan, 
2011). 
 
A further aspect of sample preparation, especially when GC-MS is used, is derivatization.  
This is discussed in the next section. 
 
1.6   CHEMICAL DERIVATIZATION  
The main aims of chemical derivatization are to reduce the polarity of a compound as well 
as increase its volatility and thermal stability (Braithwaite & Smith, 1999; Telepchak, et al., 
2004). The latter is essential due to the often high temperatures (e.g. 300 °C) used during 
GC-MS analysis. The overall outcome of derivatization should be the reduction in peak 
tailing and improved peak shape, detectability and selectivity (Telepchak, et al., 2004). 
Other advantages of derivatization include: changing the retention times which can lead 
to improved resolution; generating more abundant ions with a higher atomic mass and a 
more distinct mass spectrum resulting in less interference from other compounds in the 
matrix (Halket, 1993; Levine, 2006). 
 
1.6.1   To Derivatize or Not? 
Not all compounds require derivatization in order to be detected and reliably quantified 
and the decision of whether to derivatize or not needs to be established during the initial 
stages of method development. The nature and chemical properties of the target 
analytes, the constitution of the sample matrix and the presence of interfering substances 
that could affect the analytical results as well as the methodological approach need to be 
taken into consideration when deciding whether or not to include a derivatization step 
(Blau & Halket, 1993). Analysis by GC-MS almost always includes a derivatization step, 
especially with polar compounds, while this is not always necessary for high performance 
liquid chromatography (HPLC) or LC-MS.  However, as derivatization leads to increased 
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sensitivity and improvement in bioanalytical quantitation, it has also been used for some 
studies involving LC-MS (Holcapek, et al., 2012). 
 
Most pharmaceutical compounds are organic in nature and hence will have some degree 
of polarity due to their functional groups such as alcohols, phenols, carboxylic acids, 
amines and amides (Blau & Halket, 1993).  Therefore, a knowledge of the chemical 
structure of a molecule allows for an informed decision on whether a compound can and 
should be derivatized as well as which derivatizing reagent would be most suitable 
(Flanagan, et al., 2007).  Figure 1.3 depicts the chemical structures of the target analytes 
and their varied functional groups.  The functional groups vary even within drugs of the 
same class and give rise to varying: acid dissociation constant (Ka) values, stabilities in 
different solvents and the sample matrix, susceptibilities to derivatization, extractabilities 
from a sample matrix, interactions with the stationary phase in the GC column and mass 
spectral fragmentation patterns.  All these factors present a challenge when developing 
one analytical method that will simultaneously extract and quantify the target drugs.  In 
most instances the most suitable method in terms of recovery, precision and limit of 
detection (LOD) may still favour certain classes of drugs over others. These aspects are 
discussed in more detail in Chapters 3 and 4. 
 
The functional groups relevant for derivatization are the amine (-NH and -NH2) and 
hydroxyl (-OH) groups as depicted in Figure 1.3.  Derivatization replaces the labile 
hydrogen atom with another group that does not contain free hydrogen atoms thereby 
reducing the tendency of the molecule to bond with the stationary phase and improving 
the chromatographic properties (Knapp, 1979).  Since GC-MS was the instrumental 
method to be used in this research, a decision was made during preliminary studies to 
include derivatization in the method development, as this improved the chromatographic 
and mass spectral properties of the target drugs (section 3.2.1). This is also corroborated 
by literature references in clinical and toxicological analyses where similar drugs were 
derivatized in order to achieve better chromatographic properties when using GC-MS 
(Segura, et al., 1998; Saito, et al., 2007). 
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Figure 1.3: Chemical structures of the target analytes and functional groups relevant for derivatization (circled). 
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                 Figure 1.3 cont’d: Chemical structures of the target analytes and functional groups relevant for derivatization (circled).
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In this research, target drugs without a labile hydrogen, and hence were unaffected by 
the derivatization process, were amitriptyline, cocaine, diazepam and heroin.  All other 
drugs had at least one derivatizable site, with only morphine and piperazine having two 
(Fig. 1.3). 
 
Two main categories of derivatizing reagents used in this research, silylation and 
acylation, are described in the next section. These were selected based on their reported 
use in derivatizing various types of compounds, including drugs of abuse (Halket, 1993; 
Telepchak, et al., 2004; Farajzadeh, et al., 2014). 
 
1.6.2   Silylation 
During silylation, the labile hydrogen is substituted with an alkylsilyl group (Braithwaite & 
Smith, 1999). Popular silylation reagents include N,O-bis(trimethylsilyl)trifluoroacetamide 
(BSTFA) and N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA), which replace the 
labile hydrogen with a trimethylsilyl (TMS) group i.e. (CH3)3Si. This is depicted in Figure 
1.4, using benzylpiperazine as an example. 
 
 
Figure 1.4: Silylation reaction for benzylpiperazine. 
 
According to Telepchak (2004), almost 85 % of derivatization reactions using GC use some 
form of silylating agent due to its compatibility with most functional groups and is widely 
accepted to be quite versatile.  This is supported by Evershed (1993) and Farajzadeh 
(2014) who report silylation for enhancing chromatographic and mass spectrometric 
performance of compounds. Since most silylating agents are moisture sensitive, catalysts 
such as trimethylchlorosilane (TMCS) are normally added to the silylating agent to not 
only enhance the substitution reaction (especially for sterically hindered reaction sites) 
but to also improve its hydrolytic stability (Telepchak, et al., 2004).  Therefore for 
effective and reproducible derivatization the sample should be completely moisture-free. 
Any water in the sample can cause the decomposition of both the reagent and 
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derivatives. Hence, it is also considered good practice to use an excess of derivatization 
reagent in order to react with any possible water in the sample. The by-products formed 
are inert and highly volatile and not likely to interfere with the analyte peaks (Thermo 
Fisher Scientific, 2008). 
 
An advantage of silylation over other derivatizing reactions is that it requires no further 
evaporation and reconstitution steps as it can be directly injected onto the GC column.  
Both BSTFA and MSTFA were investigated in this research (Table 2.5). 
 
1.6.3   Acylation 
During acylation, the labile hydrogen is replaced with an acyl group to give an ester or 
amide (Segura, et al., 1998; Telepchak, et al., 2004). Acylating reagents fall under three 
main categories: acid anhydrides, acid halides and reactive acyl derivatives such as 
acylated imidazoles (ibid). The acid anhydrides, trifluoroacetic anhydride (TFAA), 
pentafluoropropionic anhydride (PFPA) and heptafluorobutyric anhydride (HFBA) were 
used in this research (Table 2.5).  An example of the acylation reaction with PFPA is 
represented in Figure 1.5 using 4-fluoromethamphetamine. 
 
 
Figure 1.5: Acylation reaction for 4-fluoromethamphetamine. 
 
Acylation is also used on a wide scale for derivatization and is often a worthy alternative 
to silylation for functional groups such as amines, hydroxyls and phenols (Blau, 1993; 
Braithwaite & Smith, 1999; Farajzadeh, et al., 2014). The resulting derivatives tend to 
have even higher and more stable atomic masses for GC-MS than TMS derivatives and are 
also sensitive to other GC detectors such as an electron capture detector (ECD) 
(Braithwaite & Smith, 1999; Telepchak, et al., 2004).  TFAA, PFPA and HFBA are similar in 
chemical behaviour and hence any can be effectively used for acylation.  The reaction 
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time and temperature, the retention time (RT), as well as final atomic mass of the 
derivative may need to be considered when making the final selection (Blau, 1993). 
 
Acylating reagents are highly reactive and can give rise to negative effects during 
chromatography such as: altering the chemical composition of the stationary phase, 
corrosion of parts of the GC-MS system and appearance of additional peaks due to re-
derivatization of compounds stuck at the head of the column. Therefore, in contrast to 
silylating reagents, the excess acylating agent and acid by-products need to be removed 
before injection thereby necessitating an additional step where the reaction mixture is 
evaporated to dryness and reconstituted in a suitable solvent (Segura, et al., 1998). 
Ultimately, the choice of derivatizing reagent would be based on the most suitable for the 
mixed target drugs under analysis, especially for the NPS, which were the focus of this 
research, with the knowledge that compromises are inevitable due to the varied chemical 
properties of the analytes. 
 
In order for the derivatization process to be beneficial to the method under development, 
it should be simple, relatively quick to conduct and should result in a single, stable 
derivative.  Most derivatizing agents require heat to be effective and to reduce the 
reaction time (Evershed, 1993; Telepchak, et al., 2004). Therefore parameters such as 
reaction time and temperature as well as the volume of derivatizing reagent used need to 
be optimised for the target analytes to ensure reproducible and reliable results (section 
3.2.2).  Optimisation also ensures that the derivatization reaction has gone to completion 
as well as determining whether the derivatives are stable (Blau, 1993; Braithwaite & 
Smith, 1999). 
 
1.6.4    Evaluating the Derivatization Reaction 
Determining when a derivatization reaction is complete (i.e. maximum conversion) is just 
as important as selecting the right derivatizing reagent. It is essential for reliable, 
quantitative analysis.  The ultimate goal with optimising the derivatization process is to 
detect the most important factor(s) that affects the completeness of the derivatization 
process for specific drugs.  However, only a few approaches in determining the optimal 
conditions for the derivatization process have been reported. The Box-Behnken approach 
has been utilised by Gonzalez-Marino (2010) and Racamonde (2013). This multivariate 
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approach is based on mathematical modelling that assesses a factor and a response to 
that factor, with the response being the dependant variable.  A set of experiments are 
used to assess the effect of a particular factor on the results e.g. derivatizing agent 
volume and reaction temperature.  Other researchers assumed derivatization was 
complete based on the presence of one derivative peak with the right mass spectral 
profile for a particular analyte (Segura, et al., 1998).  A different approach also reported in 
published literature has been to measure the increase in drug peak area (Lacina, et al., 
2013) or the relative response factor (Migowska, et al., 2012; Kumirska, et al., 2013) 
against the reaction temperature and time. The presence of one derivative peak and the 
most intense instrumental response indicates maximum conversion, and hence the 
optimal derivatization condition for that drug (Migowska, et al., 2012; Kumirska, et al., 
2013; Lacina, et al., 2013). 
 
After derivatization, the prepared samples are then analysed for qualitative and 
quantitative purposes. In the following section, instrumental techniques, relevant to this 
research are discussed. 
 
1.7   INSTRUMENTAL ANALYSIS 
The interest in the detection of emerging contaminants (including illicit drugs) in 
environmental samples has coincided with more recent advancements in analytical 
techniques capable of detecting target analytes at very low concentrations (ng/L) in 
complex matrices (Fatta, et al., 2007; Willie, et al., 2012).  These analytical techniques 
mainly comprise LC-MS and GC-MS (van Nuijs, et al., 2011a; Pal, et al., 2013).  To a lesser 
extent, HPLC with a diode array or fluorescence detector (Fatta, et al., 2007; Patrolecco, 
et al., 2013), capillary electrophoresis (Bishop, et al., 2005), GC with electron capture 
detector (GC-ECD) (Migowska, et al., 2012) have also been used. These same techniques 
have historically been used to detect illicit drugs in various biological matrices such as 
hair, urine, sweat, saliva and blood (Rivier, 2003; Boleda, et al., 2007; Bones, et al., 2007; 
Liu, et al., 2010; Peters, 2011). However, illicit drugs normally occur at much lower 
concentrations in environmental samples (ng/L) than in biological matrices (µg/mL) 
thereby requiring instrumental techniques capable of trace-level detection. 
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1.7.1   Advances in Instrumental Techniques 
Over the past decade, improvements in instrumental designs have been made to enable 
trace-level detection of emerging contaminants in various complex matrices.  Reviews by 
various authors have covered the recent trends in analytical techniques relating to the 
trace-analysis of emerging contaminants.  Hyphenated systems, and in particular those 
coupled to tandem mass spectrometry (MS/MS), have maintained their popularity and 
are increasingly being used (Farre, et al., 2012; Pal, et al., 2013).  This includes systems 
capable of achieving high resolution of compounds within a short analysis period such as 
ultra-high pressure liquid chromatography (UHPLC) (Pedrouzo, et al., 2011). The 
improvements in analytical separation techniques have coincided with improvements in 
highly sensitive mass spectrometric detectors capable of achieving very low limits of 
detection (LOD) and limits of quantification (LOQ) and increasing the range of compounds 
that can be detected by these methods (Wu & French, 2013). 
 
These include the triple quadrupole (Zuba, 2012), ion trap (Hogenboom, et al., 2009), 
time of flight (Lacina, et al., 2013) and orbitrap (Wille, et al., 2012) or various hybrid 
combinations of these.   In addition, multidimensional as well as two-dimensional LC and 
GC techniques are also growing in popularity (Farre, et al., 2012; Lacina, et al., 2013). In 
multidimensional techniques two columns are used in tandem with the first column used 
for sample pre-concentration and the second column for analytical separation. In two 
dimensional techniques the entire sample is separated on two different columns (Farre, 
et al., 2012).  Improvements in instrumentation have also enabled the move towards 
multianalyte (also referred to as multi-residue and multi-class) methods capable of 
simultaneously analysing a number of drugs with similar or different physico-chemical 
properties (Peters, 2011). Multianalyte methods save on analysis time, resources and the 
number of methods that need to be validated in the laboratory (Peters, 2011).  However 
due to the varied physico-chemical properties of compounds analysed under these 
multianalyte techniques, compromises in various aspects of method development are 
inevitable (Wille, et al., 2012). This has, nevertheless, not impeded researchers from 
utilising multianalyte techniques as the benefits far outweigh any negatives. 
 
Other notable improvements in instrumental design include automated sample 
extractions (off-line and on-line) and handling, improved software and databases for 
50 
 
interpretation, comparing and reporting of mass spectral data as well as improved 
instrument reliability (less maintenance) (Boleda, et al., 2007; Wu & French, 2013).  All 
these have led to increased sample throughput which is especially key when results are 
required within a short period of time. 
 
However, it is worth noting that while improvements in instrumental and extraction 
techniques have enhanced the detection of trace levels of compounds in complex 
matrices, this has also pushed the costs of the instruments up thereby making some of 
these techniques inaccessible to many laboratories globally (Deng, et al., 2004; de Vos, et 
al., 2013). 
 
1.7.2   Mass Spectrometry 
Chromatographic separation techniques such as GC and LC are based on the partitioning 
of components of a mixture between a stationary and mobile phase (Braithwaite & Smith, 
1999). While many different types of detectors can be coupled to gas chromatographs to 
aid in the reliable identification of the analyte, a mass spectrometer was used in this 
research due to its superior structural elucidation and confirmation abilities (Braithwaite 
& Smith, 1999; Frenich, et al., 2009; Dawling, et al., 2013).  In a mass spectrometer, the 
analytes in the gaseous phase are converted into charged molecules which are then 
separated by their mass-to-charge (m/z) ratio and accelerated towards an ion detection 
source. Different types of ions are produced depending on the ionization source which 
includes chemical ionisation (CI), electron impact ionisation (EI) and electrospray 
ionisation (ESI). The resulting mass spectrum, referred to as a total ion chromatogram 
(TIC), can provide structural information by which even unknown compounds can be 
identified, thereby making mass spectrometry a powerful technique for identification, 
confirmation and quantification of analytes (Ardrey, 2003; McNair & Miller, 2009; 
Dawling, et al., 2013). Therefore, not only does a mass spectrometer increase the 
selectivity and sensitivity of a method but it also enables accurate identification of target 
analytes among other matrix components (Repice, et al., 2013). 
 
1.7.3   Comparison between GC-MS and LC-MS 
While LC-MS with ESI is the more popular technique used in the analysis of emerging  
contaminants in wastewater, GC-MS with EI ionisation was used in this research as an  
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alternative instrumental technique for sewage epidemiological studies. 
 
When considering the analysis of drugs of abuse in waste water over the past three years, 
the majority of researchers, by far, have used LC-MS/MS (Kumirska, et al., 2013). To the 
author’s knowledge, only three studies have used GC-MS, with derivatization either based 
on silylation and iso-butyl formate (Racamonde, et al., 2012 & 2013) or no derivatization 
(Robles-Molina, et al., 2014).  In a review by Vazquez-Roig (2013), only two out of eleven 
studies for determining legal and illegal drugs in water used GC-MS while eight used 
methods based on LC-MS/MS and one on LC- quadrupole linear ion trap. Table 1.9 lists 
some of the few studies that have used GC-MS for the analysis of emerging contaminants 
in waste water over the past three years.  Only 3 out of the twelve listed were solely 
focussed on or included drugs of abuse and none of them simultaneously analysed 29 
drugs and metabolites from different classes.  Despite the increasing popularity of using 
LC-MS for the analysis of emerging contaminants in waste water, GC-MS has many 
advantages which have kept it as the instrument of choice for many types of analyses, 
and these can be capitalised on for sewage epidemiological studies.  Some of the main 
advantages and disadvantages of GC-MS are listed in Table 1.10. 
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      Table 1.9: References for GC-MS analysis of emerging contaminants in water samples. 
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         Table 1.10: Advantages and disadvantages of GC-MS. 
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On the other hand, there have been numerous studies that have used LC-MS for the 
detection and quantification of drugs of abuse in water samples over the past three years.  
The majority of studies incorporate drugs of abuse into multianalyte methods assessing 
various emerging contaminants.  Table 1.11 lists some of the sewage epidemiological 
studies that have used LC-based techniques. 
 
Table 1.11: References for LC-MS analysis of emerging contaminants in water samples. 
 
 
It was easier to find articles published over the past two years that have used LC-MS/MS 
for detecting drugs of abuse in waste water than it was to find similar published articles 
that have used GC-MS over the past five years. As listed in Table 1.12, LC-MS also has 
many advantages which have made it the instrumental method of choice for emerging 
contaminants in water samples, especially since they are usually polar and non-volatile 
(Repice, et al., 2013). However, LC-MS also has disadvantages as listed in Table 1.12. 
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         Table 1.12: Advantages and disadvantages of LC-MS. 
56 
 
The choice on whether to use GC-MS or LC-MS depends on many factors including, the 
thermal stability and polarity of the compounds to be analysed and the sensitivity of the 
detector to these compounds, availability in the laboratory and budget (Rivier, 2003).  
The methods complement each other and should not be solely regarded as either/or 
(Maurer, 2005). Some sewage epidemiological studies have utilised both methods to 
enhance the results for a wide variety of compounds (Oh & Shin, 2012; Robles-Molina, et 
al., 2014). Both types of instrument are capable of conducting unmanned, continuous 
automated assays for days without needing maintenance intervention. In addition, both 
GC-MS and LC-MS are conducive for developing methods for the simultaneous analysis of 
different compounds from different classes. 
 
However, the higher costs can limit the applicability of LC-MS and LC-MS/MS in less 
developed countries or laboratories with limited budgets (Jjemba, 2006; Racamonde, et 
al., 2013). In addition, a problem commonly associated with LC-MS, is matrix effects 
(Frenich, et al., 2009). This broadly refers to the suppression or enhancement of the signal 
from the analyte due to interference from co-extracted matrix components which may or 
may not co-elute with the analyte (Frenich, et al., 2009; Peters & Remane, 2012; Bayen, 
et al., 2013; Petrie, et al., 2013). The interference is thought to occur during the ionisation 
process (Vogeser & Seger, 2010; Peters & Remane, 2012).  Matrix effects can lead to false 
negatives and deflate or inflate the LOD and LOQ values which ultimately result in 
unreliable analytical accuracy, reproducibility and quantification (Postigo, et al., 2008; 
Wille, et al., 2012; Racamonde, et al., 2013). Therefore, matrix effects need to be 
considered during method validation for LC-MS in order to obtain reliable and realistic 
results (Peters, 2011).  Steps taken to try and minimise matrix effects include optimising 
the sample pre-treatment & clean-up/extraction methods, use of deuterated or stable 
isotope-labelled internal standards, reducing or diluting the amount of extracted sample 
matrix, and standard addition calibration, but none have been able to completely 
eliminate them (Chambers, et al., 2007; González-Mariño, et al., 2010). 
 
In addition, since compounds are normally not derivatized with LC-MS, m/z values of the 
molecular and fragment ions tend to be low and could negatively affect positive 
identification of target analytes due to isobaric compounds altering ion ratios 
(Racamonde, et al., 2013). Isobaric compounds are either structural isomers of the target 
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analyte that share its elemental formula or structurally unrelated compounds that have 
the same nominal molecular mass as the target analyte (Vogeser & Seger, 2010). 
 
Although the development and use of LC-MS-ESI for clinical, toxicological and 
environmental analysis has accelerated in the last two decades, GC-MS-EI remains the 
most widely applied analytical technique since its development in the 1950s due to its 
universality, widespread availability and lower cost of analysis (Ragunathan, et al., 1999; 
Peters, 2011; Migowska, et al., 2012; Favretto, et al., 2013; Kumirska, et al., 2013).  It can 
also be considered to have more reliable quantification especially when isotopically-
labelled internal standards are used as compared with LC-MS in which matrix effects and 
isobarism always have to be taken into account during method validation (Vogeser & 
Seger, 2010). On the other hand, GC-MS is less affected by matrix effects (Favretto, et al., 
2013; Kumirska, et al., 2013). In addition, Heath (2010) reports GC-MS to be more 
sensitive than LC-MS/MS in the analysis of acidic drugs in more complex matrices and 
several studies have shown GC-MS to have LODs rivalling or better than LC-MS/MS (Fatta, 
et al. 2007; Mwenesongole, et al., 2013; Vazquez-Roig, et al., 2013).  With regard to 
measurement uncertainty for the trace analysis of organic compounds in complex 
matrices, an inter-laboratory study showed GC-MS to be superior to LC-MS/MS (Heath, et 
al., 2010). 
 
Since very little published information was available on the analysis of waste water for 
drugs of abuse using GC-MS, this instrumental technique was used in this research to 
provide further data on its suitability for sewage epidemiological studies, and as a 
cheaper and sensitive alternative to LC-MS/MS. In addition, as a result of preliminary 
investigations, derivatization by PFPA was used as an alternative to more commonly 
applied silylation, due to its universality.  To the author’s knowledge, GC-MS, with 
derivatization by PFPA, has not been used for the analysis of drugs of abuse, especially 
NPS, in waste water. 
 
1.8   VALIDATION OF AN ANALYTICAL METHOD  
Method validation determines whether a method is suitable for its intended use by 
testing different performance characteristics.  Various published papers are available 
which explain in detail what successful method validation entails (Jimenez, et al., 2002; 
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Peters, et al., 2007; Huber, et al., 2010; Willie, et al., 2011). The extent of method 
validation, the evaluation criteria selected and the acceptance range of the results all 
depend on the intended purpose of the analytical method.  In this regard, various 
guidelines are available to assist laboratories in designing their own method validation 
strategies while maintaining the integrity and reliability of the method, such as the 
International Conference on Harmonisation (ICH, 2005) and Eurachem (Eurachem, 1998) 
guidelines.  Each laboratory can decide which are the key performance tests and the 
minor (supportive) ones (Jimenez, et al., 2002). 
 
1.8.1   Key Performance Tests 
The key performance tests which were deemed relevant for this research are briefly 
mentioned below: 
 
Selectivity - the ability of a method to accurately detect and distinguish the target analyte 
from other known and unknown compounds in the sample matrix. 
 
Linear range - the ability of a method to give test results that are directly proportional to 
the concentration of analyte in the sample, within a specific range. 
 
Precision (intra-assay and intermediate) - the closeness of agreement between a series of 
measurements obtained from multiple sampling of the same homogeneous sample under 
the prescribed conditions. 
 
A measure of the precision under the same operating conditions over a short interval of 
time is referred to as intra-assay precision. The precision measured within the same 
laboratory but on different days, or by different analysts, or different equipment etc. is 
referred to as the intermediate precision. 
 
Limit of detection (LOD) - the lowest concentration of the target analyte in the sample 
that can be reliably differentiated from background noise or a blank. 
 
Limit of quantification (LOQ) - the lowest concentration of the target analyte in the 
sample that can be reliably quantified with suitable precision and accuracy. 
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Extraction recovery - measures how efficiently the target analyte is extracted from the 
sample matrix. 
 
Stability - measures the changes in drug concentration over a pre-determined time 
interval. 
 
1.8.2  Quantification by Standard Addition 
For complex samples where a blank matrix cannot be obtained, such as waste water, the 
standard addition method of quantification is recommended (Frenich, et al., 2009; 
Cooper, et al., 2010).  In the standard addition method, increasing concentrations of a 
mixed drug standard are added to aliquots of the same volume of the sample containing 
possible target analytes. The unknown concentration of the analyte originally present in 
the sample is calculated by extrapolation.  Since the calibraton is conducted within the 
sample matrix, any co-extracted components are accounted for thereby correcting for 
any matrix effects (Furey, et al., 2013). The majority of published studies in sewage 
epidemiology used matrix-matched calibration spiked with drug standards (Baker & 
Kasprzyk-Hordern, 2013; Gilart, et al., 2014; Kumirska, et al., 2013) or calibration 
standards in pure water or solvent (Jimenez,  2013; Lai, et al., 2013a; Lopes, et al., 2014; 
Verlicchi, et al., 2014). Isotopically-labelled internal standards were used in the majority 
of studies to compensate for any variabilities during sample preparation and analysis 
(Frenich, et al., 2009). Standard addition has been avoided due to its laborious nature 
(Furey, et al., 2013). However, matrix matched calibration works best when a blank 
sample matrix is used. Due to the ever changing nature of the composition of waste 
water and surface water, it is very difficult to find a blank sample matrix with the same 
make-up as the sample matrix (Furey, et al., 2013).  As a result of this, various matrices 
have been used as a ‘substitute‘ of the blank sample matrix, such as surface water from 
uncontaminated sources, tap water, distilled or ultrapure water (Ostman, et al., 2014; 
Vuori, et al., 2014).  Some calibration standards have also been prepared in solvents such 
as methanol and acetonitrile (Nefau, et al., 2013; Lopes, et al., 2014). These do not, 
however, take into account any other matrix components that may interfere with the 
analysis. In addition, the behaviour of drugs in a neat standard is different from when in 
the complex sample matrix. Therefore, this does not adequately compensate for 
interfering matrix components even when an internal standard is used.  With standard 
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addition, the same matrix is used which takes into account any interefering matrix 
components. The method of standard addition therefore adequately compensates for 
matrix effects and removes any bias due to the use of a substitute matrix because both 
quantification and calibration are performed on the same sample (Peters, et al., 2007; 
Frenich, et al., 2013; Rabii, et al., 2014). This leads to more accurate quantification (Furey, 
et al., 2013).  However, based on a comprehensive literature review, standard addition 
has not been used for the analysis of drugs of abuse in waste water to the author’s 
knowledge. This is surprising considering standard addition is the most effective way of 
compensating for or eliminating matrix effects that plague analysis by LC-MS, the more 
commonly used analytical technique for sewage epidemiological studies (Danzer & Currie, 
1998). 
 
Therefore, in this research, to compensate for any matrix components that might 
interfere with qualitative and quantitative aspects of the analysis, to reduce any bias 
arising from the use of a substitute blank matrix, and to compensate for any variabilities 
during sample preparation and analysis, both standard addition and the use of 
isotopically-labelled internal standards were used. 
 
1.9   AIM OF THE RESEARCH 
In the light of the above discussions, the aim of this research was to develop and validate 
an analytical method based on GC-MS with a suitable derivatization reagent, for the 
simultaneous extraction, detection and quantification of 29 drugs of abuse in waste water 
samples from Cambridge, UK. 
 
The main objectives were to: 
1. Obtain real-time qualitative and quantitative data on the most commonly abused 
drugs, including NPS, in Cambridge, UK. 
2. Use the quantitative findings to estimate drug consumption in Cambridge, UK. 
3. Present GC-MS as an equally effective and more sensitive alternative to  
LC-MS/MS in sewage epidemiological studies. 
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CHAPTER TWO 
EXPERIMENTAL PROCEDURES 
This chapter details the experimental protocols and materials used during the 
development of the method for the detection of drugs of abuse in waste water. The 
chapter is divided into sub-sections which highlight the various preliminary studies 
conducted such as chemical derivatization, stability studies, and sample extraction.  The 
final method selected after optimising each segment of the method is mentioned in the 
relevant sub-section.  This is followed by protocols conducted during validation studies. 
 
2.1   DRUG STANDARDS, CHEMICALS AND SOLVENTS 
The solvents, chemicals and drug standards used are listed in Tables 2.1, 2.2 and 2.3. All 
drug standards were of analytical grade (purity ≥ 97 %), except where indicated, and were 
purchased as solids or as 1 mg/mL or 0.1 mg/mL standard solutions in methanol or 
acetonitrile. For the solids, 1 mg/mL stock solutions were prepared in methanol or 
acetonitrile (fresh individual drug stock solutions were made every 6 months). All 
standards were stored at -20 °C in the dark.  Mixed drug standards were made from 
aliquots of freshly made individual stock standards and used immediately or the solvent 
evaporated and the dried mixed standard stored at -20 °C until required. These mixed 
dried standards were later reconstituted in methanol (when used for spiking water 
samples before extraction) (section 2.4.3) or ethyl acetate (when used for instrumental 
validation studies) (section 2.5).  Un-extracted and extracted drug standards were 
derivatized and reconstituted in 0.05 to 0.1 mL ethyl acetate before GC-MS analysis. 
Alkane standards were made at concentrations of 1 mg/mL in pentane and further diluted 
to mixed working standards of 0.1 mg/mL and 0.01 mg/mL. Calibration of the pH meter 
was conducted with pH 4.0, 7.0 and 10.0 buffers (Table 2.2).  All research work was 
conducted in laboratories at Anglia Ruskin University, Cambridge, UK, which has a 
Schedule 1 Home Office ‘Licence to be in Possession’ provided under the Misuse of Drugs 
Act 1971. 
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Table 2.1: Derivatizing reagents and solvents used during research. 
 
 
Table 2.2: n-Alkanes and chemicals used during research. 
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Table 2.3: Drug standards used during research. 
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2.2   SAMPLE COLLECTION AND PREPARATION 
During the course of the method development, different water samples were used. Tap 
water was obtained from Anglia Ruskin laboratories. Deionized water was obtained from 
an Elga Purelab Option (Veolia, UK). All waste water influent and effluent samples were 
collected from Anglian Water in Cambridge, UK, in 1 L PET containers. Waste water 
samples used for preliminary studies (sections 2.4.3.2.2,  2.5.4 and 2.5.5) were grab and 
48 h composite influent and grab effluent samples randomly collected between March 
2011 and September 2012 while the sample used for quantification by standard addition 
(section 2.5.6) was a 72 h composite influent sample collected in September 2012.  After 
collection, the waste water samples were immediately transported in the dark to the 
laboratory, which was only a 10 minute drive away. 
 
Ethical approval for the research project was provided by the Research Ethics 
Subcommittee at Anglia Ruskin University, Cambridge, UK.  Since the waste water 
samples were collected from a WWTP and could not be linked to a particular individual or 
group, the project was given a ‘low risk’.  
 
Prior to extraction, waste water samples were vacuum filtered through a disposable 1 L 
capacity stericup funnel and receiver system with a 0.22 µm GP Millipore Express® Plus 
membrane (Millipore, UK).  Once filtered and before extraction or storage, the samples 
were acidified with 37 % HCl to pH 2.4 to 2.7. Samples were extracted on the day of 
collection, or either stored in the dark at 5 °C and extracted within 24 h of collection or at 
-20 °C and extracted within 3 months of collection.  Frozen samples were defrosted at      
5 °C and at room temperature. Samples were stored in PP and HDPE containers (Fisher 
Scientific, UK).  See also section 1.5.1 for further background on sample collection. 
 
A risk assessment for handling the waste water samples was conducted and approved 
before research began.  All handling of the waste water was conducted according to good 
laboratory practice for biological samples i.e. use of gloves when collecting samples, 
transporting samples in sealed containers, handling of samples in designated fume hoods 
labelled with ‘biological hazard’ (in the absence of other students), and disinfecting 
and/or autoclaving of all laboratory equipment and surfaces in contact with the samples 
before re-use or disposal. 
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Throughout the method development, evaporation of organic solvents and eluants with 
volumes ≤ 10 mL was conducted with a MiVAC DNA concentrator (Genevac, UK) at 
temperatures between 35 and 40 °C.  For volumes > 10 mL, evaporation was conducted 
on a rotary evaporator (Bibby Scientific Ltd, UK). 
 
2.3    GAS CHROMATOGRAPHY-MASS SPECTROMETRY (GC-MS) 
Instrumental parameters used during this research are listed in Table 2.4. 
 
Table 2.4: Instrumental parameters for GC-MS. 
 
 
Instrumental analysis was conducted on a Perkin Elmer Clarus 500 GC-MS. Two different 
types of columns were used during the method development, a Phenomenex ZB-1 
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column (30 m x 0.25 μm x 0.25 mm i.d.) used during early preliminary studies and a 
Supelco EquityTM-5 capillary column (30 m x 0.25 μm x 0.25 mm i.d.) used during later 
preliminary studies and method validation. The stationary phase on the ZB-1 column was 
100 % dimethylpolysiloxane while for the EquityTM-5 column it was 5 % 
diphenylpolysiloxane/95 % dimethylpolysiloxane. The carrier gas was helium (BOC,    
99.95 %) at a flow rate of 1 mL/min. The mass analyser was a single quadrupole. All data 
was collected, analysed and processed using TurboMass™ 5.4 GC-MS software.  Further 
instrumental settings are listed in Table 2.4. 
2.4    PRELIMINARY INVESTIGATIONS 
The following sections provide experimental procedures undertaken during preliminary 
investigations as discussed in Chapter 3. 
 
2.4.1   Chemical Derivatization 
2.4.1.1   Comparison of Derivatizing Reagents 
The various derivatizing reagents assessed during comparative investigations are listed in 
Table 2.5, together with the experimental parameters. 
 
Table 2.5: Derivatizing reagents and conditions used. 
 
 
In Table 2.5 Part A, a mixed drug standard containing aliquots of individual drugs taken 
from stock solutions was placed in six vials and evaporated to dryness. 0.2 mL of the 
derivatizing reagent was added into five of the vials and after the appropriate reaction 
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time, the derivatizing reagent was evaporated to dryness and the sample reconstituted in 
0.2 mL ethyl acetate resulting in a final drug concentration of 100 µg/mL. One vial was not 
derivatized but was evaporated and also reconstituted in 0.2 mL ethyl acetate. The drugs 
assessed under this study are listed in Table 3.1.  
 
In Table 2.5 Part B, a mixed drug standard containing aliquots of individual drugs taken 
from stock solutions was placed in two vials and evaporated to dryness. 0.2 mL of the 
derivatizing reagent was added into the vials and after the appropriate reaction time. 
PFPA was evaporated to dryness and the sample reconstituted in 0.2 mL ethyl acetate 
resulting in a final drug concentration of 100 µg/mL. BSTFA was not evaporated and the 
sample was analysed as is. The drugs assessed under this study are listed in Figures 3.3 
and 3.4.  
 
2.4.1.2   Optimisation of PFPA Derivatization Reactions  
After comparative derivatization studies, PFPA: ethyl acetate (2:1v/v) was selected for 
further optimisation studies (section 3.2.2). Table 2.6 lists the variables assessed under 
this section.  Internal standards added to the mixed drug standards prior to derivatization 
were COC-d3 at 25 µg/mL, MDMA-d5 and AMP-d6 at 20 µg/mL and MOR-d3 at 10 µg/mL. 
 
Table 2.6: Variables assessed during PFPA optimisation of a mixed drug standard. 
 
Drugs included in this study are shown in Figures 3.9, 3.10 and 3.11.  
 
2.4.1.3   Derivatization Reactions for a Mixed Opiate Standard 
Separate derivatization studies were conducted on a mixture of morphine and 6-MAM 
(section 3.2.3). Table 2.7 lists the variables assessed under this section. COC-d3 was used 
as the internal standard at a concentration of 16.67 µg/mL. 
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Table 2.7: Variables assessed during PFPA optimisation of a mixed opiate standard. 
 
 
2.4.1.4   Individual Analysis of MOR, 6-MAM and Heroin 
0.1 mL each of 100 µg/mL MOR, 6-MAM and heroin was derivatized at 90 °C for 30 min 
with 0.1 mL of PFPA: ethyl acetate (2:1v/v).  After evaporation of the derivatizing reagent, 
the drugs were individually reconstituted in 0.1 mL ethyl acetate. 
 
2.4.2   Stability Studies 
As part of the method development, different stability studies were conducted on the 
unextracted mixed drug standards. Table 2.8 lists the stability studies undertaken and 
experimental conditions used. 
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    Table 2.8: Methods and conditions for mixed drug standard stability studies. 
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Autosampler and derivatized storage stability was conducted on a PFPA-derivatized mixed 
standard reconstituted in ethyl acetate, while underivatized storage stability was 
conducted on a mixed drug standard in methanol.  For autosampler stability, the mixed 
drug standard was divided into 23 vials and analysed over a 27 h period, with a solvent 
blank injected between each sample injection. For each storage stability trial, the same 
initial mixed drug standard was divided into two separate vials and stored at the different 
temperatures.  Three aliquots from each temperature were analysed at the relevant time 
points. 
 
The analysis time point indicates the time intervals at which the storage stability samples 
were analysed with, ‘0’ denoting the initial time point. 
 
2.4.3   Analyte Extraction Methods 
LLE and SPE techniques were both explored during preliminary studies in order to 
determine the most suitable extraction method for the target analytes. 
 
2.4.3.1   Liquid-liquid Extraction (LLE) 
Different extraction solvents and varying pH values were assessed for LLE to determine 
which would be the most suitable for the target analytes. 
 
2.4.3.1.1   Selection of Extraction Solvent 
The two different LLE extraction protocols investigated during preliminary studies were 
adapted from Tsutsumi (2005) and Raikos (2009). These were based on 
chloroform:isopropyl alcohol (3:1, v/v) and chloroform:ethyl acetate:ethanol (3:1:1, v/v), 
respectively. A 2 mL aliquot of deionised water was spiked with a mixed drug standard 
containing 26 drugs and 3 internal standards MDMA-d5, COC-d3 and MOR-d3 (with 
individual drugs ranging in concentration from 0.6 to 2.8 µg/mL). The pH was adjusted to 
10.5 with 35 % NH4OH. A 5 mL aliquot of extraction solvent (3 fractions) was used and the 
mixture was vortexed for 1 min then centrifuged at 3000 x gr for 5 min. The organic layer 
was evaporated to dryness after which it was derivatized and reconstituted in 0.1 mL 
ethyl acetate.  In order to enable the calculation of recovery, a similar unextracted mixed 
drug standard was evaporated, derivatized and reconstituted in ethyl acetate.  Drugs 
included in this study are listed in Table 3.7. 
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2.4.3.1.2   Optimisation of pH 
Extraction recovery using chloroform:ethylacetate:ethanol (3:1:1, v/v) was conducted on 
150 mL deionized water spiked with a mixed drug standard containing 26 drugs with 
individual drugs ranging in concentration from 2.5 to 4.7 µg/mL (except 2-FPP at             
6.6 µg/mL).  The internal standards MDMA-d5 and MOR-d3 were added at concentrations 
of 0.17 µg/mL while COC-d3 was added at a concentration of 1.7 µg/mL.  pH values of 5.0, 
7.0 and 10.5 were investigated.  The pH was adjusted with 35 % NH4OH or 37 % HCl. A 
250 mL separating funnel and 30 mL of extraction solvent (3 fractions) were used. The 
mixture was agitated for at least 10 min and sodium sulfate was added to the organic 
layer to ensure removal of any residual moisture.  The organic layer was then filtered and 
the sulfate particulates rinsed with the extraction solvent.  Lastly, the organic layer was 
evaporated to dryness, derivatized and reconstituted in 0.1 mL ethyl acetate. Drugs 
included in this study are listed in Table 3.8. 
 
2.4.3.2   Solid Phase Extraction (SPE)  
SPE preliminary experiments concerned the selection of a suitable sorbent, sample pH 
and elution solvents for the drug analytes under investigation. A VisiprepTM Vacuum 
Manifold with 24 ports (Supelco, UK) was used for all extractions. Oasis®SPE cartridges 
(Waters, UK) were used for all extractions. 
 
2.4.3.2.1   Comparison of the SPE Sorbents, Oasis® MCX and HLB 
Oasis MCX and HLB sorbents were investigated at different pH values, as shown in Table 
2.9, using methods adapted from Waters (2006a), Bones (2007) and González-Mariño 
(2010). 150 mL of deionised water was spiked with a mixed drug standard containing 26 
drugs with individual drugs ranging in concentration from 2.5 to 4.7 µg/mL (except 2-FPP 
at 6.6 µg/mL).  The internal standards MDMA-d5 and MOR-d3 were added at 
concentrations of 0.17 µg/mL while COC-d3 was added at a concentration of 1.7 µg/mL. 
pH adjustment was made with 35 % NH4OH or 37 % HCl. Method blanks using unspiked 
deionised water samples and unextracted standards for recovery calculations were 
analysed simultaneously. The drugs included in this study are listed in Table 3.9. 
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Table 2.9: Protocols for solid phase extraction with Oasis MCX and HLB sorbents. 
 
2.4.3.2.2    Comparison of Elution Solvents for MCX at pH 2.0 
Using the MCX protocol in Table 2.9, two elution solvents were compared with each 
other; 5 % (v/v) NH4OH in methanol (Tarcomnicu, et al., 2011) and 5 % (v/v) NH4OH in 
acetone:ethyl acetate (1:1v/v) (Bones, et al., 2007). 
 
A mixed drug standard (individual drugs ranged in concentration from 0.81 to 1.3 µg/mL, 
except 3-FMC at 2.3 µg/mL) was spiked into 50 mL of waste water (pH 2.5) and extracted 
for each of the solvents. Internal standards AMP-d6, MDMA-d5 and COC-d3, all at 1 µg/mL, 
were added to the drug mix before extraction. Eluants were evaporated, derivatized and 
analysed. 
 
The drugs included in this study are shown in Figure 3.25.  The final SPE protocol used for 
validation studies and application to a waste water sample is listed in Table 2.10. 
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Table 2.10: Final protocol for solid phase extraction with Oasis MCX. 
 
2.5    METHOD VALIDATION STUDIES 
Method validation parameters, as discussed in section 1.8.1, were assessed by the use of 
a derivatized mixed working solution reconstituted in ethyl acetate as well as waste water 
spiked with known concentrations of analytes.  The derivatization and SPE protocols 
optimised during preliminary studies were used (Table 2.10 and section 3.2.4). 
 
2.5.1   Instrumental Linear Range 
The instrumental linear range was determined by dilution of a derivatized mixed drug 
standard prepared in ethyl acetate at concentrations ranging from 2.0 x 10-4 to 1.4 µg/mL.  
Triplicate analyses were conducted for each concentration point. Drugs included in this 
study are listed in Table 4.1. Internals standards were added at 0.07 µg/mL for AMP-d6, 
MDMA-d5, and COC-d3. 
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2.5.2   Precision (Intra-assay and Intermediate) 
Intra-assay precision of the instrument was determined over an 18 h period under the 
same instrumental conditions. Three concentrations of mixed drug standards (0.005, 0.1 
and 1 µg/mL) were assessed. 
 
Intra-assay precision of the analytical method was assessed over a 6 h period under the 
same instrumental conditions using a mixed drug standard spiked in 100 mL of treated 
waste water. Individual drugs ranged in concentration from 0.81 to 1.3 µg/mL, except 3-
FMC at 2.3 µg/mL. This study was incorporated as part of the extraction and recovery 
study (section 2.5.4). 
 
Intermediate precision of the instrument was verified at three concentrations (0.005, 0.1 
and 1 µg/mL) on three separate days. Drugs included in this study are listed in Tables 4.2, 
4.3 and 4.4. 
 
2.5.3   Instrumental Detection and Quantification Limits 
Instrument quantification and detection limits were determined by dilution of a 
derivatized mixed drug standard in ethyl acetate and measuring the detector response 
until a signal to noise ratio (S/N) of 10:1 (for LOQ) and 3:1 (for LOD) was attained.  This 
was accomplished through a function available in the Perkin Elmer Clarus 500 GC-MS 
TurboMass™ 5.4 software. Drugs included in this study are listed in Table 4.5. 
 
2.5.4   SPE Extraction and Recovery Using Optimised Instrumental Method 
Matrix-based recovery of the drugs from treated waste water was conducted using the 
SPE protocol in Table 2.10. 100 mL aliquots of treated waste water were spiked with a 
mixed drug standard before extraction (individual drugs ranged in concentration from 0.8 
to 1.3 µg/mL, except 3-FMC at 2.3 µg/mL). AMP-d6 (1 µg/mL), MDMA-d5 (1 µg/mL), & 
COC-d3 (1.5 µg/mL) were added as internal standards.  Separate 100 mL aliquots of waste 
water were spiked after elution for recovery calculations. Unextracted standards were 
also analysed as positive controls.  A further 100 mL aliquot of waste water was extracted 
and not spiked with any drugs pre- or post-extraction and was used as a background 
control sample. 
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The eluants were evaporated to dryness, derivatized and stored at -20 °C.  On the day of 
analysis, they were reconstituted in 0.1 mL ethyl acetate. Drugs included in this study are 
listed in Table 4.7. 
 
2.5.5   Matrix-based Stability 
The stability of the underivatized drugs in the sample matrix was investigated by spiking 
500 mL of untreated waste water (pH 2.5) with a mixed drug standard and dividing it into 
50 mL portions. Individual drugs ranged in concentration from 0.8 to 1.3 µg/mL, except   
3-FMC at 2.3 µg/mL. Internal standards AMP-d6, MDMA-d5 and COC-d3 were added at       
1 µg/mL. The portions were stored at 5 °C then extracted, derivatized and analysed at 
time points 0, 3 days and 7 days.  Drugs included in this study are listed in Table 4.8. 
 
2.5.6   Standard Addition  
A six point standard addition curve of drugs and internal standards (0.0003, 0.0022, 
0.0188, 0.2500, 1.0, 3.750 µg/mL) was prepared in untreated waste water before 
extraction and used for the quantification.  The drug standards were spiked into 25 mL of 
72 h composite waste water diluted 1:1 with deionised water to give a total volume of 50 
mL (section 2.2). Internal standards AMP-d6, MDMA-d5 and COC-d3 were added at 0.06 
µg/mL. Duplicate extractions of unspiked deionized water (method blank) and the same 
volume of waste water as the calibrators but spiked only with internal standards (matrix 
control) were also conducted. Drugs included in this study are as previously listed in  
Table 4.8. 
 
2.6   SYSTEM SUITABILITY TESTS (SST) AND QUALITY CONTROL (QC) 
Column performance and shifts in RT before, during and after a sample batch were 
assessed by the use of a GC column check standard (Phenomenex), a mixture of 10          
n-alkane standards (C8-C28, as shown in Table 2.2) as well as QC samples (0.1 µg/mL). 
The QC samples either contained a mixture of 3 of the target drugs plus an internal 
standard (piperazine, MDMA, MDMA-d5 and diazepam) or were positive controls 
containing all target drugs.  The alkane and QC standards were included at the beginning, 
middle and end of the batch (for long batches) and the beginning and end of a batch (for 
short batch runs).  Solvent blanks (i.e. ethyl acetate) were also run in-between sample 
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injections to check for carryover and any other anomalies such as contamination from GC 
septa or vial lids. 
 
The GC-MS instrument was subjected to regular tuning, mass calibration and 
maintenance (change of filament, liner, septum, column and needle as well as baking the 
column and cleaning the source) as necessary and comprehensive maintenance once a 
year. 
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CHAPTER THREE 
RESULTS AND DISCUSSION – PRELIMINARY STUDIES 
 
This chapter discusses the results obtained from preliminary studies undertaken prior 
to the method validation studies. Preliminary studies involved selecting and 
optimising the derivatizing reagent, the sample extraction method and stability 
studies to guide sample pre-treatment, preparation, storage and analysis. 
 
3.1   INTRODUCTION 
As one of the key aims of this research involved the development of a method to 
simultaneously analyse a number of drugs, all preliminary studies were conducted on 
mixed drug standards. However, mass spectra and ion ratios of individual derivatized 
and underivatized drugs were initially obtained in scan mode for comparison with 
mass spectra and ion ratios of the drugs in respective mixed standards.  In addition, 
mass spectra were compared with published literature or the National Institute of 
Standards and Technology (NIST) mass spectral search program [Version 2.0(2)]. To 
compensate for variability across the entire analytical process, sample preparation 
was done in duplicate or triplicate and internal standards were added to the mixed 
drug standards before various assays.  A background to the selection of internal 
standards used during this research can be found in Appendix IV. 
 
During method development, there are various factors that need to be considered in 
order to improve the sensitivity and selectivity of the method as well as ensure 
reliable and reproducible results.  Those related to sample preparation are discussed 
in sections 1.5 to 1.6 and 3.2 to 3.4, and those related to instrumental analysis are 
discussed in section 3.5. 
 
3.2   CHEMICAL DERIVATIZATION 
Based on the polar nature of the target drugs under investigation, an informed 
decision was made to derivatize the drugs in order to determine whether 
chromatographic and mass spectral parameters would be improved (section 1.6.1). 
Due to the different functional groups of the drugs (amine, hydroxyl and ester), the 
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most commonly used derivatizing reagents based on silylation and acylation were 
investigated. 
 
3.2.1   Comparison of Derivatizing Reagents 
Following the procedures as detailed in Table 2.5, Part A (section 2.4.1.1), five 
derivatizing reagents were investigated in order to determine the most suitable for 
the mixed drugs under investigation. Figures 3.1 and 3.2 show the TICs of drugs 
derivatized with PFPA and BSTFA (selected to represent acylation and silylation, 
respectively). A mixed standard was also analysed for comparative purposes and this 
is shown in Figure 3.6 (page 88).  During this initial investigation, ten drugs 
representing the different classes of drugs and RTs that would form part of the 
validated multianalyte method were assessed. 
 
The criteria used for the selection of most suitable derivatizing reagent was the 
presence of one derivative peak per original drug in the mixed standard, representing 
complete derivatization of the initial drug as confirmed by a comparison of mass 
spectra of the underivatized drugs with mass spectra of the expected derivatives 
(section 1.6.4), and the distinctiveness of mass spectra generated with higher m/z 
ratios (Halket, 1993).  Any extra peaks were evaluated as they could arise from 
artefacts, adducts or from underivatized drug.  Likewise, if fewer peaks were detected 
then the derivatization process was evaluated as it may not have been suitable for the 
drugs under analysis. In addition, when targeted diagnostic ions from underivatized 
drugs were detected, this indicated that the conversion process was incomplete (Mol, 
et al., 2000). 
 
COC and DIAZ do not get derivatized (section 1.6.1) and hence their RT and mass 
spectra remain the same in all chromatograms. Aside from the presence of peaks 
corresponding to underivatized EME (EME-UD) for both acylating and silylating 
reagents, the TICs for drugs derivatized by the acylating reagents had one derivative 
peak per original drug with no other additional peaks (Figure 3.1). 
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Figure 3.1: Total ion chromatogram of 10 PFPA-derivatized drugs reconstituted in ethyl acetate (UD = underivatized).
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Figure 3.2: Total ion chromatogram of 10 BSTFA-derivatized drugs reconstituted in ethyl acetate (UD = underivatized).
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On the other hand, drugs derivatized by silylation, especially BSTFA, had several extra 
unknown peaks in their TICs as well as peaks corresponding to underivatized AMP, 
MAMP and EME. For instance, the TIC for BSTFA had 19 peaks when only 11 drugs 
were in the original mixed standard (quinoline was initially added then discounted as 
an internal standard but is mentioned here as it contributed to the number of peaks 
observed). 
 
While evaporation of the derivatizing reagent and reconstitution of the derivatives in 
a suitable organic solvent prior to instrumental analysis is essential for acylating 
reagents, it is not always necessary for silylating reagents (sections 1.6.2 & 1.6.3).  
Silylating reagents can be analysed directly after the derivatization reaction or can be 
diluted with a suitable solvents such as ethyl acetate, prior to analysis or during the 
derivatization reaction (Blau & Darbre, 1993; Evershed, 1993; Migowska, et al., 2012; 
Kumirska, et al., 2013). However, since all excess derivatizing reagents (including the 
silylation reagents) were evaporated and the derivatives reconstituted in ethyl 
acetate, a decision was made to conduct additional derivatization reactions for PFPA 
and BSTFA, without dilution with ethyl acetate or evaporation of the derivatizing 
reagent for the latter (Table 2.5, Part B in section 2.4.1.1).  This was to eliminate any 
potential contribution of ethyl acetate to the presence of the underivatized products 
observed in the BSTFA TIC (Figure 3.1).  Analysis for both derivatization reagents was 
conducted on a mixed drug standard containing additional drugs (i.e. 27) to also 
factor in the effect of a higher number of drugs as may be found in a waste water 
influent sample. Some of the analytes, such as quinoline, methadone, 
benzoylecgonine and cannabis, were subsequently discounted as target analytes in 
order to focus on the NPS. The drugs included in the additional preliminary 
derivatization reactions are listed in Figures 3.3 and 3.4. 
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Figures 3.3 and 3.4 depict the chromatograms from the additional PFPA and BSTFA 
derivatization reaction, respectively.  While fully derivatized MOR and 6-MAM peaks 
were observed for BSTFA as compared to PFPA, which had incompletely derivatized 
MOR and 6-MAM peaks, the TIC for BSTFA still had a number of extra unknown peaks 
compared with PFPA. In addition, phenylethylamines, piperazines and cathinones, the 
key target analytes, were not derivatized with BSTFA but were completely derivatized 
with PFPA. The heroin peak was not observed in either chromatogram. 
 
Therefore, based on the number of derivative peaks observed and the higher number 
of completed derivatives for the key target analytes, the acylating reagents performed 
better than the silylating reagents, and were further assessed for suitability.   The 
silylating reagents were eliminated from the method development.  With multianalyte 
procedures, compromises are inevitable and therefore the derivatization reagent that 
gave better results for the emerging drugs of abuse (i.e. NPS) over the classic drugs of 
abuse was selected. 
 
However, BSTFA appeared to perform better for opioids and cannabinoids and this 
will be taken into consideration for future analyses that specifically target these 
compounds. 
 
To confirm whether PFPA was the most suitable of the acylating reagents, the RT and 
peak areas for the PFPA-, HFBA-, acetic anhydride:pyridine (AcAn:Pyr)-derivatives  and 
underivatized drugs are listed in Table 3.1. PFPA-derivatives had higher peak areas 
than both HFBA- and AcAn:Pyr-derivatives for all the drugs.  However, COC and DIAZ 
had higher peak areas in the underivatized chromatogram than for the acylated 
products.  As both COC and DIAZ do not have derivatizable groups, perhaps the 
derivatization process causes some degradation of these products e.g. hydrolysis in 
the presence of ethyl acetate and anhydride (PFPA). AcAn:Pyr did not have a peak 
corresponding to EME-UD indicating complete derivatization of EME in contrast to 
PFPA and HFBA in which EME-UD could still be detected.  MOR was not detected in 
the AcAn:Pyr and underivatized chromatogram indicating that derivatization with the 
appropriate reagent was particularly essential for its detection. Therefore, based on a 
combination of peak area and number of drugs fully derivatized, PFPA was the most 
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effective derivatizing reagent and could have been selected as the derivatizing 
reagent at this stage. 
 
Table 3.1: Retention time and peak area of acylated drug derivatives and  
underivatized drugs. 
 
 
86 
 
However, in addition to peak area it was necessary to also evaluate the selectivity of 
the m/z ions contributing to the peak areas for the acylating reagents.  Figure 3.5 
shows the mass spectra for acylation products for 4-MEOPP.   
 
 
Figure 3.5: Mass spectra of AcAn:Pyr-, HFBA- and PFPA-derivatives of 4-MEOPP. 
 
The quantifier ion for 4-MEOPP when AcAn:Pyr  is used as a derivatizing reagent is 
m/z 162 while that for HFBA and PFPA are m/z 338 and m/z 388, respectively. 
Therefore, the mass spectra for PFPA- and HFBA-derivatives resulted in ions with 
higher m/z values than for AcAn:Pyr. This was seen to be an advantage especially 
since waste water contains a multitude of unknown compounds and the aim was to 
try and distinguish the target drugs from other matrix components, after extraction 
and derivatization, to aid with positive identification. 
 
Overall, the fragmentation patterns for PFPA and HFBA were very similar differing 
only in the last two m/z ions.  In the example of 4-MEOPP, PFPA- and HFBA-
derivatives  share the 56, 120, 135 and 191 m/z ions but differ in the molecular ion 
m/z i.e. 338 and 388, respectively.  As a result, PFPA was selected as the derivatizing 
reagent based on a combination of highest peak areas (intensity) and mass spectra 
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that were distinctive enough. Other observations made that helped guide the 
selection of PFPA for derivatization were that PFPA-products had the lowest RTs 
(Table 5.1), which help reduce the analysis time, and evaporation of the derivatizing 
reagent took half the time of that for the AcAn:Pyr mixture. 
 
To further confirm the informed decision to proceed with derivatization as opposed to 
not derivatizing at all, the TIC and mass spectra of PFPA-derivatized and underivatized 
drugs was compared (Figure 3.6). 
 
Aside from the higher intensity of the PFPA-derivatized peaks (Table 3.1), the method 
resulted in peak separation for all 11 analytes (including quinoline).   In addition, the 
RT increased as a result of a higher molar mass and hence slightly longer interaction of 
the drug with the stationary phase. 
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An example of the derivatization reaction for BZP showing a higher molar mass of the 
derivative is depicted in Figure 3.7.  The molar masses of derivatives for the remaining 
target analytes can be found in Appendix VI a-f.  
 
 
Figure 3.7: PFPA derivatization reaction for BZP showing increased molar mass of 
derivative. 
 
In addition to higher peak areas, derivatization led to improved peak shape and mass 
spectra as opposed to underivatized drugs.  This is depicted in Figure 3.8, using  
4-TFMPP as an example. 
 
 
Figure 3.8: Total ion chromatogram and mass spectra for underivatized  
(A1 and A2) and derivatized (B1 and B2) 4-TFMPP showing improved  
peak shape and mass spectrum for the latter. 
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In summary, PFPA was selected as the derivatizing reagent based on a combination of 
highest peak areas (intensity), one derivative per drug added, mass spectra that were 
distinctive enough to enable selectivity in complex matrices, better peak shape 
(versus underivatized) and lowest RT. 
 
After selection of PFPA as the derivatization reagent for the method under 
development, the next step was to optimise the reaction temperature and time for 
the target drugs.  The results are discussed in section 3.2.2. 
 
3.2.2   Optimisation of PFPA Derivatization Reactions  
Since earlier PFPA derivatization studies conducted at 70 °C for 60 min had not 
resulted in the complete derivatization of EME (Table 3.1 and Figure 3.1), a decision 
was taken to perform further derivatization studies at higher reaction temperatures 
of 80 and 90 °C. The aim of selecting higher temperatures was, therefore, an attempt 
to improve the degree of conversion as well as reduce the derivatizing time. 
 
Following the procedures as detailed in section 2.4.1.2, Figures 3.9, 3.10 and 3.11 
depicts the results of drugs and internal standards derivatized at 80 and 90 °C. The 
derivatization reaction was regarded as complete when there was no change in peak 
area with increasing time at each temperature (Lacina, et al., 2013). In addition, the 
number of peaks in the chromatogram and the presence of relevant diagnostic ions 
for the derivatives were used to assess the completion of the derivatization reaction 
(section 1.6.4). 
 
In the chromatogram for the drugs and internal standards derivatized at 80 °C (Figure 
3.9), the majority of peak areas continued to increase with time indicating that 
perhaps the derivatization reaction was still progressing even after 45 min. The only 
exceptions were 4-MPP and 4-MEOPP which were fully derivatized by 15 min.  When 
derivatized at 90 °C (Figure 3.10), most drugs and internal standards, including EME, 
had been fully derivatized by 30 min indicating complete derivatization.  Figure 3.11 
shows the expanded graphs for 3-FMC. The opioids (MOR, 6-MAM and heroin) were 
not detected at 80 and 90 °C during this derivatization trial, possibly due to low 
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instrumental response, and hence were analysed separately to better understand 
their interactions (section 3.2.3). 
 
Since internal standards would subsequently be used in the calculation of the peak 
area ratio (PAR), the internal standard itself needs to be completely derivatized under 
the conditions of testing in order to obtain reliably quantifiable results.  The internal 
standards, AMP-d6, MDMA-d5, COC-d3, and MOR-d3 were added to the mixed drug 
standard and evaluated simultaneously as detailed in section 2.4.1.2. The graphs from 
the derivatization of the internal standards are included in Figures 3.9 and 3.10. At   
80 °C, the peak areas for AMP-d6, MDMA-d5, and COC-d3 also increased with 
derivatization time even up to 45 min (COC-d3 was included in the study even though 
it does not get derivatized).  At 90 °C the maximum peak area was achieved by the 30 
min reaction time for AMP-d6, MDMA-d5, and COC-d3. Although MOR-d3 was also 
added, it was not detected as per other opioids (section 3.2.2). Therefore, these 
results indicate that the internal standards, AMP-d6 and MDMA-d5 were fully 
derivatized at 90 °C after a 30 min reaction time (the same time as the drugs in the 
mixed standard) and hence were suitable for use in calculating the PAR. The use of 
the PAR of the target analytes, with respect to their assigned internal standard, is 
standard practice and has been used in various publications to assess different 
validation parameters and for quantification (Al-Asmari & Anderson, 2007; Saito, et 
al., 2007; Capriotti, et al., 2013; Furey, et al., 2013; Belsey, et al., 2014; Carmona, et 
al., 2014; Kankaanpää, et al., 2014; Negreira, et al., 2014) 
 
The use of high reaction temperature was a concern as the stability of PFPA and the 
drugs at that temperature had not been evaluated by the author.  However, based on 
the work of other researchers who derivatized similar drugs at 90 °C and 100 °C using 
PFPA (Wang, et al., 2006; Damm, et al., 2009) as well as the evaluation of the reaction 
products (one single derivative, high peak area) during this research, the PFPA 
derivatives were considered to be stable at the reaction conditions. 
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Figure 3.9: Graphs showing derivatization optimisation results for various drugs  
at 80 °C. Error bars represent standard deviation at n = 3. 
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Figure 3.10: Graphs showing derivatization optimisation results for various  
drugs at 90 °C. Error bars represent standard deviation at n = 3. 
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Figure 3.11: Graphs showing derivatization optimisation results for 3-FMC.  
Error bars represent standard deviation at n = 3. 
 
Therefore, in this research, optimisation of derivatization was conducted by varying 
the reaction temperature and time and finding the optimal combination of these two 
factors (Kumirska, et al., 2013; Lacina, et al., 2013). Based on the results from the 
detected drugs in the mixed standard (the exceptions were MOR, 6-MAM and heroin), 
the derivatization conditions of 90 °C for 30 min was selected as the most suitable for 
the method under development. 
 
3.2.3   Derivatization Reactions for a Mixed Opiate Standard 
Since all opioids were not detected in the derivatization optimisation studies for the 
mixed drug standard (section 3.2.2), a decision was made to further investigate the 
derivatization reactions for opioids (MOR, 6-MAM and heroin) separately as these 
were essential target drugs and metabolites for quantification in waste water. 
 
Following the procedures as detailed in section 2.4.1.3, the RT and diagnostic ions of 
the opiate drugs and derivatives are listed in Table 3.2.  In this first part of the opiates 
derivatization trial, only MOR and 6-MAM were included in the mixture. Heroin was 
excluded so as to remove its possible contribution to both MOR and 6-MAM through 
hydrolysis (Guillot, et al., 1997). 
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Table 3.2: Retention time and diagnostic ions of opiate drugs and derivatives. 
 
 
Four peaks were observed in the chromatogram at different RTs (Table 3.2). Mass 
spectra (SIM) of the peaks corresponded with diagnostic ions for MOR-2PFP, MOR-
PFP, 6-MAM-PFP and 6-MAM even after a 60 min reaction time. 
 
MOR has two derivatizable sites (Fig 1.3). When both sites are derivatized, this is 
denoted as -2PFP and when only one site is derivatized, this is denoted as –PFP.  The 
mass spectra and proposed fragmentation pattern for both MOR-2PFP and MOR-PFP 
are depicted in Figure 3.12. 
 
 
Figure 3.12: Mass spectra and fragmentation patterns for MOR-2PFP and MOR-PFP. 
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In addition, the PAR for 6-MAM-PFP, 6-MAM, MOR-2PFP and MOR-PFP was plotted 
against the reaction time and the results are depicted in Figure 3.13. The PAR was 
calculated by dividing the peak area of the drug with the peak area of the internal 
standard. In this instance, COC-d3 was used as the internal standard for the calculation 
of PAR since MOR-d3 was also not detected in earlier studies (section 3.22). 
 
 
Figure 3.13: Graphs of PAR versus reaction time for (A) 6-MAM-PFP and 6-MAM and 
(B) MOR-2PFP and MOR-PFP.  Error bars represent standard deviation at n=3. 
 
All four compounds reach their maximum PAR at 30 min after which the PAR 
decreases, possibly due to degradation. Greater standard deviations were observed 
for fully derivatized morphine (MOR-2PFP) and 6-monoacetylmorphine (6-MAM-PFP), 
especially at 30 min possibly due to degradation reactions being more pronounced at 
the 30 min time point leading to greater fluctuations in detector response.   However, 
higher PARs occurred for the fully derivatized analogues (6-MAM-PFP and MOR-2PFP) 
than for the underivatized (6-MAM) or partially derivatized (MOR-PFP) analogues 
throughout the time frame of analysis. This would indicate that at any one time during 
the reaction, the derivatized analogues were present at much higher concentration 
(indicated by the PAR) than the underivatized analogues and therefore the reaction 
favoured the fully derivatized product.  This has been represented in Figures 3.14 and 
3.16-B. 
 
Two possible explanations are suggested by the author for the observance of both 
underivatized and derivatized 6-monoacetylmorphine (6-MAM and 6-MAM-PFP, 
respectively). These are depicted in Figures 3.14 and 3.15. 
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Figure 3.14: Proposed partial acetylation of MOR to 6-MAM in the presence of ethyl 
acetate. 
 
In Figure 3.14, the MOR present in the mixture is partially acetylated to 6-MAM with 
ethanol as a side-product. As no heroin was detected, it is unlikely that further 
acetylation occurred to form heroin (unless it was present below the LOD). 
 
 
Figure 3.15: Proposed reversible reaction between underivatized 6-MAM and  
the derivatized product (6-MAM-PFP). 
 
In Figure 3.15, the reaction between 6-MAM and the acylating agent is reversible, 
leading to a mixture containing both derivatized and underivatized products. 
 
With regard to morphine, the presence of both partially derivatized (MOR-PFP) and 
fully derivatized (MOR-2PFP) products suggest the following: (1) partial derivatization 
of MOR; (2) de-acetylation of MOR-2PFP to MOR-PFP.  These reactions are depicted in 
Figure 3.16 as A and B, respectively. 
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Figure 3.16: Proposed partial (MOR-PFP) and full (MOR-2PFP) derivatization of 
morphine. 
 
Since no underivatized MOR was detected, the most likely explanation for the 
presence of MOR-PFP is therefore cleavage of one -PFP moiety from MOR-2PFP in a 
reversible reaction (B in Figure 3.16). 
 
3.2.3.1   Individual Analysis of MOR, 6-MAM and Heroin 
To understand whether the observations mentioned above were once-off or regular 
occurrences, the opioids, MOR, 6-MAM and heroin, were analysed individually at 
much higher concentrations (100 µg/mL) according to the procedure in section 
2.4.1.4.  The chromatograms were assessed for all peaks as observed in Table 3.2 plus 
the heroin diagnostic ions m/z 327 and 369.  Similar results as discussed above 
(Section 3.2.3) were observed. For the morphine standard, MOR-2PFP was found to 
occur together with MOR-PFP confirming the reaction in Figure 3.16-B. Heroin does 
not have derivatizable functional groups (Figure 3.6) but it was found to occur with 
underivatized 6-monoacetylmorphine (6-MAM). This indicates that heroin had most 
likely undergone hydrolysis to 6-MAM (Figure 3.17). 
 
 
Figure 3.17: Hydrolysis of heroin to 6-MAM.  
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With regard to 6-MAM, both 6-MAM-PFP and 6-MAM were detected confirming 
earlier suggestions of the cleavage of the -PFP moiety (Figure 3.15).  Therefore, 
underivatized 6-MAM occurred when both heroin and 6-MAM-PFP were analysed 
separately indicating that hydrolysis to 6-MAM was the favoured reaction (Huizer & 
Poortman, 1989). 
 
The opioids investigated have hydroxyl and/or ester functional groups, which are 
prone to transacetylation, hydrolysis or esterification when dissolved in methanol or 
ethyl acetate and injected into the GC-MS, depending on which other drugs are 
present in the mixture. Heroin has long been known to hydrolyse to 6-MAM or MOR 
(Fig 3.17) during GC-MS analysis due to various factors such as the solvent used, 
derivatization reagent used, injection process, use of glass wool in the injection liners 
and the presence of oxygen or water in the carrier gas (Huizer & Poortman, 1989; 
Guillot, et al., 1997; Cole, 2003; Flanagan, et al., 2007). On the other hand MOR is 
known to undergo esterification to 6-MAM or heroin (Fig 3.14) (Flanagan, et al., 
2007).  Although published hydrolysis and esterification reactions have been reported 
for underivatized opioids especially when methanol is used as a solvent, observations 
from this research indicate that these reactions also occur even when MOR and         
6-MAM are derivatized with PFPA in the presence of ethyl acetate. Both methanol 
and ethyl acetate are commonly used as reconstitution solvents for GC-MS analysis 
after evaporation of the acylation reagent (Baptista, et al., 2002; Damm, et al., 2009; 
Migowska, et al., 2012).  The reactions depicted in Figures 3.14 to 3.16 are theoretical 
proposals based on observations made during this research and the exact reaction 
mechanism is unknown at the time of writing of this thesis. However, suggestions 
include the influence of PFPA, use of glass wool in injection liners and ethyl acetate 
(Huizer & Poortman, 1989). 
 
Therefore, what was initially thought as incomplete derivatization of MOR, and  
6-MAM could very well be due to transacetylation, esterification and hydrolysis 
reactions. These reactions can result in fluctuations in the concentration of opioids 
and lead to under or over-reporting of concentrations depending on which reaction is 
occurring at the time of analysis.  Some suggestions of avoiding transacetylation are 
by using silylating agents for derivatization (Huizer & Poortman, 1989) or using         
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on-column injection or programmable temperature injection to avoid degradation 
during injection (Guillot, et al., 1997). These unwanted reactions observed for the 
opioids were discovered later on during the method development and may account 
for some of the observations made during stability and recovery studies as discussed 
in sections 3.3 and 3.4.2.1, respectively.  As noted earlier on in this section, although 
the PARs for the derivatized products were much higher than for the underivatized 
products (Figure 3.14), the impact of these reactions on the total amount of MOR 
detected would need to be taken into consideration.  Further work would take 
account of these reactions and the suggested ways of reducing or preventing them. 
 
3.2.4   Final Derivatization Conditions 
In light of the results obtained in sections 3.2.2 and 3.2.3 above, the optimal 
derivatization conditions for the drugs under analysis and their respective internal 
standards were: 0.1 mL PFPA: ethyl acetate (2:1 v/v) at 90 °C for 30 min.  The final 
derivatization conditions were the most ideal for the mixed drug standard but not 
necessarily the best for some individual drugs. For instance, most drugs could have 
been derivatized at 70 °C or 80 °C for 15-30 min (Dickson, et al., 2010a) but the 
presence of EME, MOR and 6-MAM which were not fully derivatized (or as later found 
out were undergoing degradation reactions) meant a higher temperature of 90 °C was 
used. 
 
3.2.5   Diagnostic Ions and Mass Spectra 
Figure 3.18 depicts the TIC of the PFPA-derivatized drugs and their internal standards. 
The careful evaluation of chromatograms for extra peaks was continually made 
throughout the method development to ensure the optimised method was suitable 
even when different concentrations and combinations of drugs were used. As 
indicated in Figure 3.18, extra peaks could be due to underivatized drugs, column 
bleed, artefacts or adducts and hence they needed to be categorized. 
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Table 3.3 lists the RT, retention index (RI), internal standards and diagnostic ions for 
the PFPA-derivatized drugs which were used during preliminary studies, method 
validation (Chapter 6) and standard addition (Chapter 7). 
 
Table 3.3: Retention time, retention index, internal standard and diagnostic ions for 
derivatized drugs. 
 
 
The RI was calculated based on Kovat’s retention index formula for linear temperature 
programing as shown in Appendix V. The reproducibility of the method is shown by 
comparison with earlier chromatographic data in which the RI differs by < 0.40 % even 
though different GC-MS parameters were used (see Mwenesongole, et al., 2012, in 
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Appendix I b, Table 4, page 160). Further identification and confirmation of target 
drugs within spiked and unspiked samples was based on a RT or RI within ± 0.2 min or 
1 % of the reference standard (WADA, 2003) and at least one ion ratio within ± 20% of 
the reference standard (EC, 2002; Cooper, et al., 2010; van de Steene, et al., 2010; 
Baker & Kasprzyk-Hordern, 2011a; Trinh, et al., 2011; Migowska, et al., 2012). 
 
The corresponding mass spectra and proposed fragmentation patterns for all drugs 
analysed can be found in Appendix VI a-f, some examples of which are provided in 
Figures 3.19 and 3.20.  Although some researchers monitored only 2 diagnostic ions 
(Migowska, et al., 2012; Kumirska, et al., 2013), in this thesis at least 3 diagnostic ions 
(one quantifier and at least two confirmation ions) were monitored to improve the 
reliability in identifying and confirming the detected drugs (WADA, 2003).  Using 3 
diagnostic ions would also enable a minimum of 1 ion ratio for identification according 
to recommended guidelines (EC, 2002). The diagnostic ions were selected based on a 
combination of the most abundant ions and those with a high relative molar mass as 
per their mass spectral patterns. The ion with the highest relative abundance was 
used for quantification (Tarcomnicu, et al., 2011; Racamonde, et al., 2013).  
References for some of the spectra and/or diagnostic ions for PFPA-derivatized drugs 
can be found in literature as indicated in Table 3.3.  However, reference spectra 
and/or diagnostic ions could not be found for over half of the drugs especially for the 
NPS (i.e. piperazines and cathinones).  Therefore, as far as the author is aware, this is 
the first time PFPA spectra and diagnostic ions have been reported for drugs such as 
CAT, 3-FMC, MCAT, 2 and 4-FPP, 4-MPP, MBZP, 2-and 4-MEOPP, and BUTY.  The 
diagnostic ions for these and other drugs have recently been published 
(Mwenesongole, et al., 2012 & 2013). Since the molecular structure of the derivatized 
and underivatized NPS were known (Fig 3.7), the mass fragmentation pattern could be 
predicted based on various theoretical rules related to the interpretation of mass 
spectra (Watson & Sparkman, 2007). 
 
3.2.5.1    Peak Separation and Isomers 
As shown in Table 3.3 and Figure 3.18, all peaks were separated from each other apart 
from partial co-elution between BZP and 4-FPP and MBDB and 4-TFMPP. The internal 
standards (AMP-d6, MDMA-d5, COC-d3 and MOR-d3) also co-eluted with their 
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respective undeuterated analogues.  However, the extracted or SIM diagnostic ions 
for the co-eluting compounds were different and hence could be distinguished from 
each other (Table 3.3).  The mass spectra for MBDB and 4-TFMPP, together with their 
proposed fragmentation patterns, are depicted in Figure 3.19. Although they co-elute, 
their diagnostic ions are sufficiently different to maintain selectivity and enable 
independent quantification since a different quantifier (not present in the other drug) 
is used for each drug. 
 
 
Figure 3.19: Mass spectra and proposed fragmentation patterns for MBDB and        
4-TFMPP showing different diagnostic ions. 
 
In addition, there were four sets of constitutional isomers included in the method i.e.   
2-FPP/4-FPP, 3-TFMPP/4-TFMPP, 2-MEOPP/ 4-MEOPP and BZP/4-MPP.  These 
constitutional isomers have similar mass spectral patterns and hence quantification 
would be difficult if they occurred at the same RT since they would share the same 
m/z ions. However, all these isomeric pairings occurred at different RT and could 
therefore be independently quantified (Table 3.3).  The similarity in the mass spectral 
patterns for 2-MEOPP and 4-MEOPP is depicted in Figure 3.20.  Although they share 
the same quantifier ion m/z 338, the mass spectrum for 4-MEOPP has a higher 
abundance of the m/z 323 ion (triangulated) which would result in different ion ratios 
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when used in calculations and hence can be used for identification purposes if for 
some reason the actual isomer included in the drug mix was unknown (e.g. in the case 
of an unmarked sample or labelling error). 
 
 
Figure 3.20: Mass spectra and proposed fragmentation patterns for the 
constitutional isomers 2-MEOPP and 4-MEOPP. 
 
Therefore, despite the presence of co-eluting compounds and isomers, the developed 
method was selective enough to enable reliable quantification as evidenced by the 
results from the application of the method (Chapter 5). 
 
3.2.6   PFPA Derivatives – Novel in Sewage Epidemiology 
This is the first time, as far as the author is aware, that derivatization with PFPA has 
been reported for sewage epidemiological studies on illicit drugs. The majority of 
research in the field of sewage epidemiology has been conducted with LC-MS and 
therefore derivatization has not been necessary.  The few researchers that have used 
GC-MS have used alkylation (Verenitech, et al., 2006), silylation (Mari, et al., 2009; 
Sebok, et al., 2009; González-Mariño, et al., 2010; Lacina, et al., 2013) and iso-
butylchloroformate (Racamonde, et al., 2013).  In preliminary trials, Gonzalez-Marino 
(2010) had investigated various silylating reagents and found MSTFA to be the most 
suitable for the target analytes. However, they acknowledged that MSTFA derivatives 
106 
 
had low m/z values for amphetamines and a single product ion in MS/MS results 
which could lead to false positives or negatives when identifying analytes from a 
complex matrix.  The higher m/z values produced by derivatization with PFPA as well 
as more distinct mass spectral patterns (more ions with abundances greater than  
50 %) can therefore lead to more reliable positive identification of analytes in complex 
matrices. In order to increase the sensitivity of the method and thereby improve the 
detection of the target analytes within a complex matrix such as untreated waste 
water, splitless injection and SIM using the selected diagnostic ions in retention time 
windows was incorporated into the method validation (section 3.5.1). 
 
3.3   STABILITY STUDIES 
Determining the appropriate analysis and storage conditions that prevent the 
degradation of the drugs throughout the analytical process is essential for reliable 
quantitative analysis. Stability studies were conducted on derivatized and 
underivatized mixed drug standards according to the procedures as detailed in section 
2.4.2 and Table 2.8. 
 
3.3.1   27 Hour Autosampler Stability of a Derivatized Mixed Standard 
Autosampler stability study was conducted on a derivatized mixed drug standard in 
order to determine the stability of the analytes during instrumental analysis. The 
stability was evaluated by regression analysis on a plot of PAR against the injection 
time. Instability was indicated by a negative slope, significantly different from zero  
(p ≤ 0.05) (Saar, et al., 2010).  Statistical analysis was done with Microsoft Excel 2010© 
and GraphPad Prism 4.03©. 
 
Figure 3.21 shows the plots from the analysis of EME and MAMP as examples.  Plots 
of all drugs can be found in Appendix VII a-g. Based on the results, slopes from 23 of 
the drugs, including MAMP were not significantly different from zero (p ≤ 0.05) 
indicating stability during the 27 h analysis period. These include the newer drugs of 
abuse BZP, BUTY, 4-FMA, 3-FMC, 2-FPP, 4-FPP, MEPH, 3-TFMPP, 4-TFMPP, 4-MPP, 
KET, 2-MEOPP, 4-MEOPP, and MBZP. However, EME (shown in Figure 3.21), 6-MAM 
and heroin had slopes significantly different from zero indicating instability. This is 
indicated by the higher correlation coefficient for EME (0.5431), 6-MAM (0.4042) and 
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heroin (0.4094) compared with the rest of the drugs as shown in Table 3.4, which lists 
the slopes and correlation coefficient (R2) from the linear regression equation. 
 
 
Figure 3.21: Graphs of PAR versus injection time for EME and MAMP, 
including R2 and regression equation, n=24. 
 
Aside from EME, it is interesting to note that the drugs which were found to be 
unstable are the same drugs which were observed to undergo degradation reactions 
during the PFPA optimisation studies (section 3.2.3).  Therefore, the degradation 
reactions played a role in the autosampler instability of 6-MAM and heroin.  EME is 
known to undergo hydrolysis to ecgonine and this could be the reason for the 
observed instability (Castiglioni, et al., 2008; Gheorghe, et al., 2008). 
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Table 3.4: Correlation coefficients (R2), slopes and p-values for autosampler stability. 
 
 
Since the internal standards MDMA-d5, COC-d3 and MOR-d3 were used in calculating 
the PAR, they were added to the mixed drug standard prior to derivatization and their 
PAR assessed against each other as shown in Figure 3.22. 
 
For example, the PAR for MDMA-d5 was calculated using COC-d3 and MOR-d3 and the 
results plotted against the injection time. MDMA-d5 and COC-d3 had fewer 
fluctuations in PAR when used against each other but MOR-d3 caused greater 
fluctuations in PAR wherever it was used. Therefore, MOR-d3 was eliminated from use 
as an internal standard for MOR, 6-MAM and heroin due to its instability and the PAR 
for these drugs was re-calculated using COC-d3.  As well as its proximity, in terms of 
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RT, to the opioids, COC-d3 was seen as a suitable replacement because it also had 
similar functional groups (ester and tertiary amine groups) (see Figure 1.3 and Table 
3.3). 
 
 
Figure 3.22: Graphs of PAR versus injection time for MDMA-d5, COC-d3 and MOR-d3.  
 
Based on these results, for overnight runs on the GC-MS instrument, sample vials 
were kept refrigerated and put on the autosampler to ensure that they would not 
stand for more than 20 h before injection. 
 
3.3.2   4 Week Storage Stability of a Derivatized Mixed Standard 
In case of unforeseen circumstances such as instrument breakdown, sometimes 
derivatized samples may need to be stored for several days or weeks.  Therefore, 
longer term stability of PFPA derivatives was also determined over a 4 week period 
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(Table 2.8). The change in PAR from time point zero was used to evaluate the stability. 
Data was analysed and interpreted as: a loss of < 15 % is considered stable (denoted 
as 1), a loss of ≥ 15 - ≤ 30 % is considered moderately stable (denoted as 2) and a loss 
of > 30 % is considered unstable (denoted as 3) (Saar, et al., 2012). Statistical analysis 
was conducted with Microsoft Excel 2010©. The results are summarized in Table 3.5. 
 
Table 3.5: PAR change (%) for 4-week storage stability of a derivatized mixed 
standard. 
 
 
According to the tabulated results, all investigated drugs were stable to moderately 
stable for up to 2 weeks at -20 °C while only EME and DIAZ showed instability after 2 
weeks at 5 °C. After 4 weeks of storage, EME, BZP, 4-FPP, 4-MPP, 2- and 4-MEOPP,    
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3-CPP, DIAZ and heroin showed instability at both temperatures (including 6-MAM at 
5 °C). The overall percentage change in PAR at both temperatures ranged from            
1 – 14 % for the majority of drugs indicating stability.  However, EME showed the 
most dramatic change in PAR at 86 % after 2 weeks and by 98 % at 4 weeks when 
stored at 5 °C. When stored at -20 °C, the change in PAR was 28 % and 51 % at 2 and 4 
weeks, respectively. This can be attributed to hydrolysis reactions as stated in section 
3.3.1. 
 
On the other hand, MAMP, which showed stability throughout the study period at 
both temperatures, had overall percentage changes in PAR ranging from 2 to 13 %.  
Figure 3.23 depicts plots of the PAR against analysis time point for EME and MAMP. 
 
 
Figure 3.23: PAR versus analysis time point for EME and MAMP. 
Error bars represent standard deviation at n = 3. 
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The other unstable drugs mentioned above showed percentage PAR changes ranging 
from 30 - 51 % for storage at 5 °C and 39 - 64 % or storage at -20 °C. 
 
Therefore, the majority of PFPA-derivatized drugs, dissolved in ethyl acetate and 
investigated in this research, can be stored up to 4 weeks without any significant 
degradation at both 5 and -20 °C.  However, the degradation observed for EME and 
DIAZ at 5 °C was enough to ensure that drugs were stored at -20 °C throughout the 
method development.  Since more drugs showed instability after 4 weeks storage at 
both temperatures, it is not advisable to store the investigated drugs for longer than 2 
weeks in ethyl acetate. In practice, during this research, derivatized samples in ethyl 
acetate were never stored for more than 1 week and hence the two week cut-off was 
more than adequate.  In comparison with published literature for different 
derivatizing reagents, Gonzalez-Marino (2010) reports silylated derivatives of similar 
drug classes to be stable for up to a week at -20 °C while Kosjek (2012) reports 
acylated benzodiazepines to be stable for up to 2 weeks.  However, both research 
groups do not mention the acceptance criteria for stability and in the latter example 
even the storage conditions are not mentioned. 
 
3.3.3   4 Week Storage Stability of an Underivatized Mixed Standard 
In order to determine how long mixed drug standards could be stored before being 
used, a 4 week stability study of the underivatized mixed drug standards stored  in 
methanol was conducted (Table 4.8).   The samples were only derivatized after 
removal from storage immediately prior to analysis at time points zero and 4 weeks.  
Evaluation of stability was as stated in section 3.3.2. The results are summarized in 
Table 3.6. 
 
All drugs were stable to moderately stable when stored at -20 °C for 4 weeks except 
for 3-FMC.  At 5 °C, all drugs were stable to moderately stable except 3-FMC, MEPH 
and heroin.  In fact, 3-FMC was not detected at 5 °C. 
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Table 3.6: PAR change (%) for 4-week storage stability of an  
underivatized mixed standard. 
 
 
A notable difference in stability was observed for heroin at the two storage 
temperatures. Figure 3.22 compares the stability of heroin and 3-TFMPP.  Heroin had  
degraded by 43 % of its original PAR when stored at 5 °C and by only 1 % when stored  
at -20 °C.  On the other hand, after 4 weeks of storage 3-TFMPP had degraded by 12 % 
at 5 °C and 8 % at -20 °C.  Therefore, for heroin, storage at -20 °C or lower is 
imperative.  In addition, EME, which was only moderately stable when stored as the 
PFPA-derivative in ethyl acetate at -20 °C for 2 weeks, was stable when stored  
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underivatized in methanol. Therefore EME possibly also undergoes degradation 
reactions in ethyl acetate similar to the opioids. 
 
 
Figure 3.24: PAR versus analysis time point for heroin and 3-TFMPP. 
Error bars represent standard deviation at n = 3. 
 
Overall, when stored at -20 °C, 25 of the 26 drugs had shown a change in PAR of         
1- 23 % after 4 weeks which falls in the stable to moderately stable range.  A similar 
trend was observed for drugs stored at 5 °C with PAR losses ranging from 2 - 21 %, 
with the exception of MEPH (53 %) and heroin (43 %). 
 
The main aim with this study was to determine the stability of the target drugs after a 
4 week storage period. The 4 week timeframe was chosen based on the practical 
length of time during which a mixed drug standard was used after being made in this 
research. Based on the results, for all but one drug (3-FMC), storage of up to 4 weeks 
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as a mixed standard in solution at -20 °C is suitable. 3-FMC should preferably be 
added fresh to the mixed standard on the day of analysis.  Based on standard 
toxicological practice (Cooper, et al., 2010; Saar, et al., 2012), all individual drug stock 
solutions and mixed drug standards were stored at -20 °C even prior to this 
investigation. The results therefore confirmed why storage of drugs in solvent at          
-20 °C is imperative for many drugs.  To err on the side of caution, the approach taken 
in this research was to make new individual drug stock solutions every 6 months from 
which several vials of mixed standards were immediately made.  These ‘fresh’ working 
solutions were then evaporated to dryness before storage at -20 °C until further 
analysis. Drying the mixed standards before storage at -20 °C was thought to be a 
better way of curbing drug-drug interactions and analyte degradation and save time 
during future sample preparation.  However, the stability of the dried mixed drug 
standard was not evaluated during the time frame of this research but has been noted 
for further investigation.  All internal standards were stored at -20 °C and added 
individually to the mixed drug standards on the day of analysis. Mixed drug standards 
in methanol have reportedly been prepared every 3 months and stored at 4 °C but 
there is no mention of stability studies conducted to determine if these storage 
conditions were appropriate (Loganathan, et al., 2009). 
 
No mention of autosampler or storage stability of drug stock standards or mixed 
standards has been reported for sewage epidemiology. Stability studies are 
recommended as part of method validation especially for biologically active samples 
and have been reported in clinical and toxicological studies (Saar, et al., 2012). 
Although the actual study undertaken needs to be relevant for the method under 
validation, the stability of  any mixed drug standard stored in liquid form should be 
conducted in order to determine if there is any degradation or interconversion due to 
drug-drug interactions. Results from stability studies of multianalyte methods depend 
on the combination of drugs mixed together and hence should form part of the 
method validation. 
 
For all the stability studies conducted, the author is not aware of similar studies 
incorporating this combination and number of emerging and classic PFPA-derivatized 
drugs of abuse being reported. 
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In addition to derivatization, the extraction method used for isolating the drugs from 
the matrix played an important role in whether the drugs could be detected.  
Therefore, the next step in method development was to select and optimise an 
extraction method. 
 
3.4   ANALYTE EXTRACTION METHODS 
Although discussed in separate sections (3.4.1.2 and 3.4.2.1), preliminary LLE and SPE 
studies were alternately conducted around the same time period in order to compare 
the results and decide which was the most suitable for the drugs and matrix under 
analysis.  The effectiveness of an extraction method was assessed based on the 
percentage recovery of a known concentration of a drug spiked into a matrix.   
 
The recovery was calculated according to Equation 3.1 using absolute peak areas 
(Baker & Kasprzyk-Hordern, 2011a). 
 
  Equation 3.1                                                                                                                              
 
The un-extracted mixed drug standard was regarded as representing 100 % recovery. 
 
3.4.1    Liquid-Liquid Extraction (LLE)  
Even though the majority of published work in sewage epidemiology had reported 
SPE, it was worth investigating whether some of the known advantages of LLE would 
apply to extraction of trace analytes from an aqueous matrix (section 1.5.3.3 and 
Table 1.7). 
 
For the optimisation of a LLE method, the emphasis was on the selection of an 
extraction solvent and a suitable sample pH as discussed in the following sections. 
 
3.4.1.1   Selection of Solvent 
The initial stage of LLE optimisation investigated the extraction solvent following the 
procedures as detailed in section 2.4.3.1.1. The results from the comparison of 
chloroform:isopropyl alcohol (CHCl3:IPA) 3:1 v/v and chloroform:ethyl acetate:ethanol 
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(CHCl3:EtOAC:EtOH) 3:1:1 v/v as extraction solvents are provided in Table 3.7. 
Highlighted areas indicate the highest recovery obtained for that particular drug. 
 
Table 3.7: Comparison of recovery (%) using CHCl3:IPA 3:1 v/v  
and CHCl3:EtOAC:EtOH, 3:1:1 v/v. 
 
A theoretical background to LLE has been described in section 1.5.3.2.  There are 
numerous types and combinations of extraction solvents that can be used for LLE 
(Table 1.6) but in this research CHCl3:IPA (3:1 v/v) and CHCl3:EtOAC:EtOH (3:1:1 v/v) 
were used as reported by Tsutsumi (2005) and  Raikos (2009), respectively.  An initial 
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low volume of sample matrix (2 mL) and high drug concentration (0.6 to 2.8 µg/mL) 
was used to improve the chances of recovery and detection. 
 
Recoveries of drugs from both solvent systems were somewhat similar. The majority 
of drugs had recoveries of between 24 - 55 % with the highest recoveries obtained for 
MDMA-d5 with CHCl3:IPA (3:1 v/v) at 79 % and CHCl3:EtOAC:EtOH (3:1:1 v/v) at 83 % . 
Some drugs such as PIP, AMP, MAMP, 4-FMA, 3-FMC & EME had low recoveries 
ranging from 0 - 16 % in both solvents.  Although it had much lower recoveries for 
AMP and MAMP, CHCl3:EtOAC:EtOH (3:1:1 v/v) was selected as the extraction solvent 
as it had higher recoveries for piperazines, cathinones and ketamine, which are 
included under NPS. 
 
According to the Henderson-Hasselbalch equation (Equations A-1 and A-2, Appendix 
III), for basic drugs with a pKa range of 7.5 to 9.9 an optimal extraction pH would range 
from 9.5 to 12, respectively.  At this pH, the drugs would be unionised and hence 
more amenable to extraction into the organic solvent (Telepchak, et al., 2004; 
Flanagan, et al., 2007).  Therefore, a sample pH of 10.5 was more suitable for some 
drugs such as BUTY and KET (pKa 7.5) which had recoveries of 55 and 53 %, 
respectively.  For the first 6 drugs listed in Table 3.7, which had the lowest recoveries, 
it would appear that some loss of the analytes occurred during sample preparation 
and/or extraction. Of these 6 drugs, only the pKa of AMP and MAMP was known i.e. 
9.9 for both. In order for drugs with a pKa of 9.9 to be completely unionised, a more 
suitable pH would have been pH 12.  It would appear that at a pH of 10.5, a portion of 
the drugs were still present as the protonated conjugate acid (Equation A-2, Appendix 
III) and hence more soluble in the aqueous phase.  Although sample preparation was 
carefully done, low recoveries could also be attributed to loss during the transfer of 
samples between vessels, during evaporation or in the case of heroin (which was not 
detected), hydrolysis to 6-MAM or MOR (Figure 3.17). 
 
As per observations during derivatization studies (section 3.2.3), both MOR-2PFP and 
MOR-PFP were detected but MOR-PFP had much higher recoveries (> 100 %).  This 
was due to a higher peak area for the extracted standard than for the unextracted 
standard possibly as a result of loss of analyte during evaporation or contribution 
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from the deacetylation of MOR-2PFP to MOR-PFP (Figure 3.16).  In addition, 6-MAM 
was also detected at higher recoveries than 6-MAM-PFP possibly due to the hydrolysis 
of heroin to 6-MAM (Figure 3.17). 
 
As observed from the variable recoveries, with multianalyte methods containing drugs 
from different classes and with different pKa values and derivatives formed, 
compromises will be made and hence some drugs will have better recoveries than 
others at a particular pH and with a particular solvent (Appendix III). 
 
Therefore the next stage was to optimise the LLE method based on extraction with 
CHCl3:EtOAC:EtOH (3:1:1 v/v) at different sample pHs to determine if higher 
recoveries could be attained. 
 
3.4.1.2   Optimisation of pH 
Following the procedures as detailed in section 2.4.3.1.2, sample extraction with 
CHCl3:EtOAC:EtOH (3:1:1 v/v) was conducted at pH 5.0, 7.0 and 10.5.  A higher volume 
of deionised water (150 mL) and low drug concentrations (< 5 µg/mL) were 
incorporated into the method to correlate with volumes of waste water samples that 
would be used later.  The results are shown in Table 3.8. 
 
Out of the 26 drugs, 22 were detected at pH 10.5 including heroin and 3-FMC which 
were not detected at the other pHs and in the unextracted standard (hence recovery 
could not be calculated for them).  Only 13 and 15 drugs were detected at pH 5.0 and 
pH 7.0, respectively.  Aside from heroin at pH 10.5, none of the opioids were detected 
in any of the matrices.  Overall, recoveries were less than 20 % for the majority of 
detected drugs across the 3 pHs (e.g. PIP, 2-FPP, MDMA, and KET) but some drugs had 
recoveries above 100 % (e.g. MEPH, BUTY and COC). The low recoveries observed 
could be due to several factors including the use of a 20:1 injection split ratio which 
meant that only 5 % of the already low concentration of drugs injected (1 µL) was 
actually available for detection. 
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Table 3.8: Comparison of extraction pH using CHCl3:EtOAC:EtOH, 3:1:1 v/v. 
 
 
Additionally, there could have been analyte loss during the sample preparation and 
extraction process as stated in section 3.4.1.1. For the deuterated internal standards, 
only COC-d3 was detected, most likely due to the higher concentration added          
(1.7 µg/mL) compared to the lower concentration added for both MDMA-d5 and 
MOR-d3 (0.17 µg/mL). Recoveries > 100 % were due to a higher concentration of the 
drugs in the extracted standards than the unextracted standards, possibly due to loss 
during the evaporation steps. 
 
As can be expected based on the pKa ± 2 rule for selection of extraction pH, the most 
suitable pH for this combination of drugs with average pKa ranging from 8-10 was 
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pH 10-12.  Therefore at pH values close to the pKa of the drugs, such as pH 10.5 for 
AMP and MAMP which have pKa of 9.9, the drugs would still mainly be ionized and 
hence more soluble in the aqueous phase (Appendix III).   But for drugs with pKa less 
than 9, such as KET, heroin and 3-TFMPP, better recoveries would be expected. 
 
Overall, recoveries for LLE of a 150 mL spiked sample were poor and not reliable. 
These factors, in addition to the time consuming process, led to the decision to 
proceed with SPE which had shown much better recoveries under the same 
experimental conditions (section 3.4.2.1). On the other hand, Mol (2009) had found 
both SPE and LLE to be suitable for extraction of acidic drugs from 500 mL of waste 
water. However, they also selected SPE over LLE due to its time efficiency. 
 
3.4.2    Solid Phase Extraction (SPE) 
The method optimisation process for SPE focussed on the selection of a suitable 
sorbent, sample pH and elution solvent following the procedures as detailed in 
section 2.4.3.2. Preliminary SPE optimisation studies were conducted on various 
volumes of deionised water, tap water, treated and untreated waste water spiked 
with the mixed drug standard.  Internal standards were spiked together with the drug 
analytes before extraction to determine their percentage recovery and hence 
suitability for use for PAR calculations if needed. Method blanks using unspiked 
samples were also co-currently extracted and analysed together with the spiked 
analytes.  These were checked for analyte peaks or potential co-eluting interferents 
from the matrix or SPE sorbents. 
 
3.4.2.1   Comparison of the SPE Sorbents, Oasis® MCX and HLB 
In order to determine which sorbent type would be most suitable for the types of 
drugs under investigation, preliminary studies were conducted using two SPE 
cartridges, MCX and HLB at various pHs, according to the procedures as detailed in 
section 2.4.3.2.1 and Table 2.9. The same sample volume, concentration, number of 
drugs and instrumental method as per the LLE method (section 3.4.1.2 above) was 
used for comparison purposes. 
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Recovery (%) was calculated using equation 3.1 and the results are listed in Table 3.9.  
Highlighted areas indicate the highest recovery obtained for that particular drug for 
each type of cartridge. 
 
Table 3.9: Comparison of Oasis MCX and HLB sorbents at different pH values. 
 
Considering that the same experimental conditions were used as per LLE (Table 3.8), 
the results from SPE show much higher overall recoveries (38 to 152 %), indicating 
better extraction and concentration of analytes from the sample matrix. In addition, 
the SPE extraction process was more amenable to conducting multiple extractions at 
the same time which was seen as an advantage since high sample throughput is part 
of the process of ensuring a quick turn around with results. 
 
MCX 
The MCX (pH 2) sorbent gave higher recovery values for the majority of drugs, ranging 
from 48 - 101 %.  In addition, 3-FMC, COC and COC-d3 were only detected at pH 2 and 
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not at pH 5.5 and 10. However, some drugs such as AMP, MAMP, MBZP, 2-MEOP, 
BUTY and AMIT were recovered at relatively high percentages (> 67 %) at both pH 2 
and pH 10.  This is because at pH 2, the basic drugs were 100 % ionised but at pH 10, 
they were still about 50 % ionised as the pH was close to the pKa value for a number 
of the drugs (AMP, MAMP).  This would still enable some interaction with the 
negatively charged sulphonic group on the MCX sorbent (Figure 1.2). This indicates 
that the pKa ± 2 rule is not as straightforward with SPE or LLE (Hendriks, et al., 2007) 
and systematic optimisation is needed to ensure the optimal conditions for the drugs 
under investigation. 
 
The use of two elution solvents in tandem for MCX, i.e. 100 % methanol (pH 5.0) and 
2-5 % ammonium hydroxide in methanol (pH 10-11), enables the elution of acidic, 
basic and neutral drugs. Either solvent could be used alone to improve the specificity 
of the method depending on the acid-base properties of the compounds under 
investigation.  If interest was only in acidic compounds from the matrix, then only 
methanol could be used and if basic compounds were the analytes of interest, then 
basified methanol could be used alone.  Both basic and amphoteric drugs were 
included in this research so both solvents were used. 
 
HLB 
For the HLB sorbent, a sample matrix of pH 7.5 gave better recovery values (59 -     
165 %) compared with pH 2.8 and 8.5.  However, an extra 5 - 9 drugs, including COC 
and 3-FMC, were detected at pH 8.5 than at pH 2.8 and 7.4.  This correlates with 
published reports where sample pHs of between 7.0 and 8.5 have been used with HLB 
sorbents (Gonzalez-Marino, et al., 2010; Gracia-Lor, et al., 2010; Tarcomnicu, et al., 
2011). Two elution solvents were also used with HLB to target the different types of 
drugs present in the sample. Ethyl acetate was used to recover phenylethylamines 
followed by acetone to extract the remaining drugs. The amine group is thought to 
react with the carbonyl group of acetone leading to interference during derivatization. 
Therefore, the fractions were eluted separately and the acetone fraction was 
evaporated to dryness before the ethyl acetate fraction was added to it (Gonzalez-
Marino, et al., 2010). 
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The opioids were not detected for all sorbents and pHs possibly due to their low 
detector response and degradation reactions mentioned in section 3.2.3. 
 
Oasis MCX and HLB sorbents have been the most widely reported in sewage 
epidemiology for multianalyte extraction of acidic, basic and neutral pharmaceutical 
compounds (Boles & Wells, 2010; van Nuijs, et al., 2011a; Wille, et al., 2012).  
Depending on the extraction protocol and pharmaceuticals under analysis, either the 
Oasis MCX or HLB sorbent were found to be suitable (Gheorghe, et al., 2008; Gracia-
Lor, et al., 2010; Vazquez-Roig, et al., 2013). A background to the chemical structures 
of these sorbents can be found in section 1.5.3.1.1 (Figure 1.2). MCX has strong 
cationic exchange properties suitable for bases while HLB is a universal reverse phase 
sorbent that can retain polar acids and bases and neutral analytes. 
 
In reference to the Henderson-Hasselbalch equation and pKa ± 2 rule, basic drugs are 
expected to have better recoveries at acidic pH values at least 2 pH units below the 
pKa using the MCX sorbent. This is because basic drugs are protonated under acidic pH 
thereby forming an ionic bond with the negatively charged sulphonic group on the 
MCX sorbent during the loading step (Figure 1.2).  During elution, the basified organic 
solvent neutralizes the charge on the basic drugs thereby disrupting the ionic bond 
and causing the analytes to elute.  Acidic and neutral drugs are not ionized at acidic 
pH but because MCX sorbents also have an HLB backbone, these drugs will be 
retained by the reverse-phase HLB backbone and be eluted by the methanol which 
disrupts these non-polar interactions (Table 2.9).  As most of the drugs investigated in 
this research were bases with pKa between 8 and 10, they were more suited to 
extraction by the MCX sorbent at a sample pH of 2. 
 
Another observation made from the results in Table 3.9 is that some recoveries for 
both MCX and HLB extractions were excessively high for drugs such as AMP, MAMP 
and 4-FMA. This was due to possible loss of analytes during evaporation of 
unextracted standards.  The peak areas of the unextracted standard were sometimes 
inexplicably lower than those of the extracted standard and this affected recovery 
calculations by resulting in unrealistically high recoveries (> 1000 %). Interference 
from co-eluting compounds can also not be ruled out (i.e. from the cartridge or 
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solvents used). The unextracted standard is supposed to represent 100 % recovery 
and hence should have higher peak areas than the extracted standard (Richards, 
2010). During method validation, use of a post-extracted standard instead of an 
unextracted standard was expected to reduce some of these anomalies (section 4.5). 
Overall, MCX (pH 2) gave much better recoveries and number of detected drugs than 
HLB (pH 7.4 & 8.5). Therefore, the final SPE protocol selected was based on MCX 
cartridges with a sample pH of 2.  This is in line with other published reports in which 
acidic sample pHs result gave better recoveries on MCX cartridges for basic drugs 
(Baker & Kasprzyk-Hordern, 2011a). Another advantage of using the MCX cartridge 
was that pH adjustment of samples was not required before extraction since samples 
were acidified to pH 2 before storage to prevent the degradation of analytes (section 
1.5.2) (Vazquez-Roig, et al., 2013). 
 
It is worth noting that with multianalyte methods, extraction conditions are often a 
compromise therefore some analytes will have lower recoveries due to a non-ideal 
pH, sorbent or elution solvents used for their extraction (Couchman & Morgan, 2011).  
Perhaps some recoveries could have been improved had different elution solvents 
been used at the various pHs since the acid-base equilibria of the drugs would also be 
different. In addition, the sample matrix, sample preparation, extraction protocol, 
instrumental conditions, and analyte type and concentrations used can also affect 
results and hence intra- and inter-laboratory comparisons can yield different values. 
Table 3.10 compares the results from the extraction of drugs on MCX (pH 2.0) using 
different matrices, spiked drug concentrations and instrumental parameters. 
 
The comparison shows varying recoveries of the same drug across different matrices. 
However, in at least 2 out of the 4 comparisons, recoveries were less than 15 % 
different for some drugs such as MEPH, BZP, MDMA, 4-TFMPP, AMIT and COC 
indicating that the method was reproducible for some drugs.  The internal standards 
MDMA-d5 and COC-d3 had reproducible recoveries across at least three matrices. 
Sometimes, drugs were not detected (e.g. MDMA in column D) as a result of loss of 
sensitivity during analysis but in other cases it was due to degradation or low detector 
response for the drug (e.g. MOR and heroin). For waste water samples, any peak 
areas corresponding to the target analytes (from the unspiked sample) were taken 
126 
 
into account during recovery calculations. The manual extraction set-up used during 
this research also introduced its own set of variabilities such as different average flow-
rates used between cartridges and from day to day (5 - 8 mL/min) and different 
elution solvent compositions which had to be freshly made (average pH of 2.4 - 2.8) 
This contributed to the variability in reproducibility for intra-day and inter-day 
analyses. 
 
Table 3.10: Comparison of recoveries of different spiked matrices using Oasis  
MCX at pH 2.0. 
 
The low recoveries of some drugs (i.e. < 6 %) could be due to factors related to the 
SPE protocol such as the sorbent choice, pH of sample in relation to the pKa of the 
drug and elution solvent used and/or factors ouside the SPE process such as the 
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evaporation temperature and time and derivatization process.   All these factors have 
been attributed to the loss of analytes by other authors as well (Bogusz, et al., 1985; 
Baker & Kasprzyk-Hordern, 2011b; Wille, et al., 2012). During this research, some loss 
of analytes occurred for the unextracted standards which resulted in much inflated 
levels of recoveries when using Equation 3.2, as observed in Table 3.10 for AMP, 
MAMP and 4-FMA.  The exact point at which analytes could have been lost is 
unknown but suggestions by the author include: during the evaporation stages 
(before and after derivatization), through the use of unsilanised glassware or during 
analysis. 
 
Aside from matching the sample pH to the drugs under analysis and the SPE sorbent 
used, the elution solvent also plays a large role in terms of recovery of the drugs 
(Baker & Kasprzyk-Hordern, 2011b). Therefore, the next stage in SPE optimisation was 
to evaluate two elution solvents used for the MCX cartridge which was selected as the 
most suitable sorbent for the drugs under analysis. 
 
3.4.2.2   Comparison of Elution Solvents for MCX at pH 2.0 
The most reported basified organic elution solvent in literature for the MCX sorbent is 
2-5 % (v/v) ammonium hydroxide in methanol (Waters, 2006b; Lai, et al., 2011; 
Tarcomnicu, et al., 2011).  Very few alternatives, such as 5 % (v/v) ammonium 
hydroxide in acetone:ethyl acetate (1:1 v/v) have been used (Bones, et al., 2007).   As 
mentioned in section 3.4.2.1, a basified organic solvent is essential for the elution of 
basic drugs. Although 5 % (v/v) ammonium hydroxide in methanol was used in earlier 
SPE optimisation studies, it was decided to evaluate whether there would be a 
difference in recovery if 5 % (v/v) ammonium hydroxide in acetone/ethyl acetate (1:1 
v/v).  Following the procedure as detailed in section 2.4.3.2.2, the results are 
presented in Figure 3.25. 
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   Figure 3.25: Comparison of peak area using 5 % (v/v) ammonium hydroxide in methanol versus 5 % (v/v) ammonium hydroxide in acetone:ethyl   
   acetate (1:1 v/v) as elution solvents, n=2. 
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Results show that elution with 5 % (v/v) ammonium hydroxide in acetone:ethyl 
acetate (1:1 v/v) resulted in higher peak areas than elution with 5 % (v/v) ammonium 
hydroxide in methanol for 24 out of the 32 drugs and internal standards.  In particular 
MAMP and EME showed much larger increases in peak areas.  A few drugs such as 
AMP, MEPH and 3-FMC had higher peak areas in 5 % (v/v) ammonium hydroxide in 
methanol but these were in the minority.  Therefore, 5 % (v/v) ammonium hydroxide 
in acetone:ethyl acetate (1:1 v/v) was selected as the elution solvent for further 
studies due to the stronger elution properties of a combined acetone and ethyl 
acetate solvent mixture as well as the quicker evaporation of the two solvents as 
compared to methanol alone (Table 1.6) (Bones, et al., 2007; Richards, 2010). 
 
The findings from this research correlate with results as reported by Bones (2007) 
with different drugs having higher recoveries in the different solvents.  However, 
MDMA, COC, DIAZ and MOR, which had higher recoveries in this research with 5 % 
(v/v) ammonium hydroxide in acetone:ethyl acetate (1:1 v/v), had lower recoveries in 
Bones’s (2007) study. However, a different SPE cartridge from a different 
manufacturer, but with similar chemical characteristics (mixed-mode strong cation 
exchange), was used and this could account for some differences. 
 
Optimisation of elution solvents for MCX cartridges has only been reported in a few 
published manuscripts as the premise has been to just use what has been reported 
before or manufacturers’ recommendations (Bones, et al., 2007).  However, as this 
study has shown, it is worth comparing different solvents for drugs under 
investigation because inter-laboratory differences will always exist which can have a 
profound influence on the results obtained. 
 
Therefore, the final SPE method used in this research for method validation was as 
presented in Table 2.10 
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3.4.3   Selectivity through Extraction and Recovery  
Although the extraction and recovery studies served primarily to determine the 
efficiency of the SPE process, they also verified whether the optimised derivatization 
protocol (section 3.2.4) and selected diagnostic ions (Table 3.3), especially the 
quantifier ion, were suitable and selective enough for application in a complex matrix. 
 
Figure 3.26 shows the TICs of unspiked and spiked (5 µg/mL mixed drug standard) 
untreated waste water samples.  Both chromatograms show the complexity of the 
waste water samples with regard to the presence of high concentrations of non-
targeted matrix components.  However, in the TIC for the spiked sample, the internal 
standards MDMA-d5 and COC-d3 can be detected among other matrix components. 
The remaining drugs were detected through SIM. Although other drug standards were 
spiked into the waste water sample, MDMA-d5 and COC-d3 are used here for 
illustration purposes since their peaks could clearly be seen above the baseline.  Both 
internal standards were spiked at 5 µg/mL. A further illustration of the complexity of 
untreated waste water samples can be found in Appendix VIII where a comparison 
with the chromatogram of a mixed drug standard is shown. 
 
In spite of the complexity of the waste water matrix, some of the target drugs could 
still be detected in unspiked waste water samples during preliminary studies and 
method optimisation. Figure 3.27 shows the SIM spectra of MOR (m/z 414) and KET 
(m/z 320) detected in the unspiked, untreated waste water sample shown in Figure 
3.26.  The RT and selected diagnostic ion was used for confirmation of identity when 
compared to a spiked waste water sample. An ethyl acetate blank analysed directly 
before the unspiked waste water sample was used to check for any carryover.  In the 
unspiked waste water sample (Figure 3.27), the MOR peak at a RT of 20.41 and the 
KET peak at RT of 16.45 have ion counts of 293 and 130, respectively. Corresponding 
MOR and KET peaks in the ethyl acetate blank have ion counts of 3 and 6, 
respectively, indicating negligible carryover at less than 5 % (van Nuijs, et al., 2012). In 
addition, Figure 3.27 further highlights the selectivity of the method as there was 
minimal interference from other matrix components for the selected diagnostic ions. 
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        Figure 3.26: Total ion chromatograms of spiked and unspiked untreated waste water samples. 
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        Figure 3.27: Detection of KET (RT 16.45) and MOR (RT 20.41) in an unspiked waste water sample.
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As the method development progressed, 3 diagnostic ions and at least 1 ion ratio (EC, 
2002; Cooper, et al., 2010; Migowska, et al., 2012; Kumirska, et al., 2013) were used in 
confirming the detection of the target analytes in spiked and unspiked waste water 
samples (Table 3.3, page 102).  Appendix IX a&b shows, as an example, SIM spectra 
and ion ratios used in detecting and confirming the presence of MOR in waste water 
samples collected in different months and years using different sampling methods i.e. 
grab and  48 h composite.  This indicates that perhaps MOR is consistently present in 
waste water collected from a WWTP serving the Cambridge, UK, area. 
 
Figure 3.28 shows the quantifier and confirmation ions for AMP and 4-TFMPP 
recovered from an untreated waste water sample spiked with 1 µg/mL mixed drug 
standard.  The SIM spectra of the quantifier ions for the rest of the target drugs can 
be found in Appendix X a-d. 
 
 
Figure 3.28: Quantifier (Q) and confirmation ions (C1 and C2) for AMP and 4-TFMPP. 
 
Based on the detection of all diagnostic ions during various preliminary investigations 
as detailed in sections 3.4.1 and 3.4.2, the derivatization protocol optimised for mixed 
drug standards also resulted in the complete derivatization of all drugs within a waste 
water sample. All relevant m/z values for derivatized drugs were detected and no 
underivatized m/z values were detected (aside from MOR and 6-MAM as explained in 
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section 3.2.3). Therefore, the chosen derivatization reaction conditions were also 
suitable for the analysis of spiked waste water samples. 
 
The challenge with derivatizing waste water samples is the unknown amount and 
variety of compounds within the sample matrix, both desired and undesired, polar 
and non-polar. As mentioned in section 1.5.3.1, page 32, other components in the 
matrix can have a negative influence on the detection of target drugs. For derivatized 
drugs, the effect is two-fold: signal suppression or enhancement and incomplete 
derivatization process (Mol, et al., 2000). The presence of other components within 
the matrix can affect the completion of the derivatization reaction by competing for 
the reagent and also influence which derivative is formed, especially for analytes with 
multiple derivatization sites such as PIP and MOR (Jimenez, et al., 2002; Racamonde, 
et al., 2013). Incomplete derivatization would result in lower amounts of the 
derivatized drug since some of it would still be in underivatized form and lead to 
inaccurate quantification. 
 
However, in the examples shown in Figures 3.27 & 3.28 there is a lack of noticeable 
interference from other matrix components on quantifier ions.  Although the 
presence of other matrix components varied from sample to sample, and their 
detector response varied depending on the concentration of the target drugs, the 
quantifier ions were always distinguishable from other peaks and confirmation was 
made by using 2 to 3 diagnostic ions (quantifier and confirmation) and respective ion 
ratios. 
 
This adds credence to the importance of carrying out derivatization optimisation 
studies on mixed drug standards to determine the chromatographic and mass spectral 
properties of the completely derivatized drug (i.e. mass spectrum, ion ratios, RI). The 
results are then used to compare with chromatographic and mass spectral parameters 
from analysis of field samples which should be similar. 
 
During this research, the optimised derivatization and recovery protocols ensured 
that identification of the target drugs in waste water samples could be made with 
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reliability and confidence during method validation (Chapter 4) and application of the 
method (Chapter 5). 
Whilst conducting the extraction optimisation studies, various aspects of the protocol 
were fine-tuned in order to maximise the recovery of the drugs.  These are discussed 
in the following sections. 
 
3.4.4   Maximising Analyte Recovery 
A series of measures were put in place during the SPE process in order to maximise 
the recovery of the target drugs. These included assessing the optimal sample volume 
to use depending on the matrix and cartridge as well as ensuring minimal loss of 
analytes during the rinsing and elution stages. 
 
3.4.4.1   Sample Volume 
For the cartridge and sorbent size used in this research (Oasis MCX 60 mg, 3 mL), it 
was found that 200 mL of filtered untreated waste water could be analysed before 
clogging started occurring.  Therefore sample sizes were confined to 50 to 150 mL per 
cartridge during extraction studies. This was also in line with sample volumes used in 
published literature (Hernandez, et al., 2011; Bijlsma, et al., 2013a&b) although 
volumes up to 1500 mL have reportedly been used without sample breakthrough 
(Rodriguez, et al., 2003).  Breakthrough occurs when analytes pass through the SPE 
cartridge unretained due to overloading of the sorbent and can result in an 
underestimation of the percentage recovery. Composite and passive sampling offer 
an advantage over large volume grab sampling in that less sample volume can be used 
(50 mL to 100 mL) which can also be regarded as a compromise between achieving 
sensitivity and minimizing matrix effects (Postigo, et al., 2008b). 
 
3.4.4.2   Rinsing Stage 
Another stage in the SPE process where loss of analytes can potentially occur is during 
the rinse stage (Table 2.10). A careful balance needs to be made between using 
solvents that are strong enough to remove interferences without causing premature 
elution of target analytes (Telepchak, et al., 2004).   Results from the evaluation of the 
rinse solvent during extraction of a 150 mL deionised water (DH2O) sample spiked 
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with 5 µg/mL of a mixed drug standard are presented in Table 3.11. The rinse 
solutions (Tables 2.9 and 2.10) were collected and analysed separately. 
 
Table 3.11: Analyte (%) in rinse solvent from extraction of 150 mL spiked DH2O. 
 
 
The % loss was calculated by dividing the absolute peak area of the analyte in the 
rinse solvent by the absolute peak area of the analyte in the elution solvent and 
multiplying by 100. The % loss of the majority of analytes was less than 5 % and this 
was considered to be a negligible loss (van Nuijs, et al., 2012).  Even though EME 
showed a loss of 22 %, the rinse step was included in this research since having 
cleaner extracts was worth the loss in one analyte.  These are some of the 
compromises that need to be made with multianalyte methods. However, this didn’t 
seem to affect recovery of EME which was 109 % during validation studies (Table 6.7). 
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In addition, other authors also report no negative effect of the rinse step on the 
recovery or sensitivity of analytes (Bijlsma, et al., 2009; Baker & Kasprzyk-Hordern, 
2011b). 
 
3.4.4.3   Elution Solvent Volume 
To ensure the volume of elution solvent used was sufficient to elute all target analytes 
and hence increase recovery, two lots of eluants were collected from each cartridge 
consecutively. These were referred to as eluant A and eluant B.  Eluant A was 
collected immediately after the rinse and drying stage as per the SPE protocol.  The 
same cartridge was then eluted a second time with the same solvents and volume as 
in the first elution. This was eluant B. Both eluants A and B were analysed separately 
with the premise that elution B should contain none or a negligible percentage of 
analytes as found in eluant A. The percentage of analytes in eluant B, relative to those 
in eluent A, was calculated by dividing the absolute area of the analytes in eluant B by 
the absolute area of the analytes in eluant A and multiplying by 100. 
 
Results from the evaluation of the elution solvent during extraction of various water 
samples are presented in Table 3.12. 
 
The percentage of analytes present in eluant B was found to be less than 5 % of that 
found in eluant A, for the majority of drugs, indicating that the volume of solvent used 
was sufficient in eluting the majority of analytes.   However, to err on the side of 
caution and further optimise the elution, the solvent was allowed to stand in the 
cartridge for a few minutes prior to elution to maximise the disruption of bonds 
between the analyte and the sorbent (Metcalfe, et al., 2010). In addition, for a 4 mL 
volume of elution solvent, five fractions of 0.8 mL were used with the first one being 
allowed to stand in the cartridge or 5 minutes before elution while the others were 
left for about 2 minutes.  AMP, EME and 4-FPP showed percentage losses ranging 
from 26 to 41 % in a few of the samples but since the losses were not consistent 
across the various matrices, this was regarded as possible random error introduced 
during the extraction process. 
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During the preliminary studies as described above (i.e. derivatization, stability and 
extraction), various instrumental parameters were simultaneously being optimised to 
ensure the reliability of the results obtained. These are discussed in the next section. 
 
Table 3.12: Analyte (%) in elution solvent B from extraction of various water 
samples. 
 
 
3.5    OPTIMISATION OF INSTRUMENTAL PARAMETERS 
The instrumental parameters that were optimised for method validation were SIM 
analysis with splitless injection (which followed on from derivatization studies and the 
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selection of suitable diagnostic ions, section 3.2), the GC oven temperature program 
(Table 2.4), and the photomultiplier tube (PMT) (section 3.5.3). 
 
3.5.1   SIM Analysis  
For method validation studies, SIM was used in conjunction with splitless injection. 
Various combinations of dwell time and number of ions per window were investigated 
resulting in the final parameters that were used in this research (Table 2.4).  For the 
29 drugs and 4 internal standards under investigation 14 retention time windows 
containing 3 to 12 ions were used. Windows with more ions were as a result of the 
proximity of the RTs of drugs to each other within a particular section of the TIC.  
Dwell times for each ion within a RT window ranged from 20 to 60 ms depending on 
the number of other ions present.  Setting up the retention time windows and dwell 
times was time-consuming but it contributed to increased sensitivity (González-
Mariño, et al., 2010; Migowska, et al., 2012). In Migowska (2012) study, the sensitivity 
increased at least two-fold through the use of SIM and retention time windows. Since 
at least 3 diagnostic ions were monitored (Table 3.3), this resulted in at least 87 ions 
being monitored.  While this appears to be a large number, it shows the capability of 
modern instruments, especially those with mass analysers, to facilitate multianalyte 
method development while maintaining sensitivity and producing reliable, 
quantifiable results. This has led to regions of 40 to > 100 pharmaceuticals being 
monitored in multianalyte methods using mass analysers (Kolpin, et al., 2004; Nodler, 
et al., 2010; Baker & Kasprzyk-Hordern, 2011a&b; Hernandez, et al., 2011). 
 
3.5.2   GC Oven Temperature Program 
Various GC oven programs were trialled during the course of the method 
development resulting in the final method with a run-time of 31.17 min (Table 2.4). 
Published GC-MS methods for waste water analysis range from 28 - 45 min (Gonzalez-
Marino, et al., 2010, Racamonde, et al., 2012) which seem long compared to average 
run times of 6-13 min on LC-MS systems (Gracia-Lor, et al., 2010). However this 
depends on the combination of drugs being analysed and the column used.  When a 
wider selection of drugs were analysed, run times of 34 min were also reported for 
LC-MS (Baker & Kasprzyk-Hordern, 2011a&b). Although shorter run times are desired 
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for increased sample throughput, for multianalyte methods a compromise has to be 
made with regards to analysis time versus peak separation and increased sensitivity. 
 
3.5.3   Photomultiplier Tube (PMT) Voltage 
The voltage at which the PMT on the mass spectrometer was set also had a significant 
impact on the detector response.  During preliminary studies the PMT voltage was 
automatically set at a range of 350 - 450 V (dictated by the results of tuning). This was 
then manually adjusted to 500 V and ultimately 600 V when lower drug 
concentrations were used during SIM analysis.  The results from a comparison of peak 
areas for selected drugs using PMT settings of 500 and 600 V are shown in Table 3.13. 
 
Table 3.13: Comparison of peak area at PMT settings of 500 and 600 V. 
 
 
A PMT setting of 600 V led to over a 500 % increase in the peak area compared with a 
setting at 500 V as depicted for selected drugs.  In this regard, a PMT voltage of 600 V 
was the final setting used for validation studies as it resulted in a significant increase 
in detector response to the target analytes.  This was a key advantage in being able to 
detect trace amounts of these drugs in a complex waste water sample. 
 
Although the number of drugs analysed during preliminary investigations varied in a 
few studies, for method validation studies, all optimised methods and instrumental 
parameters were applied to 29 drugs and 4 internal standards as discussed in Chapter 
4.  As mentioned earlier, although MOR-d3 was included in the mixed drug standards 
used, it was not used in the calculation of PAR (section 3.3.1, pages 108-109). 
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CHAPTER 4 
RESULTS & DISCUSSION – METHOD VALIDATION 
This chapter discusses the results from the key performance tests undertaken in 
validating the method. The selectivity of the method, extraction recovery and stability 
of the drugs have been covered to a large extent in chapter three but the results 
discussed in this chapter are based on the final optimised derivatization, extraction 
and recovery and instrumental methods. 
 
4.1   INSTRUMENTAL LINEAR RANGE 
The linear range was assessed between 2.0 x 10-4 and 1.4 µg/mL as per the procedure 
in section 2.5.1.  Figure 4.1 shows an example of the linear regression plot of PAR 
versus concentration for AMP.  As already established in section 3.22 (page 91) and 
Appendix IV the PAR was used in the establishment of linear range and other 
validation parameters.  This was in order to compensate for fluctuations during 
sample preparation and instrumental response. 
 
 
Figure 4.1: Linear regression plot of PAR versus concentration for AMP, n = 3. 
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The linear regression plots for each drug investigated in this research can be found in 
Appendix XI a-e while the correlation coefficients and linear range are listed in Table 
4.1. 
 
Table 4.1: Linear range and correlation coefficients of target drugs. 
 
 
A correlation coefficient of ≥ 0.9900 is considered an acceptable measure of linearity 
(UNODC, 2009; Tarcomnicu, et al., 2011; Ammann, et al., 2012). Therefore these 
results show good linearity for all drugs assessed.  The linearity was further evaluated 
by plots of the relative response/concentration against the log of concentration as 
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recommended by ISO 17025, QA/QC (Huber, 2010). This has been depicted in 
Appendix XII using AMP as an example. 
 
Since the multianalyte method under development encompassed 29 drugs and 
metabolites from different classes the linear range was not surprisingly different for 
various drugs.  Some drugs, including phenylethylamines, cathinones and piperazines 
had wide linear ranges from 4.0 x 10-4 to 0.8 µg/mL (AMP) to 1.8 x 10-3 to 1.2 µg/mL 
(MEPH).  Other drugs, such as 3-FMC, MDMA, 3-CPP and AMIT, had a narrower linear 
range at 1.1 x 10-1 to 1.2 µg/mL.  The linear ranges for 6-MAM and heroin could not be 
established within the chosen concentration range. A much wider range 
encompassing even more orders of magnitude towards the higher concentration end 
(1.0 – 5.0 µg /ml) was needed but this would have resulted in prolonged analysis time 
which could compromise on the stability of the samples.  In addition, based on 
published studies (Table 1.2, page 9) the expected concentration of the target 
analytes in waste water samples would be towards the lower concentration end 
which was the focus of the linearity study.  A separate linear test for opioids should 
have been assessed but this was seen as defeating the purpose of a multianalyte 
method. However, other researchers also reported different linear ranges for 
different classes of drugs (Gracia-Lor, et al., 2010; Baker & Kasprzyk-Hordern, 2013).  
As discussed during preliminary investigations, challenges were experienced during 
stability and recovery studies for 6-MAM and heroin where these two drugs could not 
be detected, especially below 1 µg/ml (Table 3.4 and 3.9, sections 3.3.2 & 3.3.3).  This 
was also observed during precision studies (section 4.2) and LOD/LOQ (section 4.3). In 
addition, challenges were also experienced with these two analytes during 
derivatization studies (section 3.2.3).  In sections 4.5 and 5.4.1.5, further challenges 
experienced by other researchers and in this thesis with regard to stability and 
detection of opioids are discussed. Therefore, since the linear range was established 
for the majority of target analytes below 1 µg/ml, especially NPS, a decision was made 
to proceed with the established linear ranges with a compromise on 6-MAM and 
heroin.  Once the linear range was established the precision of the instrument could 
then be assessed. 
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4.2   PRECISION 
Both intra-assay and intermediate precision were assessed according to the 
procedure as detailed in section 2.5.2.  The results are discussed below. 
 
4.2.1    Intra-assay Precision (Instrument) 
The intra-assay precision of the instrument was evaluated at low (0.005 µg/mL), 
medium (0.1 µg/mL) and high (1.0 µg/mL) drug concentrations due to the wide linear 
range encompassing several orders of magnitude (Hartmann, et al., 1998). The results 
are listed in Table 4.2. 
 
RSDs across the 3 concentrations were well below the ≤ 15 % criteria normally set for 
higher concentrations and the ≤ 20 % criteria normally set for lower concentration 
ranges, indicating good repeatability of the method (FDA, 2001; Tarcomnicu, et al., 
2011). The RSD for 0.005 µg/mL ranged from 5.4 % (AMP) to 18.7 % (MCAT); for       
0.1 µg/mL, 1.8 % (4-FPP) to 10.9 % (6-MAM); for 1.0 µg/mL, 0.7 % (CAT) to 11.2 % 
(MOR).  The exception was 2-FPP with an RSD of 24.2 % at 0.005 µg/mL, most likely 
due to higher fluctuations in detector response normally experienced at low 
concentrations since respective RSDs at 0.1 and 1.0 µg/mL were less than 3.00 %. 
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Table 4.2: PAR and RSD from intra-assay precision (instrument). 
 
 
4.2.2   Intra-assay Precision (Analytical Method) 
The intra-assay precision of the analytical method was assessed on spiked extracted 
waste water samples.  Only the highest concentration (1 µg/mL) was assessed to 
maximise detection of the drugs.  The results are listed in Table 4.3. 
 
RSDs for the majority of the drugs (20 out of 27 detected) ranged from 4.9 % (MAMP) 
to 18.6 % (3-TFMPP), indicating good repeatability especially in a complex sample 
(Karolak, et al., 2010; Tarcomnicu, et al., 2011).  The rest of the drugs had RSDs 
ranging from 27.8 % (3-FMC) to 51.1 % (2-MEOPP).  The high RSD for MOR (38.1 %) is 
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not surprising considering that it undergoes degradation reactions (sections 3.2.3.1).  
For the other drugs high RSDs could be attributed to errors introduced during the 
sample preparation and manual extraction process such as interfering co-eluants and 
possible variabilities with the concentration of spiked (and ultimately extracted) drugs 
and SPE sorbent material. Heroin and 6-MAM were not detected as per preliminary 
extraction experiments. 
 
Table 4.3: PAR and RSD from intra-assay precision (analytical method). 
 
 
4.2.3   Intermediate Precision (Instrument) 
The intermediate precision of the instrument was also conducted at low (0.005 
µg/mL), medium (0.1 µg/mL) and high (1.0 µg/mL) drug concentrations and the results 
are in Table 4.4. 
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Table 4.4: PAR and RSD from intermediate precision (instrument). 
 
 
The majority of RSDs across the 3 concentrations were well below the ≤ 15 % criteria 
normally set for higher concentrations and the ≤ 20 % criteria normally set for lower 
concentration ranges, indicating good repeatability of the method over different days 
of analysis (FDA, 2001; Tarcomnicu, et al., 2011). The RSD for 0.005 µg/mL ranged 
from 0.5 % (CAT) to 16.3 % (4-FMA); for 0.1 µg/mL, 0.7 % (BUTY) to 13.2 %                  
(2-MEOPP); for 1.0 µg/mL, 1.3 % (MAMP) to 20.3 % (6-MAM).  As observed with intra-
assay precision, 2-FPP was the exception with an RSD of 23.5 % at 0.005 µg/mL 
indicating a greater variability with the detector response to 2-FPP at low 
concentrations. RSDs at 0.1 and 1.0 µg/mL, for 2-FPP, were less than 4 %. 
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The next stage with method validation was the determination of instrumental LOD 
and LOQ in order to determine whether the analytical method could detect trace 
amounts of target analytes, as normally found in waste water samples, and reliably 
quantify them. 
 
4.3    INSTRUMENTAL DETECTION AND QUANTIFICATION LIMITS 
Following the procedure as described in section 2.5.3, the instrumental LOD and LOQ 
for the drugs under investigation are presented in Table 4.5.  The LOD and LOQ were 
calculated according to empirical methods i.e. analysing decreasing concentrations of 
a mixed standard and measuring the detector response (Baker & Kasprzyk-Hordern, 
2011a).  The LOD was taken as the concentration that resulted in a peak (measured 
from its maximum height) with a signal-to-noise (S/N) ratio of 3:1 while the LOQ was 
based on a peak with a S/N ratio of 10:1.  Root mean square (RMS) integration, rather 
than peak-to-peak, was used to calculate the S/N ratio.  RMS is based on the standard 
deviation of the fluctuation in the baseline rather than just on a maxima and minima 
as with peak-to-peak (Shimadzu, 2013). The results are presented in Table 4.5. 
 
The LOD of the majority of drugs ranged from 1.36 x 10-4 µg/mL (e.g. AMP, BZP) to         
5.33 x 10-3 µg/mL (e.g. 4-MEOPP) and LOQs ranged from 3.33 x 10-4 (e.g. AMP) to             
5.33 x 10-3 µg/mL (e.g. KET). Some drugs such as 6-MAM and heroin had relatively 
high LODs of 1.33 x 10-1 and 5.62 x 10-1 µg/mL, respectively which also meant that 
their LOQs were also relatively high.  In terms of drug groups, phenylethylamines and 
cathinones had lower LODs/LOQs than piperazines and opioids.  Opioids are thought 
to undergo degradation during GC-MS analysis so their high LOQs for the developed 
method are not surprising (section 5.2.3.1).  Although the LOD for heroin was 
observed to be 5.62 x 10-1 µg/mL, at times it was not detected at 1.0 µg/mL (Tables 
4.2 & 4.4) further indicating the unpredictable behaviour of this drug (and other 
opioids) during this research. 
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Table 4.5: Instrumental LOD and LOQ 
 
 
Due to different injection volumes used on different instruments i.e. 1 - 2 µl in this 
research (Table 2.4) and 20 µl for LC-MS (Bagnall, et al., 2012), pg on column was used 
to compare LOD and LOQ values obtained in this research with those from published 
literature (normalized to a 1 µl injection).  The comparisons are shown in Table 4.6. 
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Table 4.6: Comparison of LOD and LOQ with literature (pg on column). 
 
 
For AMP and MAMP, the LOD values (0.14 and 0.33 pg, respectively) reported in this 
thesis are lower than those for GC-MS/MS i.e. 1.6 pg and 2.9 pg, respectively, from 
published literature (Gonzalez-Marino, 2010).  However, for MOR and heroin, the LOD 
values obtained in this research (66.67 and 562.40, respectively) were much higher 
than those reported by Gonzalez-Marino (2010) at 2.05 pg and 17.25 pg, respectively. 
However, silylation was used and this could have been a better derivatization method 
for the opioids especially with regards to degradation during injection or in solvents 
which was experienced with the PFPA derivatives (section 5.2.3.1). 
 
In a separate comparison, LOQs from this research were much lower than those 
reported by Castiglioni (2006) on an LC-MS/MS instrument for MOR (250 pg), AMP 
(380 pg), MAMP (208 pg), and MDMA (278 pg) but was higher than that reported for 
COC (18 pg). This shows that the analytical method used in this research (based on 
derivatization with PFPA and GC-MS) is more sensitive than GC-MS/MS or LC-MS/MS 
for some drugs.  Therefore, GC-MS is just as sensitive for trace analysis in complex 
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matrices as triple quadrupole instruments and hence can be used routinely for 
sewage epidemiological studies (Vazquez-Roig, et al., 2013). 
 
4.4   SPE EXTRACTION AND RECOVERY USING OPTIMISED INSTRUMENTAL METHOD 
Following the procedures as detailed in section 2.5.4, the recoveries of drugs in spiked 
treated waste water are listed in Table 4.7.  For validation purposes, Equation 4.1 
(Chambers, et al., 2007; Karolak, et al., 2010) was used to calculate the recovery as it 
was expected to give more representative results than Equation 3.1 that was used 
during preliminary investigations (section 3.4, page 116). 
 
 
                                                                                                                               Equation 4.1 
 
The treated waste water samples were evaluated for the presence of target analytes 
and any found to be present were accounted for during calculations. 
 
The RSDs for over half of the extracted analytes ranged from 4.4 % (AMP-d6) to 19.3 % 
(MEPH), which are within the ≤ 20 % criteria (FDA, 2001; Tarcomnicu, et al., 2011). 
The exceptions with RSDs ranging from 21.7 to 60.6 % included PIP, 3-FMC, MOR and             
2-MEOPP.  This indicates that there was a combination of low and high extraction 
precision for different drugs as observed in Table 4.3 (the same matrix and 
experimental conditions were applied).   RSD values for the post-extracted spiked 
sample were much better, with the majority ranging from 1.7 % (AMP-d6) to 18.2 % 
(MOR-d3). The exceptions, with RSDs ranging from 21.4 to 52.0 %, were 2-FPP, 3 and 
4-TFMPP, 4-MPP and 2-MEOPP.  High RSDs can be attributed to errors during the 
sample preparation and manual extraction process as discussed in section 3.4.2.1. 
This suggestion is further confirmed by the much lower overall RSDs for the drugs 
spiked into the post-extracted sample.  For instance the RSD for CAT was 46.1 % in the 
extracted spiked sample but reduced to 3.5 % in the post extracted spiked sample. 
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Table 4.7: Recovery (%) of a treated waste water sample. 
 
 
Since the drugs spiked into the post-extracted sample have not been through the 
extraction process, RSDs are expected to be less than for the extracted standards as 
the drugs are exposed to less intrinsic variables associated with the extraction 
process. The exceptions were for 2-FPP, 3-TFMPP and 4-TFMPP which saw an increase 
in RSDs in the post extracted spiked sample possibly due to errors during drying, 
derivatization and analysis. 
 
153 
 
Most of the drugs had recoveries falling between 64 and 162 %.  PIP exhibited a very 
low recovery (8 %) possibly due to signal suppression by co-eluting interferents as 
higher recoveries (36 to 93 %) had previously been obtained (Table 3.10).  The 
recoveries greater than 100 % are not unusual in sewage epidemiology (Vazquez-Roig, 
et al., 2013) and can be due to many factors such as the higher concentration of 
extracted standard compared with the post-extracted standard (section 3.4.2.1), loss 
of sensitivity during analysis (Bogusz, et al., 1985) or interfering co-eluants from the 
matrix or SPE cartridges (Gonzalez-Marino, et al., 2010; Gracia-Lor, et al., 2010; Baker 
& Kasprzyk-Hordern, 2011b). Low recoveries can be due to loss during extraction or 
evaporation (Mol, et al., 2000; Burgard, et al., 2013), unsilanised glassware (Baker & 
Kasprzyk-Hordern, 2011b) or signal suppression due to matrix effects (Kasprzyk-
Hordern, et al., 2007). 
 
However, use of Equation 4.1 to calculate recovery gave more realistic results than 
Equation 3.1 used during preliminary investigations (section 3.4, page 116).  Using the 
peak area of the sample spiked after the extraction process (added to the eluant) as 
the denominator ensured that the drugs were exposed to relatively similar solvents 
and sample preparation post extraction to those spiked before extraction (i.e. longer 
evaporation, matrix components and derivatization).  The neat unextracted standard, 
as used in Equation 3.1 during preliminary investigations (section 3.4, page 116), was 
not exposed to the post elution process (i.e. longer evaporation and matrix 
components) and hence greater errors could be introduced in recovery calculations 
resulting in unusually high recoveries [Table 3.8 (LLE) & Table 3.9 (SPE)].  In addition, 
for raw waste water samples, any drugs already present in the sample would be 
accounted for with the post-extraction standard leading to more accurate recovery 
calculations.  Therefore, only Equation 4.1 was used in extraction and recovery studies 
for method validation. 
 
In this study an EME recovery of 109 % was obtained which is an improvement on the 
recovery of 35 % reported by van Nuijs (2009b).  Baker & Kasprzyk-Hordern (2011a) 
also report recoveries of drugs greater than 60 % in raw waste water but acknowledge 
that some drugs such as EDDP and EMDP showed highly variable recoveries across the 
different matrices studied, as was also observed for some drugs in preliminary 
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investigations during this research (Table 3.10). 6-MAM and heroin were not detected 
in this study and during preliminary investigations which correlates with findings from 
published reports where these drugs were below the LOQ or were not detected 
(Boleda, et al., 2009; Baker & Kasprzyk-Hordern, 2011a).  This is attributed to possible 
deacetylation of heroin to 6-MAM which then hydrolyses to morphine  (Boleda, et al., 
2009). 
 
Internal standards were included in the study to evaluate their recovery especially 
when used for calculation of PAR where 100 % recovery is assumed.  From Table 4.7, 
one can see that the recoveries for AMP-d6, MDMA-d5 and COC-d3 were 79, 64 and 
156 %, respectively.  The recovery for COC-d3 is due to a higher concentration of 
extracted standard compared with the post-extracted standard due to a number of 
factors as described above. 
 
A comparison of the recoveries with column C from Table 3.10 (similar type matrix) 
shows a much lower recovery for PIP (8 versus 36 %) but recoveries > 70 % for some 
drugs such as MBZP,  MDMA , AMP and 2-FPP.  This indicates the potential of the 
method to give reproducible recoveries for some drugs even though the sample 
matrices were different (untreated versus treated waste water) collected on different 
days and using a different GC oven program. No two waste water samples have the 
same composition and hence the matrix components present will also differ and give 
rise to the different recoveries obtained.  As a result of this, with multianalyte 
methods, the analytical process used is a compromise for the different analytes and 
therefore it would be unrealistic to expect high recovery and low RSDs for all 
compounds in the mixture (Jimenez, et al., 2002).  In this regard, the acceptance 
criteria applied to recovery is that the values should be reproducible and precise 
regardless of the percentage value obtained (FDA, 2001; UNODC, 2009; Tarcomnicu, 
et al., 2011). 
 
Considering the different variables that are introduced with manual extraction and 
different sample matrices, the recovery values and RSDs achieved in this research 
showed that the method was suitable and reproducible for extracting the majority of 
targeted drugs. 
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4.5   MATRIX-BASED STABILITY 
Following the procedures as detailed in section 2.5.5, Table 4.8 lists the data from the 
stability study of drugs in untreated waste water stored at 5 °C over 7 days . Stability 
was assessed as stated in section 3.3.2, page 110. This stability study incorporated 29 
emerging and classic drugs of abuse and metabolites. As far as the author is aware, no 
other waste water stability study has incorporated this combination and number of 
illicit drugs to date, especially for cathinones and piperazines. 
 
The majority of the drugs  were stable to moderately stable after 3 days of storage 
(see Table 4.8 footnote).  EME, MOR and 6-MAM showed instability.  After 7 days of 
storage, the majority of drugs were still stable to moderately stable with only 3-FMC 
showing instability in addition to the drugs already mentioned. However, overall 
percentage change in PAR over the 7 day study period was less than the 30 % criteria 
for stability with the majority of drugs experiencing a change in PAR of < 18 %. 
 
MOR and 6-MAM had percentage increases > 100 % over the 7 day period and heroin 
was not detected.  Based on the proposed hydrolysis and deacetylation reactions as 
depicted in Figures 3.12 to 3.15, it can be postulated that perhaps the hydrolysis of 
heroin led to the increase in the concentrations of 6-MAM and MOR.  There is also a 
possibility that the increase in MOR concentration was due to the deconjugation of 
morphine-3-glucuronide and morphine-6-glucuronide  back to MOR, which naturally 
occurs in waste water (Melis, et al., 2011; van Nuijs, et al., 2011a; Castiglioni, et al, 
2013b; Senta, et al., 2014) as mentioned in section 1.4.3, page 26. 
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Table 4.8: Matrix-based stability of drugs stored at 5 °C. 
 
 
In contrast to the stability studies in sections 3.3.1, 3.3.2 and 3.3.3 which were 
conducted on mixed drug standards in an organic solvent, this study investigated 
stability in a real waste water sample in order to determine the extent of the 
degradation of drugs after sample collection and establish how long they can be 
stored for before extraction. 
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Marix based stability results for EME, 6-MAM and heroin correlate with earlier 
findings in sections 3.3.1, 3.3.2 and 3.3.3 where these drugs were the most unstable 
in relation to the other drugs.   Another observation made was that 3-FMC was highly 
unstable when stored as the underivatized drug (section 3.3.3) but quite stable when 
stored as the derivatized drug (sections 3.3.1. and 3.3.2).  In this study, 3-FMC was 
spiked into the matrix as the underivatized drug and than only derivatized on the day 
of analysis and the results correlate with those in section 3.3.3, i.e. unstable when 
underivatized. 
 
The results from this study correlate with findings from Baker & Kasprzyk-Hordern 
(2011b) for similar drugs in acidified waste water stored for over 72 h at 2 °C and with 
Chen (2013) for BZP, 3-TFMPP and MEPH stored at 4 °C, which were also stable.  
Although in Baker & Kasprzyk-Hordern‘s (2011b) study, AMP, KET, MOR, 6-MAM and 
heroin were all stable under the conditions of testing (with no derivatization). 
 
There is little in-sewer stability data on NPS but some biodegradation of KET, MEPH, 
and MDMA has been reported from stability studies conducted at pH 7.2 (Reid, et al., 
2014 a&b).  However, as presented in Table 4.8, the majority of drugs analysed in this 
thesis, in particuar the ATS and NPS (cathinones and piperazines) were stable to 
moderately stable at pH 2.5, with the exception of 3-FMC.  The stability of emerging 
drugs such as PIP, 4-FMA, CAT, 3-FMC, 2-FPP, 4-FPP, 4-MPP, MBZP, 2-MEOPP, and     
4-MEOPP in waste water has not been reported before. 
 
Although a number of matrix-based stability studies from published literature were 
conducted after sample collection (as in this research), a handful were also conducted 
in simulated sewage conditions to assist with a better understanding of the 
degradation process from their points of excretion to the sampling point (van Nuijs, et 
al., 2012; Senta, et al., 2014; Thai, et al., 2014). Results between the two types of 
stability studies correlate to a large extent especially with regards to the stability of 
ATS and BZE but differ on the stability of COC, MOR, EME and 6-MAM (Castiglioni, et 
al., 2013; Vazquez-Roig, et al., 2013). In Thai’s (2014) stability study conducted in 
simulated sewerage conditions (pH 7.5), a significant degradation of COC and 6-MAM 
was observed, while MAMP, MDMA and BZE did not undergo any significant 
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degradation. Significant changes were also observed for 6-MAM, COC, and MOR in 
Senta’s (2014) study while ATS were stable. van Nuijs (2012) also reports the stability 
of ATS and BZE under in-sewer conditions but the degradation of COC, EME and 6-
MAM.  However, in results from this thesis, COC did not undergo significant 
degradation but 3-FMC, EME, MOR and 6-MAM did (Table 4.8). This indicates that 
differences in results from stability studies between research groups is expected due 
to the varied composition and pH of the waste water samples, the drug mix 
combination and spiking concentration, sample extraction and preparation, stability 
study conditions and instrumental methods used (Baker, et al., 2012; Castiglioni, et 
al., 2013; Senta, et al., 2014).  However, few studies have been able to detect heroin 
and 6-MAM during sewage epidemiological studies owing to their significant 
degradation, which results in concentration levels below the LOD of most methods 
including LC-MS which do not involve a derivatization step (Baker, et al., 2014; Thai, et 
al., 2014; Vuori, et al., 2014; Yargeau, et al., 2014).  Therefore, the challenges 
experienced in this thesis with regards to the analysis of opioids are not unique and 
occur whether derivatization is included in the method (GC-MS) or not (LC-MS). 
 
Simulated in-sewer stability tests help with understanding the degradation process of 
drugs between their points of excretion and sampling. For example, in urban 
sewerage networks, it can take anything from 0.5 to 15 h for waste water to reach the 
sampling point, depending on the size of the WWTP (Castiglioni, et al., 2013; Chen, et 
al., 2013). Drugs that show significant degradation within hours, therefore, can be 
detected at levels below LOD or not at all. In addition to the stability in the sewer 
system, the length of sampling is also a potential source of error, especially when it is 
extended. Since samples collected in composite autosamplers (as in this thesis) can 
stay at the sampling point from 12 to 72 h, the stability of drugs during sampling 
needs to also be considered. However, while 24 h composite sampling has been 
regarded as a potential source of error in one study (Baker, & Kasprzyk-Hordern, 
2011b), in a separate study most of the target analytes were highly stable when 
stored for 72 h at 4 °C, except 6-MAM and COC which exhibited significant 
degradation (Senta, et al., 2014).  Therefore, even if the target analytes can be 
stabilised after collection, analyte loss throughout the sewage network and in the 
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autosamplers at WWTPs can be difficult to estimate especially for target analytes 
which experience significant degradation within hours (Chen, et al., 2013). 
 
Reported stability studies in waste water have been conducted over 12 h (Thai, et al., 
2014), 3 days (Castiglioni, et al., 2006; Baker & Kasprzyk-Hordern, 2011b; Senta, et al., 
2014), 5 days (Gheorge et al., 2008) and 7 days (Castiglioni, et al., 2006).  Longer term 
stability studies on MCX cartridges loaded with spiked acidified sample matrix, 
wrapped in aluminium foil and stored at -20 °C for 6 weeks before elution found all 
analytes to be stable (Baker & Kasprzyk-Hordern, 2011b).  A similar study on HLB 
cartridges loaded with non-acidified spiked waste water samples and stored at -20 °C 
for up to 3 months prior to elution also found all analytes to be reasonably stable 
(Gonzalez-Marino, et al., 2010). Therefore, for storage space considerations, 
cartridges loaded with samples are a worthy alternative to storage of bottles 
containing waste water samples (Baker & Kasprzyk-Hordern, 2011b). 
 
It has already been established that acidification and storage at -20 °C is thought to 
curb any biological activity, preserve the analytes and allow for longer time periods 
between sample collection and extraction (months versus days or weeks) (section 
1.4.4). Although the majority of drugs in this study were stable in acidified waste 
water for up to 7 days at 5 °C, precautions were taken to curb the observed 
degradation of some of the drugs.  This involved filtration of the sample, then 
acidification to pH 2.5 followed by storage at  5 °C for extraction within 72 h or at         
-20 °C for longer storage before extraction. 
 
Overall the majority of target drugs studied were stable in acidified untreated waste 
water (pH 2.5) for up to 7 days when stored at 5 °C.  However,  the sampling method, 
the type of sample preservation technique, e.g. acidification, all play a crucial role in 
the levels of drugs detected in waste water and this needs to be taken into account 
during method development, especially with multianalyte methods containing drugs 
with different physico-chemical properties (Senta, et al., 2014).  For drugs that show 
significant degradation during stability studies, i.e. 3-FMC, 6-MAM, this would need to 
be taken into account when estimating the relevant drug consumption. In addition, 
knowledge about the HRT is required for each target analyte in order to more 
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accurately estimate the level of degradation (Thai, et al., 2014). It could be that any 
results obtained (quantification or linking to community consumption) could be a 
gross under- or over- estimation of the actual levels of the drugs in waste water or 
their consumption (van Nuijs, et al., 2012).   A full understanding of the different 
chemical interactions that drugs are subject to whilst in waste water was beyond the 
realm of this research.  However, the matrix-based stability study undertaken during 
this research, and in published studies, provides a general approach for determining 
the stability of drugs of similar classes to those used here.  Further studies on the 
effect of the attenuation processes (section 1.3.4.2) on the target analytes, in 
conjunction with the type of sewer system and treatment processes applied, is 
required in order to provide a more accurate estimation of drug consumption using 
the sewage epidemiological approach (Thai, et al., 2014). 
 
Stability is, therefore, an important criterion when selecting a target analyte to be 
used in estimating illicit drug consumption. As a result, stability estimations have 
recently started being incorporated into back-calculations for drug consumption 
(Baker, et al., 2012 & 2014). 
 
The various tests discussed in this chapter showed that the developed method was 
suitable and ready for application on untreated waste water samples. 
 
In Chapter 5, the results from the application of the validated method to untreated 
waste water samples collected from a WWTP serving the Cambridge, UK, area are 
discussed in more detail with respect to detection and linking to community 
consumption. 
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CHAPTER 5 
RESULTS AND DISCUSSION - APPLICATION OF THE VALIDATED METHOD 
This chapter presents results from the application of the validated method to a 72 
hour composite sample collected from Anglian Water in Cambridge, UK, using 
standard addition for quantification. 
 
5.1  STANDARD ADDITION PLOTS 
Standard addition was carried out following the procedures as detailed in section 
2.5.6.  Figure 5.1 depicts an example of the standard addition plot of the PAR against 
the concentration for COC. 
 
 
Figure 5.1: Standard addition plot of PAR versus concentration for COC, n = 3. 
 
With standard addition, the y intercept is 0 when no drug standard has been spiked 
into the sample i.e. 0 = mx + c. When the sample matrix is spiked with a mixed drug 
standard, the intercept becomes positive from the response of the analyte already 
present in the sample. Standard addition plots for the rest of the detected drugs are 
in Appendix XIII a&b. All plots were linear with R2 ≥ 0.9900 (UNODC, 2009; Cooper, et 
al., 2010; Ammann, et al., 2012). 
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5.2  DETECTED DRUGS 
Table 5.1 lists the correlation coefficients and concentrations of the drugs detected in 
untreated waste water. 
 
Table 5.1: Correlation coefficients (R2) and concentration (µg/mL) of drugs  
detected in a 72 h composite waste water sample from Cambridge, UK, n=3. 
 
 
Out of the 29 target analytes, 11 drugs and metabolites were detected in waste water 
within their established linear range and LOQ (Tables 4.1 and 4.5, respectively).  These 
include the emerging drugs of abuse belonging to the cathinone group, MCAT, MEPH 
and BUTY; the piperazine group, 3-TFMPP and 4-MEOPP as well as classic drugs of 
abuse such as AMP, MAMP and COC. Also detected were EME (COC metabolite) and 
the therapeutic drugs KET and MOR.  Appendix XIV a&b gives an example of the 
calculation for the concentration of COC in waste water using standard addition. 
 
The highest concentration levels detected were for MCAT (0.253 ± 0.083), MEPH 
(0.549 ± 0.046) and MOR (0.256 ± 0.058), all in µg/mL as expounded upon in sections 
5.4.1.5, 5.4.2 and 5.4.2.1. 
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5.2.1   Confirmation of Detected Drugs 
With complex matrices such as waste water, analytes are present at trace levels and 
therefore the chances of observing co-eluting interferents of similar or higher 
concentrations are greatly increased.  In addition waste water is hugely variable in 
composition and hence no one blank sample exists from which the background can be 
subtracted for all future analyses (Bijlsma, et al., 2009).  It is therefore realistic to 
expect that with complex and unpredictable matrices, matrix components that share 
a particular m/z value with an analyte may be present and could offset the ion ratios 
(Gracia-Lor, et al., 2010; Portoles, et al., 2011). This problem is even more pronounced 
when only one ion is monitored since any matrix component sharing that m/z value 
can lead to a false positive result (Pozo, et al., 2006).  In this research, throughout the 
method development, confirmation using 3 or more diagnostic ions (for the majority 
of analytes) could be reliably made. The exception was AMIT which only gave one 
diagnostic ion (m/z 58) of relative abundance greater than 10% (Appendix VI).  When 
at least three diagnostic ions (and hence at least one ion ratio) are monitored in a 
sample matrix with respect to the analytical standard, it is highly unlikely that another 
matrix component will share the same three ions at a particular RT (so-called isobaric 
effects) (Rivier, 2003).  However, its presence in even one of the monitored ions will 
offset the ion ratios when compared to the unextracted standard (Gracia-Lor, et al., 
2010).  These so-called isobaric effects are more likely to be a factor in single 
quadrupole GC-MS or LC-MS and hence the more diagnostic ions that are chosen for 
SIM analysis the less likely the errors when reporting findings (Couchman & Morgan, 
2010; Vogeser & Seger, 2010).  This also gives the opportunity of maintaining at least 
one ion ratio if one is out of acceptable limits due to matrix interferents (Pozo, et al., 
2006). 
 
In this research, at least one ion ratio was within acceptable limits for all detected 
compounds i.e. ± 20 % (EC, 2002; Cooper, et al., 2010; van de Steene, et al., 2010; 
Baker & Kasprzyk-Hordern,  2011a; Trinh, et al., 2011; Migowska, et al., 2012).  In 
addition to diagnostic ions and ion ratios, other parameters used to confirm the 
identity of target analytes were the RT and RI, thereby exceeding the criteria of three 
identification points (IPs) as recommended by the applicable guideline adopted for 
this research i.e. EC 2002. [IPs used in this research include at least 3 diagnostic ions 
164 
 
(equivalent to 1 IP per ion), at least 1 ion ratio (equivalent to 1 IP per ion ratio falling 
within specifications), the RT (equivalent to 1 IP), the RI (equivalent to 1 IP)]. It is 
worth mentioning that there are no specific guidelines for criteria used in the 
identification and confirmation of analytes in variable and complex waste water 
samples.  The EC, 2002 guidelines have been ‘adopted’ by some researchers within 
sewage epidemiology, including this author, but they are in no way prescriptive or 
regulatory and aim only to guide individual laboratories in achieving future goals 
(Cooper, et al., 2010). 
 
While some researchers commented on the lack of specificity for some of the 
diagnostic ions produced by their method (Gonzalez-Marino, 2010), derivatization 
with PFPA ensured specificity with regards to diagnostic ions. In addition, GC-MS has 
been widely applied for confirmation of analytes in complex matrices due to the 
wealth of valuable information obtainable by using EI ionization and comparison of 
spectra with databases (Pozo, et al., 2006; Vazquez-Roig, et al., 2013). When using 
SIM mode, the monitoring of 3 or 4 ions is normally considered sufficient for the 
confirmation of trace analytes (Pozo, et al., 2006). However, to further aid in 
confirming the identity of detected drugs as well as to increase the sensitivity of the 
method, simultaneous SIM and SCAN mode was used for this thesis (Migowska, et al., 
2012).  The ions monitored for this research have already been mentioned in an 
earlier chapter (Table 3.3, page 102). 
 
As an illustration, Figures 5.2 and 5.3 depict the SIM and SCAN spectra used to 
confirm the identity of KET, in the 72 h composite waste water sample.  In Figure 5.2, 
the RTs of the diagnostic ions of the KET peak in the untreated waste water sample, 
column B (19.36 min), corresponds with the RTs of the diagnostic ions of the mixed 
drug standard, column A (19.32 min).  An ethyl acetate blank, run directly before the 
waste water sample, acted as quality control to check for any carryover from the drug 
standards or other contamination.  No peaks were present at the corresponding RT 
indicating that the presence of the KET peak in the unspiked waste water sample was 
not as a result of contamination. 
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Figure 5.2: Identification and confirmation of ketamine in a 72 h composite  
waste water sample (SIM). 
 
Table 5.2 lists the corresponding diagnostic ions, peak areas and ion ratio of the mixed 
drug standard (column A) in reference to that of the unspiked and untreated waste 
water sample (column B).   
 
Table 5.2: Diagnostic ions, peak areas and ion ratio for ketamine in an untreated 
waste water sample and mixed drug standard. 
 
 
The percentage difference between the ion ratios was 18 %, thereby meeting the 
criteria for at least one ion ratio being within ± 20 % of the respective standard (EC, 
2002; Cooper, et al., 2010).  Therefore, the presence of KET could be reliably 
confirmed in the waste water sample.  
 
To further confirm the presence of KET in the unspiked untreated waste water 
sample, an extracted ion spectrum of the KET diagnostic ions was conducted (Figure 
5.3).  The RT (19.32 min) and ion ratios between the unspiked waste water sample 
and mixed standard corresponded indicating the presence of the same compound. 
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Figure 5.3: Identification and confirmation of ketamine in a 72 h composite waste 
water sample (SCAN) in relation to a mixed drug standard, showing corresponding 
diagnostic ions. 
 
Figure 5.4 shows the corresponding TIC spectra of the waste water sample depicting 
the position of KET in relation to other matrix components.  The selectivity of the    
GC-MS method with PFPA derivatization developed in this research is demonstrated 
through the positive identification of KET in the presence of much higher 
concentration levels of numerous unwanted co-extracted matrix components.  This 
was also discussed earlier in section 3.4.3 where KET and MOR were detected in 
independent untreated waste water samples during preliminary investigations (Figure 
3.27 & Appendix IX).  Appendix IX is mentioned here again as it further reiterates the 
detection of MOR in various untreated waste water samples, with confirmation 
through corresponding RTs and ion ratios in comparison to a drug standard. 
 
Not all quantifiable drugs could be detected in SCAN mode due to much lower 
concentration levels but they were identified through their SIM spectra and ion ratios 
(Section 3.4.3, page 130-134; Appendix X). 
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Figure 5.4: TIC of unspiked 72 h composite waste water sample depicting the 
position of ketamine in relation to other matrix components. 
 
The standard addition method used for quantification also increased the reliability of 
the method with regards to identification and confirmation of the target analytes.  In 
literature comparisons between standard addition and matrix-matched calibration, 
higher concentration values were obtained with the former (Furey, et al., 2013).   In 
Furey’s (2013) publication, significant errors attributed to ion suppression in the 
matrix-matched calibration were also observed when compared to standard addition 
which had fewer errors.  With the standard addition method, the same matrix is used 
for calibration and quantification and hence any matrix effects or interferents will be 
identical for each injection and will be automatically accounted for. This makes 
standard addition an effective and reliable method of accurately determining the 
actual analyte concentration (Gorazda, et al., 2013; Furey, et al., 2013). 
 
Based on the calculated concentration of drugs found in waste water, a back-
calculation can be made to determine the estimated usage of these drugs (in 
milligrams per day) in the community served by the WWTP. 
 
5.3   ESTIMATION OF COMMUNITY USAGE 
The information required in order to calculate the estimated community drug usage is 
discussed in section 1.4.4. The Anglian Water WWTP in Cambridge serves a population 
of around 145, 310 (2012 figures) comprising domestic waste from the city of 
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Cambridge and surrounding villages as well as trade effluent.   The average daily flow 
of waste water at the plant ranges from 37, 330 L/day during dry weather (no 
contribution from storm water run-off) to 109, 987 L/day (with contributions from 
rainfall and storm run-off).  A mid-range of 73, 658 L/day was used in calculations. 
 
5.3.1   Conversion Factors (CF) for Back-calculating Drug Consumption 
In order to calculate drug consumption, the urinary excretion rate of major or minor 
metabolites in humans is required.  This allows for the back-calculation to the total 
drug consumed. Not all drugs of abuse included in this study, especially piperazines 
and cathinones, have established human urinary excretion profiles, in-sewer stability 
profiles, as well as commercially available standards of their metabolites (Castiglioni, 
et al., 2013; Gautam, et al., 2013; Baker, et al., 2014; Chen, et al., 2014; Reid, et al., 
2014a).  Therefore, back-calculations for drug consumption estimations could not be 
conducted for them.  However, daily loads of the target drug into the WWTP (in 
mg/day), normalized against the flow at the WWTP and the number of people served 
by the particular WWTP (Equation 5.1), could be calculated for comparison with 
published reports, where available, as these do not rely on the urinary excretion 
profile of the target analyte (Baker, et al., 2014; Khan, et al., 2014).  As the composite 
sample for this research was collected over 72 h, the calculated loads are for a 72 h 
period. 
 
 
For drugs with known excretion profiles in humans, back-calculations were 
normalized against the flow at the WWTP and the number of people served by the 
particular WWTP and the urinary excretion profile. Normalizing the results in this 
manner is essential for comparisons of drug consumption estimates obtained from 
different sources, cities and countries (Castiglioni, et al., 2013). As a result, most 
recent publications in sewage epidemiology report normalized daily mass loads or 
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drug consumption as opposed to concentration, especially when comparisons with 
other studies are being made or when spatial or temporal drug usage trends are being 
reported (Thomas, et al., 2012; Nefau, et al., 2013; Baker, et al., 2014; Kankaanpaa, et 
al., 2014; Khan, et al., 2014; Ort, et al., 2014; Ostman, et al., 2014). 
 
Therefore, for the 11 drugs and metabolites detected and quantified in Table 5.1, only 
those with available human urinary excretion profiles and commercially available 
standards of the major metabolite, at the time of writing of this thesis, could be used 
in back-calculations to levels consumed.  These were AMP, COC, EME, KET, MAMP and 
MOR.  The urinary excretion rates and CF, as calculated using Equation 1.2, are listed 
in Table 5.3. A background to the main metabolites for these drugs has been 
discussed in Appendix II. 
 
Table 5.3: Excretion profile and conversion factors used in back-calculations to 
estimate community drug consumption. 
 
 
Using Table 5.3, the CF is calculated according to Equation 5.2. 
 
 
 
An example of how the CF was calculated for COC, using EME as the major excretion 
product has already been shown in Equation 1.2 (page 27), but repeated here. 
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The calculations of the CF for COC and heroin could be conducted using their major 
metabolites (EME and MOR, respectively). The CF for COC was also calculated using 
the parent drug since it was also detected in waste water.  For drugs such as AMP and 
MAMP, the parent compound is excreted as the major metabolite (30 and 43 %, 
respectively) and hence was used in the CF calculation. Calculation of CF using the 
parent drug was conducted for KET because its major metabolites were not 
monitored for this research.  However, using a  parent drug as a target analyte and 
low urinary excretion rates (e.g. 2 % for KET) potentially introduces higher 
uncertainties for back-calculation estimates since a distinction cannot be made 
between consumption and direct disposal (Khan and Nicell, 2011; Baker, et al., 2014). 
Once established, the CF can then be used to back-calculate to the total amount of 
drug consumed. 
 
5.3.2   Drug Consumption Calculations 
Once the CF (of COC) is known, it can be applied in Equation 1.1, resulting in the 
consumption of COC as depicted in Equation 5.3 (Lai, et al., 2013a): 
 
 
 
The COC consumption, in mg/day, is then normalized for the number of people served 
by the WWTP in Cambridge, i.e. 145,310 people, expressed in mg/day per 1000 
people (Equation 5.4). 
 
 
In like manner, the estimated drug consumption values for the rest of the drugs were 
calculated. These, in addition to daily loads, are listed in Table 5.4. 
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From the drug consumption results, KET has the highest consumption figures, 
followed by total COC and MOR (2463.5, 412 and 399.4 mg/day per 1000 people, 
respectively).  These figures are put in perspective of global and UK drug consumption 
in section 5.4. 
 
Table 5.4: Estimated 72 h loads and drug consumption levels in Cambridge, UK 
(mg/day per 1000 people). 
 
 
5.3.2.1   Assumptions Made in Estimating Drug Consumption Levels 
The sewage epidemiological approach is still under development and while many 
advances have been made since the idea first came to light almost 15 years ago 
(Daughton, 2001b), several aspects still need further investigation. Therefore, due to 
the evolving nature of the sewage epidemiological approach, any calculations (daily 
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mass loads or drug consumption) are based on the current knowledge at the time of 
sampling.   
 
There are many variables that have an impact on the calculation of drug usage 
patterns, such as urinary excretion patterns, degradation within the sewer system, 
attenuation processes, the fluctuating flow rates and population served by a WWTP, 
and sampling method (Banta-Green, et al., 2009; van Nuijs, et al., 2011b; Baker & 
Kasprzyk-Hordern, 2011b; Lai, et al., 2011; Castiglioni, et al., 2013). All these variables 
cannot be determined with great accuracy and give rise to uncertainties with any drug 
consumption calculations.  This has led to a few recent published articles that provide 
an assessment of the entire sewage epidemiological approach from sampling to the 
back-calculation, in order to highlight uncertainties/limitations arising from the 
approach (Lai, et al., 2011; Castiglioni, et al., 2013 & 2014; Baker, et al., 2014). 
 
The key variables and uncertainties/limitations, and recommendations for reducing 
them have been summarized in Table 5.5 which has been adapted from Castiglioni’s 
(2013 a&b) publication, with contributions from other published articles (EMCDDA, 
2008 & 2014b; Ort, et al.,  2010a&b; Lai, et al., 2011; van Nuijs, et al., 2011a; Baker, et 
al., 2014). 
 
Some of the information required under ‘recommendations’, such as hydrochemical 
parameters and flow-rate, can be obtained by communication with personnel at the 
WWTP (van Nuijs, et al., 2011a; Castiglioni, et al., 2013 & 2014). 
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Table 5.5: Variables, limitations and recommendations for the sewage epidemiological approach. 
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             Table 5.5 cont’d: Variables, limitations and recommendations for the sewage epidemiological approach. 
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During the research discussed in this thesis, the following key assumptions were made 
which had an impact on the final drug consumption estimations as presented earlier 
in Table 5.4: 
 
 A static population served by the WWTP i.e. 145, 310 (section 5.3). 
 A static flow-rate estimate i.e. average of 73, 658 L/day (section 5.3). 
 A constant urinary excretion rate for the target analytes e.g. 9 % for COC        
(Table 5.3). 
 Insignificant degradation of target analytes in waste water (based on Table 4.8). 
 The concentration of detected drugs is due to human consumption with no 
contribution from direct disposal. 
 No loss of waste water along the sewage pipe network from source to WWTP. 
 
However, a number of recommendations were incorporated into the method 
developed during this research in order to reduce some of the uncertainties as 
presented in Table 5.5.  These included the use of stable-isotope labelled internal 
standards and incorporating quality control measures to reduce uncertainties during 
sample analysis (section 2.6). In addition, waste water samples were acidified and 
refrigerated/frozen to minimize analyte degradation. Stability studies were also 
conducted in order to understand the stability profile of the analytes under different 
conditions and determine the effect on the final results. As the sewage 
epidemiological approach is still in its infancy, a lot of the recommendations have 
been evolving and published when more knowledge was obtained from various 
research studies in various parts of the world.  A number of recommendations were 
not publicly available during the time of sampling for this research and some were 
beyond the scope of this research e.g. use of hydrochemical parameters to estimate 
population and chiral chromatography for differentiating between pharmaceutically 
active and inactive enantiomers. 
 
Due to the huge potential of the sewage epidemiological approach, research in this 
area has, therefore, recently turned its focus towards refining the approach in order 
to minimise these uncertainties and enhance the reliability of the back-calculation 
method for drug consumption. This includes modification of the formula originally 
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suggested by Zuccato (2005) to account for the use of therapeutic drugs as well as 
the stability of the target drugs (Lai, et al., 2011; van Nuijs, et al., 2011 a&b; Baker, et 
al., 2012 & 2014). Aspects of environmental engineering are also being incorporated 
into sewage epidemiological studies (Repice, et al., 2013). 
 
Refining the sewage epidemiological approach will also ensure that data can be 
adequately compared between different sites and countries as well as provide 
reliable estimates of drug consumption that complement alternative drug monitoring 
methods. In this regard ‘best practice protocol’ has been developed by leading 
researchers in this field based on current learnings with respect to sample collection, 
storage and analytical procedures (Castiglioni, et al, 2013 a&b; EMCDDA, 2013).  The 
majority of recommendations had been adopted during the research discussed in this 
thesis. However, the recommendations themselves are dependent on current 
knowledge and should not be prescriptive as they will undoubtedly also evolve as the 
sewage epidemiological approach continues to be refined.  For instance, while some 
researchers report the adsorption of drugs onto suspended solids as a possible 
source of uncertainty (Baker & Kasprzyk-Hordern, 2011b; Verlicchi, et al., 2012; 
Baker, et al., 2014), it is now widely believed that this factor has a negligible impact 
on the uncertainty since less than 9 % of target analytes are adsorbed onto 
suspended solids (Gheorghe, et al., 2008; Gonzalez-Marino, et al., 2009; Metcalfe, et 
al., 2010; Castiglioni, et al., 2013b; Repice, et al., 2013). 
 
In addition, the recommendations also have their own limitations which need to be 
taken into consideration when adopting them. For instance, while LC-MS has become 
the preferred analytical method for the sewage epidemiological approach (Thomas, 
et al., 2012; Repice, et al., 2013), it is still plagued by limitations such as matrix 
effects.  On the other hand, GC-MS-EI, with PFPA derivatization, produces very 
distinct mass spectra for the majority of drugs, is not as affected by matrix effects as 
LC-MS is and is capable of LODs lower than or as good as LC-MS/MS (Heath, et al., 
2010; Vazquez-Roig, et al., 2013).  Therefore, GC-MS is equally viable for sewage 
epidemiological studies and its advantages have been listed in Table 1.10. 
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The main research gaps with the sewage epidemiological approach, as identified by 
Castiglioni (2014), include the improvement of sample analysis methodology through 
standardised protocols, the improvement of stability data to further understand 
contributions due to degradation, conducting additional pharmacokinetic studies on 
target drugs to provide more accurate human urinary excretion profiles, and 
developing a way of more accurately estimating the number of people contributing 
to the waste water sample. 
 
However, despite these uncertainties and research gaps, sewage epidemiological 
results often correlate well with those from other drug monitoring sources and, 
therefore, any  calculated drug consumption results are a generally good estimation 
of actual values (Banta-Green, et al., 2009; Thomas, et al., 2012; Lai, et al., 2013c; 
Khan, et al., 2014). 
 
In this research, since the composite sample used for standard addition was collected 
over 72 h, there was probably loss of some analytes through degradation or ex-
filtration leading to them not being detected or detected below their LOD and LOQ 
(Lai, et al., 2011; Burgard, et al., 2013).  In addition, time-proportional sampling, as 
has been used by many other research groups, was used (Thomas, et al., 2012; Lai, et 
al., 2013b; Khan, et al., 2014; Vuori, et al., 2014). However, composite sampling has 
more advantages that negate the possible loss due to degradation, such as obtaining 
time-weighted drug concentrations as well as average concentration values based on 
influent flow rate (Repice, et al., 2013; Boles & Wells, 2014).  Corrections for stability 
were beyond the scope of this research and hence were not performed as part of the 
main results. In addition, as samples were collected for a specific period only, the 
results cannot be used as a general pattern of drug consumption in Cambridge or the 
rest of the UK. 
 
5.4   LINKING DETECTED DRUGS WITH GLOBAL AND UK CONSUMPTION 
This section puts into perspective the results from the drug consumption calculations 
obtained from this research with information obtained from social surveys and other 
published articles that reflect the types and levels of drugs consumed within the UK 
and on a more global scale.  As far as the researcher is aware, only three other 
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research groups have included cities in the UK in sewage epidemiological studies 
(Bones, et al., 2007; Zuccato, et al. 2008 and the group comprising Baker & Kasprzyk-
Hordern (2007 - 2013).  Comparative UK studies for the past three years can only be 
made with Baker & Kasprzyk-Hordern’s publications.  In addition, samples in this 
thesis were collected over a 72 h period as compared to the 24 h composite samples 
collected by other researchers, with which comparisons have been made.This allowed 
more time for any target analyte to be collected, if present, as compared with a 12 or 
24 h composite sample, assuming negligible attenuation processes and sample 
degradation (section 1.3.4.2). 
 
5.4.1   Classic Drugs of Abuse 
Classic drugs of abuse such as cannabis, cocaine, amphetamines, ecstasy, and opioids 
still remain the most abused drugs in Europe (EMCDDA, 2014a). Heroin use has seen a 
significant downward trend and ecstasy and methamphetamine are showing trends of 
resurgence after a downward spiral in the past few years (ibid).  In England and Wales, 
cannabis, cocaine, ecstasy and amyl nitrate remain the most abused classic drugs 
(CSEW, 2014) while in the UK overall, crack cocaine and the opioids (heroin and 
methadone) top the list together with cannabis and NPS [Centre for Social Justice 
(CSJ), 2013]. 
 
It is, therefore, not surprising that AMP, MAMP, EME, COC and MOR were detected 
and quantified in waste water samples from Cambridge, UK (Tables 5.1 and 5.4). 
These are discussed in more detail below.  Comparisons between data obtained from 
Cambridge, UK (i.e. this research) with that from published articles have been made 
based on daily loads (Equation 5.1) and/or consumption data (Equations 5.3 and 5.4). 
 
5.4.1.1   Amphetamine  
Sources of AMP in waste water include illicit use and prescription drugs such as 
Dexedrine and dexamphetamine, used for the treatment of attention deficit 
hyperactivity disorder (ADHD) (Lai, et al., 2013a). It is also formed as a metabolite of 
selegiline (for Parkinson’s disease) and MAMP (van Nuijs, et al., 2011a; Moffat, et al., 
20llb). Therefore, the total estimated daily loads of AMP into the WWTP in 
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Cambridge, UK, and consumption of AMP can be attributed to both illicit and 
therapeutic use. 
 
Table 5.6 compares daily loads and consumption levels for AMP as determined in this 
research with those from published literature.  Maximum concentrations are quoted 
except where indicated. 
 
Table 5.6: Amphetamine daily loads and consumption data from different countries. 
 
 
At daily loads of 11.7 ± 7.4 mg/day/1000 people, data from Cambridge is similar to 
that from some cities in Sweden, such as Koping and Trelleborg (10 - 18 mg/day/1000 
people), but much lower than that from other cities in Sweden, such as Soderhamn 
and Gothenburg (100 - 140 mg/day/1000 people) and Eindhoven in The Netherlands 
(3040 mg/day/1000 people). In like manner, at 38.9 ± 24.8 mg/day/1000 people, 
consumption data from Cambridge is similar to that from Mora in Sweden (47 
mg/day/1000 people) but lower than that from other parts of England (102 ± 3.8 
mg/day/1000 people), Finland (150 - 400 mg/day/1000 people) and France (93 
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mg/day/1000 people).  Overall, AMP consumption levels range from 47 - 610 
mg/day/1000 people but this range could be higher if the daily load of 3040 
mg/day/1000 people (The Netherlands) is normalized to consumption. The daily loads 
and normalized consumption data from several studies conducted in different 
countries indicate varied AMP consumption as a result of different drug use 
preferences and habits, waste water composition and sources, population sizes 
served by the WWTPs, sampling methods, etc.  These factors are expounded upon in 
section 5.5.1 below. 
 
5.4.1.2   Methamphetamine 
Table 5.7 compares consumption levels for MAMP as determined in this research with 
those from published literature. 
 
Table 5.7: Methamphetamine daily loads and consumption data from different 
countries. 
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MAMP, mainly used illicitly, also has limited therapeutic use in the treatment of 
attention deficit hyperactivity disorder (ADHD) and narcolepsy and is also a 
metabolite of selegiline (Lai, et al., 2011).  Therefore, the total calculated 
consumption for MAMP (84.3 ± 59.1 mg/day per 1000 people) also does not 
differentiate between illicit or therapeutic use.  
 
At 84.3 ± 59.1 mg/day/1000 people, the MAMP consumption result from Cambridge is 
lower than that from Hong Kong (190 ± 11 mg/day/1000 people) but higher than that 
from other parts of England (29.8 ± 0.9 mg/day/1000 people) and Sweden (2.3 - 71 
mg/day/1000 people). Overall, MAMP consumption levels range from 2.3 - 190 
mg/day/1000 people across Europe. However, the daily load for Cambridge (36.2 ± 
25.5 mg/day/1000 people) was lower than that from China (121.7 mg/day/1000 
people) and Norway (117.3 mg/day/1000 people). 
For both AMP and MAMP, direct disposal into the sewage system can also not be 
ruled out since the parent drugs were used in the back-calculations (Boles & Wells, 
2014). In addition, both AMP and MAMP are known to exist as a pair of enantiomers 
which differ in pharmacological activity and metabolism.  The S-(+)-enantiomer is 
known to be more potent and is present in recreational formulations, while the R-(-)-
enantiomer is less potent and often present in pharmaceutical products (Kasprzyk-
Hordern, et al., 2009a; Bagnall, et al., 2013; Emke, et al., 2014). Therefore, the only 
way to truly distinguish between recreational and pharmaceutical AMP and MAMP is 
by separation and analysis of their enantiomers through derivatization or chiral 
chromatography, which was beyond the scope of this research (Herraez-Hernandez, 
et al., 2002; Emke, et al., 2014). However, other research groups have been 
investigating enantiomeric profiling of drugs in waste water to enable better 
estimations of illicit use (Kasprzyk-Hordern & Baker, 2012; Emke, et al., 2014). 
 
AMP has been more widely abused than MAMP in Europe over the past few years but 
MAMP has seen a recent increase in usage (EMCDDA, 2014a). Results from this 
research, where MAMP was detected at a higher concentration than AMP, therefore, 
correlates with findings from the EMCDDA (2014a) report. 
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5.4.1.3   Other Phenylethylamines 
Other phenylethylamines analysed in this research but not detected include MBDB,         
4-FMA and MDMA.    MBDB was also not detected elsewhere in England probably due 
to low consumption but MDMA has been detected at consumption levels of 148 
mg/day/1000 people (Baker & Kasprzyk-Hordern, 2013; Baker, et al., 2014). It is 
surprising that MDMA was not detected especially since it is a popular ‘club drug’  
among students and ‘yuppies’ which make up a substantial portion of the 
demographics of Cambridge, UK, and also as one of the top drugs consumed in 
England & Wales (CSEW, 2014).  In addition, it had a low analytical LOD and LOQ (0.33 
and 1.33 pg on column, respectively), was stable and had relatively good recovery of 
70 %. This could be due to different drug usage habits within England with a higher 
preference for KET and MEPH in Cambridge, UK, or that its presence in the particular 
waste water sample was below the analytical LOD as also reported for Norway (Reid, 
et al., 2014a) and Hong Kong (Lai, et al., 2013b).  As far as the author is aware, this is 
the first reported method to incorporate     4-FMA in sewage epidemiological studies 
and hence no comparative figures were available at the time of writing of this thesis.  
However, it could also have been present below the analytical LOD or not 
substantially consumed in Cambridge, UK. 
 
5.4.1.4   Cocaine 
A comparison of COC consumption estimations from this research with those from 
published literature are listed in Table 5.8. 
 
The result for Cambridge was much lower than elsewhere in England (Baker, et al., 
2014), Portugal (Lopes, et al., 2014) and Belgium (van Nuijs, et al., 2011b) but higher 
than Norway (Redi, et al., 2014) and on par with Sweden and Norway (Thomas, et al., 
2012). The consumption of COC varied widely between countries and within 
cities/regions within the same country.  However, comparisons are made based on 
different target analytes used (i.e. BZE, COC and EME) which affects results as 
described in section 5.4.1.4.1 below.  In this research, COC consumption estimates 
were calculated using EME and COC as target drugs and both results were lower than 
publications that used similar target analytes (van Nuijs, et al., 2011b & Baker, et al, 
2014, respectively). Although occurrence and consumption habits differ widely 
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between countries, COC is second only to cannabis as the most commonly used illicit 
drug in Europe (EMCDDA, 2014a; Lopes, et al., 2014). 
 
Table 5.8: Cocaine consumption data from different countries. 
 
 
Results from literature reviews for sewage epidemiology found some of the highest 
consumption values for illicit drugs across countries were related to COC consumption 
(Thomas, et al., 2012; Ort, et al., 2014). 
 
5.4.1.4.1   Target Analytes for Estimating Cocaine Consumption 
In published literature, the consumption of COC has been estimated in several ways 
through the use of COC, or one or more of its metabolites, benzoylecgonine (BZE), 
nor-BZE and EME (Nefau, et al., 2013; Baker, et al., 2014; Ort, et al., 2014). The 
majority of published reports used BZE rather than EME or COC itself, citing the 
instability of both EME and COC and the high LOQ of EME as a basis for the selection 
(van Nuijs, et al., 2009c; Baker, et al., 2014).  The reasoning is that since EME and COC 
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exhibited degradation in stability studies based on sewage conditions, it was most 
likely to be unstable in the sewage system and hence the amount detected would be 
an underestimation of the original concentration in waste water samples (van Nuijs, 
et al., 2012; Thai, et al., 2014). On the other hand, BZE has been found to be stable in 
waste water stability studies (Baker, et al., 2014). Lai (2011) also targeted EME and 
BZE but only detected BZE due to instability of EME. This correlates with findings in 
this thesis where EME was observed to be unstable during matrix-based stability 
studies conducted at pH 2, although COC was stable (Table 4.8). 
 
It can, therefore, be postulated that due to the observed degradation of EME in waste 
water, the estimated COC consumption (using EME) reported in this research (195.5 ± 
95.4 mg/day per 1000 people) is most likely an underestimation and the result is 
much higher than that. 
 
The levels for COC consumption can also be calculated using the parent drug (Bones, 
et al., 2007; Karaolak, et al., 2010).  This resulted in an estimated consumption of 
216.5 ± 29.9 mg/day per 1000 people in this research.  However, this is most likely an 
overestimation of COC consumption since it does not differentiate between direct 
disposal of the parent drug into the sewer system and illicit use (van Nuijs, et al., 
2011a; Nefau, et al., 2013). In Baker’s (2013) study, COC consumption estimations 
using the parent drug were significantly higher than those when using BZE (12876 ± 
47 and 1767 ± 45 mg/day per 1000 people, respectively).  However, in this thesis, 
results for COC estimation using the parent drug and EME were similar (i.e. 216.5 ± 
29.9 and 195.5 ± 95.4 mg/day per 1000 people, respectively).  van Nuijs (2011b) 
calculated COC consumption using EME and BZE and found comparable values of 523 
and 519 mg/day per 1000 people, respectively. 
 
In this regard,  EME can also be effectively used in back-calculating for COC 
consumption since it is also a significant metabolite of COC  (Gheorghe, et al., 2008; 
Nefau, et al., 2013; Baker, et al., 2014; Khan, et al., 2014).  Improving sample 
preservation practices from the sampling to analysis stage can help in the 
measurement of significant amounts of EME in waste water in the future.  For 
instance, if the waste water samples are acidified and extracted immediately upon 
185 
 
arrival at the laboratory and analysed within 24 h of extraction, EME can still be 
detected above the LOQ, if present, as was the case in this thesis. If the sample is to 
be extracted at a later time then storage at -20 °C is imperative for EME since it 
degrades when stored at 5 °C (Table 4.8).  In addition to having a low LOQ (Table 4.5), 
EME was moderately stable when derivatized and stored at -20 °C for up to   2 weeks 
(Table 3.5) and also when stored underivatized at -20 °C for up to 4 weeks (Table 3.6).   
However, even though EME is a suitable target analyte for COC consumption, the 
reliability of the result can be improved if its degradation is incorporated in drug 
consumption calculations and if BZE and nor-BZE can be simultaneously detected for 
comparison (Baker, et al., 2013; Khan, et al., 2014). It is worth bearing in mind that 
using BZE for COC estimations also has its own drawbacks. COC is known to hydrolyse 
to BZE in waste water and hence the amount of BZE quantified maybe an 
overestimation of the initial concentration which would also give rise to uncertainties 
with the drug consumption estimations for COC (van Nuijs, et al., 2012; Castiglioni, et 
al., 2013; Thai, et al., 2014). 
 
5.4.1.5   Opiates 
MOR is a major metabolite of heroin but it is also a metabolite of the analgesic 
codeine and several other therapeutic drugs such as nicomorphine and pholcodine 
(Levine, 2006; Baker, et al., 2014). It is also a drug in its own right.   Table 5.9 
compares consumption levels for MOR as determined in this research with those from 
published literature.  In this thesis, as in published literature as well, MOR was used to 
estimate both heroin and MOR consumption, with results differing based on the 
conversion factor (CF) used (Table 5.3). 
 
From results presented in Table 5.9, the MOR daily load for Cambridge (129.6 ± 29.5 
mg/day/1000 people) was within the range for cities in Sweden (50 - 350 
mg/day/1000 people) but higher than that for Finland (50.7 mg/day/1000 people).   
 
Although MOR was not detected in raw waste water samples from a WWTP serving      
3.5 million people in an unspecified location in England (Baker, et al, 2014), it was 
detected and quantified in raw waste water samples from a WWTP in Cambridge, UK, 
serving a population of 141,310 people.  However, this difference is not surprising 
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considering the temporal and spatial differences in drug consumption values within 
the same day, country and between countries as documented in several studies 
(section 5.5.1). 
 
Table 5.9: Heroin and morphine daily loads and consumption data from different 
countries. 
 
 
In comparing heroin consumption using MOR as the main metabolite, results from 
Cambridge, UK (399.4 ± 90.8 mg/day/1000 people) are more than twice as high as 
those from London, UK (173 ± 29 mg/day/1000 people) (Table 5.9).  In England, it has 
been reported that approximately 0.01 % of morphine in wastewater is due to illicit 
use while the rest can be attributed to the therapeutic use of primarily codeine 
(Baker, et al., 2014). Therefore, using MOR to calculate the consumption of heroin 
would lead to an overestimation (ibid). As a result, the heroin consumption value of 
399.4 ± 90.8 mg/day per 1000 people using MOR as a metabolite, as in this thesis, is 
most likely an overestimation. When only the consumption of MOR was taken into 
account, using the parent drug as the main metabolite (Table 5.3), the estimated 
value for Cambridge, UK, was 168.4 ± 38.3 mg/day/1000 people.  However, as far as 
the author is aware, there was no comparative value found as few researchers 
investigated opioids in waste water. 
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During preliminary investigations, a reversible reaction between MOR-2PFP and MOR-
PFP was proposed in Figure 3.14, which most probably had an impact on the total 
MOR concentration since only the diagnostic ions of MOR-2PFP were used for 
quantification. Therefore, the estimated MOR consumption value is most likely an 
underestimation of the actual amount present in the waste water sample which in 
turn affects the calculation of drug consumption using MOR.  However, as observed in 
Figure 3.13, a higher level of MOR-2PFP was present and hence any impact of 
deacetylation to MOR-PFP on the concentration detected is expected to be minimal. 
Nontheless, in hindsight, perhaps both MOR-PFP and MOR-2PFP should have been 
quantified and their results pooled together to give total MOR concentration. 
 
A more suitable target analyte to use for estimating the consumption of heroin would 
be 6-MAM, since it is an exclusive indicator of heroin use (Karacic & Skender, 2000; 
Fugelstad, et al., 2003; Khan, et al., 2014).  However, heroin was not detected in this 
research and 6-MAM was detected below its LOQ and therefore could not be used in 
calculations due to the uncertainties this would introduce into the final result.  As 
heroin quickly hydrolyses to 6-MAM and then MOR, both heroin and 6-MAM are 
unlikely to be found in any significant amounts in waste water (Khan & Nicell, 2011; 
Jones, et al., 2013; Yargeau, et al., 2014). In another study in England, while heroin 
was also not detected in waste water, 6-MAM was detected (Baker, et al., 2014) while 
both heroin and 6-MAM were detected in France (Nefau, et al., 2013).  Although there 
are lower uncertainties when using 6-MAM, as opposed to MOR, to estimate heroin 
consumption, these increase significantly with longer in-sewer HRTs due to its 
instability and high back-calculation correction factors as a result of its low excretion 
rate of 1.3 % (van Huijs, et al., 2011a; Baker, et al., 2014; Senta, et al., 2014).  Since    
6-MAM is a minor metabolite of heroin with a low excretion rate, low LODs would be 
needed for reliable quantification.  The degradation reactions, lack of stability in 
waste water, high LOQs and lack of recovery for 6-MAM has been documented 
throughout this thesis.  Therefore, although its recovery from the sample matrix and 
detection can be improved with further work, estimating heroin consumption using  
6-MAM is still fraught with high uncertainties which still need to be addressed before 
the results can be reliable (Baker, et al., 2014). 
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5.4.2   New Psychoactive Substances (NPS) 
A background to the NPS, cathinones, piperazine and KET, has been presented in 
section 1.4.2.1 and Appendix II.  The most commonly misused drugs in these groups 
include MEPH, 3-CPP, BZP, 3-TFMPP and KET (Staack, 2007; Dickson, et al., 2010a; 
UNODC, 2013).  Within Europe, the UK leads in terms of usage reporting of NPS 
(UNODC, 2013) and MEPH and KET are among the most highly abused drugs in 
England and Wales (CSEW, 2014). These reports correlate with findings in this 
research where MEPH, 3-TFMPP and KET were detected and quantified at 
concentrations of 0.549 ± 0.046, 0.098 ± 0.004 and 0.097 ± 0.007 µg/mL, respectively. 
 
The human urinary excretion profile for NPS is largely unknown and hence 
pharmacokinetic data is also limited or non-existent (Castiglioni, et al., 2013; Reid, et 
al., 2014a).  The ever changing chemical structure and occurrence of NPS makes it 
even more difficult to predict which NPS is most prevalently consumed at any given 
time.  Hence, the choice of NPS targeted in various published studies, are based on 
reports from conventional drug monitoring processes (Table 1.5). In addition, the 
unavailability of standard analytical references for the majority of these compounds 
and their metabolites hinders accurate detection, identification, quantification and 
back-calculation to drug consumption (Favretto, et al., 2013; Helander, et al., 2014).  
In order to accurately determine the community drug consumption profile for NPS, 
relatively stable analytical standards of known excretion products are required, which 
are also specific to the drug and excreted at high enough concentrations, i.e. used by 
a sufficient number of people in the community, to be detected (Castiglioni, et al., 
2013). 
 
However, derivatization with PFPA and analysis with GC-MS, as conducted in this 
research, has shown to be a suitable method for the accurate detection, identification 
and quantification of the targeted NPS, when present in high enough quantities 
(above the LOQ of the method). In addition, some NPS, such as MDPV, have been 
detected in waste water from different parts of the world, with some results 
corroborating with those from other drug monitoring sources (Table 1.5). Therefore, 
the detection and quantification of NPS is currently possible with the sewage 
epidemiological approach and will no doubt continue to be refined as the approach 
189 
 
continues to be developed, but further work is still required to enable back-
calculation to community drug consumption. An alternative matrix for the detection 
of NPS for the sewage epidemiological approach has been pissoirs as these may 
contain higher levels of NPS or reflect a different drug use pattern to that of the 
general population as determined by samples from a WWTP (Reid, et al., 2014a). 
 
Although there has been a steady increase in sewage epidemiological studies 
targeting NPS in the analytical method, these are only few in comparison with studies 
targeting classic drugs of abuse (Castiglioni, et al., 2014).  In addition, not all studies 
have been able to detect these NPS in waste water samples. 
 
5.4.2.1   Cathinones 
Cathinones detected in this research were MCAT, MEPH and BUTY at concentrations 
of 0.253 ± 0.083, 0.549 ± 0.046 and 0.004 ± 0.002 µg/mL, respectively. The higher 
concentration of MEPH suggests a wider usage of this drug in Cambridge, UK, 
compared to the other cathinones.  However, the back-calculation to drug 
consumption could not be made due to the lack of complete data on the urinary 
excretion rate in humans (Meyer, et al., 2010; Corkery, et al., 2012; Khan, et al., 2014). 
Instead,  daily loads were used for comparison according to Equation 5.1 (Khan, et al., 
2014). Only a handful of publications have included MEPH in sewage epidemiological 
studies (Table 1.5) and even fewer report detection of MEPH in waste water (Lai, et 
al., 2013b; Chen, et al., 2014).  Maximum loads reported are 3 mg/day/1000 people 
(Chen, et al., 2014) which is much less than the 278.0 ± 23.3 mg/day/1000 people 
reported in this thesis (Table 5.4). As mentioned earlier, MEPH is among one of the 
most highly abused drugs in England and Wales, with usage not seeming to abate and 
therefore high daily loads in waste water are not surprising (Khreit, et al., 2013; CSEW, 
2014).  In addition, there have been reported increased usage of MEPH in Australia, 
and the USA and as more researchers include this NPS in their methods, higher loads 
may also be detected especially in regions known for high consumption of this drug 
(Winder, et al., 2013; Chen, et al., 2014). As far as the author is aware, this is the first 
time BUTY has been quantified and reported in sewage epidemiology and hence 
comparative values were not available in literature. However, BUTY has been 
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detected in blood and urine samples during toxicological analyses (Helander, et al., 
2014). 
 
Analysis of waste water in Norway, Sweden and Belgium has failed to detect MEPH 
and CAT  (van Nuijs, et al., 2013; Ostman, et al., 2014; Reid, et al., 2014b), while MCAT 
has not been detected during other studies in England (Baker, et al., 2014).  However, 
MCAT was detected in Australia at maximum daily load of 3.5 mg/day/1000 people 
(Chen, et al., 2014) in comparison to the daily load of 128.3 ± 42.1 mg/day/1000 
people as reported in this thesis (Table 5.4).  Therefore use of MCAT so far appears to 
be higher in Cambridge, UK but there are not many other published reports with 
which to compare results with. 
 
Other cathinones incorporated in the analytical method but not detected were CAT 
and 3-FMC.  As far as the author is aware, only one other published study included 
CAT as a target analyte but also did not detect it (Reid, et al., 2014b). With regard to 
3-FMC, its in-sewer residence time is short-lived due to its instability in waste water 
(Table 4.8) and hence it is unlikely to be detected.  In order to be detected, it would 
have to be consumed at levels similar to classic drugs of abuse, and none of the 
official reports (CSEW, 2014; EMCDDA, 2014a; UNODC, 2014) seem to indicate 3-FMC 
as an emerging drug that is increasing in usage. 
 
These results reflect the different drug usage habits of people in different countries 
and within the same country.  However, it could also reflect the different analytical 
methods used, since the other referenced publications used LC-MS/MS and matrix-
matched calibration which introduces its own uncertainties, while GC-MS with 
derivatization and the method of standard addition was used in this research. 
Therefore, the sewage methodological approach and analytical method as detailed in 
this research is suitable for the detection and quantification of MCAT, MEPH and 
BUTY. 
 
5.4.2.2   Piperazines 
It has been reported that piperazines are extensively metabolised, therefore one 
would expect to detect less of the parent drug in waste water (Staack, et al., 2003; 
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Staack & Maurer, 2003; Staack, et al., 2004).  However, 4-MEOPP and 3-TFMPP were 
all detected in waste water samples from Cambridge, UK.  4-MEOPP was detected at 
0.008 ± 0.006 µg/mL while 3-TFMPP was detected at 0.098 ± 0.004 µg/mL. 
 
As far as the author is aware, only 2 other research groups have targeted piperazines 
using the sewage epidemiological approach. In studies conducted in England, BZP and    
3-TFMPP were at times detected (Baker & Kasprzyk-Hordern, 2011a & 2013) and 
other times not detected at all (Baker, et al., 2014). BZP was also detected in studies 
conducted in Australia (Lai, et al., 2013c). Back-calculations, however, could not be 
done due to the lack of urinary excretion data and hence normalized comparisons 
could not be made.   Since BZP is also a metabolite of the antidepressant piberaline, 
its detection in waste water can be attributed to both therapeutic and illicit use 
(Staack, et al., 2002; Moffat, et al., 20llb). As far as the author is aware, this is the first 
reported sewage epidemiological study targeting 11 piperazines and the first time the 
detection and quantification of 4-MEOPP has been reported in sewage epidemiology.  
In this regard, comparative values were not available in literature.  However, the 
structural isomer, 2-MEOPP, was detected in Norway but not quantified (Reid, et al., 
2014a) showing the importance of incorporating different isomers during method 
development (section 3.2.5.1).  Although BZP and MBZP were targeted in this thesis, 
they were not detected possibly due to low usage in Cambridge, UK, or that their 
levels were below the LOD of the method. 
 
5.4.2.3   Ketamine 
It is worth noting that although a consumption rate of 2463.5 ± 182.5 mg/day per 
1000 people, was estimated for KET (Table 5.4), this is not an indication that the total 
amount of KET consumed was as a result of misuse. KET is widely abused for its 
hallucinogenic effects at nightclubs and raves and has also been implicated in drug-
facilitated sexual assaults (Lin, et al., 2010; Lian, et al., 2012; Negrusz & Gaensslen, 
2013).  However, KET is also used as a general anaesthetic and short-acting analgesic 
in human and veterinary practice (Moffat, et al., 2011b; Lian, et al., 2012; Lin, et al., 
2014). Since only the parent drug was quantified, a distinction between direct 
disposal into the sewage system as opposed to consumption is also unknown. In 
addition, as ketamine metabolites were not monitored in this research, the urinary 
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excretion profile for the parent drug as reported in Moffat (2011b) was used in the 
back-calculations. However, the increased bias in using low values, i.e. 2 % in this 
case, has been mentioned in section 5.3.1 and therefore daily loads of KET were also 
included for comparison. Table 5.10 list the daily loads and consumption figures for 
KET from this research and other publications. 
 
Table 5.10: Ketamine daily loads and consumption data from different countries. 
 
 
Daily KET loads in Cambridge, UK, are lower than those from other countries.  
However, consumption figures are higher in Cambridge than other countries due to 
the use of different target analytes for back-calculation.   Of the handful of studies 
that have incorporated KET as a target analyte, not all resulted in its detection.   KET 
and nor-KET were analysed but not detected elsewhere in England and Sweden 
(Baker, et al., 2014; Ostman, et al., 2014).  This further reflects the different spatial 
patterns in drug use within and between countries. 
 
Although detected at a concentration of 0.097 ± 0.007 µg/mL in Cambridge, UK, KET 
was detected at concentrations of up to 0.01 µg/mL in hospital effluents from Taiwan 
(Lin, et al., 2014) reflecting the effect of different usage habits and sources. As a note, 
even though  some compounds occur at low excretion rates, this does not necessarily 
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indicate that they are present at low levels in waste water influent. High levels of use 
of these compounds can compensate for the low excretion rates and hence they can 
still be detected in large quantities, as in the case of KET. The high usage levels of KET 
found in this study correlates with reported high levels of usage in England and Wales 
(Baker, et al., 2014; CSEW, 2014; EMCDDA, 2014a; UNODC, 2014) as well as in China, 
Hong Kong and Taiwan (Lai, et al., 2013b; Lin, et al., 2010 & 2014; Khan, et al., 2014).  
In fact, it has been reported that in Hong Kong, KET consumption was even higher 
than MAMP and COC (Lai, et al., 2013b). The CSEW (2014) reports a statistically 
significant increase in the illicit use of KET in 2013/2014 (0.6 %) than 2012/2013 
(0.4%) for adults between 16 and 59 years of age. 
 
Aside from its increased illicit use, the contribution of KET in wastewater from leading 
research hospitals, drug treatment centres, and other health facilities in Cambridge 
and surrounding villages cannot be ruled out. 
 
5.4.3   Amitriptyline 
AMIT is used to treat depression but has traditionally been abused for its relaxant 
properties.  Although AMIT was not reliably detected in this thesis, its consumption 
was estimated to be quite high at 2455 ± 197 mg/day/1000 people in a separate 
published study in England (Baker, et al., 2014).  Nortriptyline, one of the major 
metabolites was detected at a much less value of 117 ± 18 mg/day/1000 people (ibid). 
 
5.4.4   Diazepam 
Although obtained legitimately, benzodiazepines, especially diazepam, are among the 
most widely prescribed groups of drugs (Julien, 2005; Drummer & Wong, 2013; King, 
et al., 2013).   However, DIAZ was not detected in waste water samples from 
Cambridge, UK, as well as from other parts of England (Baker, et al., 2014) but was 
detected in raw waste water samples from Slovenia (Kosjek, et al., 2012).  The 
metabolite, nor-DIAZ, was detected in Baker’s (2013) study, further confirming that 
careful evaluation needs to be made when selecting target analytes in order to 
increase the chances of detection. 
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5.5   VARIABILITY IN DRUG CONSUMPTION RESULTS  
From the discussions in sections 5.4.1 to 5.4.4, it is evident that there is a wide 
variability in the occurrence and concentration data of the target drugs from various 
sewage epidemiological studies undertaken in different countries and even cities and 
regions within the same country. The reasons for this variability are further 
expounded upon in the following section. 
 
5.5.1   Spatial and Temporal Variability 
Spatial and temporal variability in drug consumption results can largely be attributed 
to different sample matrices (no two waste water samples are identical in 
composition), sampling techniques (type, frequency and duration), sampling site, 
weather conditions, analytical methods, etc. which all have an effect on the final 
results (Ort, et al., 2010 a&b; van Nuijs, et al., 2011a; Castiglioni, et al., 2013; Verlicchi, 
et al., 2014). Most importantly, the occurrence and type of drugs in waste water 
varies within regions and also with time within a country (Zuccato, et al.,2008; Gerrity, 
et al., 2011; Irvine, et al., 2011; Reid et al., 2011; Bijlsma, et al., 2012; Lai, et al., 
2013a; Thomas, et al., 2012). Rainfall also affects the flow rate of waste water influent 
and this in turn affects the levels of compounds present. In Kasprzyk-Hordern’s 
(2009c) study, most PPCPs in waste water influent doubled when the flow was halved 
in dry weather conditions indicating a possible dilution effect. Other attenuation 
processes have been mentioned in section 1.3.4.2.  Therefore, results obtained from 
one area are not necessarily representative of another area within the same country 
or the entire country as a whole (EMCDDA, 2014b; Vuori, et al., 2014). 
 
Other additional factors that have a significant influence on the occurrence and 
concentration of drugs include the different habits of each city and/or country, with 
regards to consumption and or direct disposal of therapeutic and drugs of abuse 
(Kümmerer, 2009; Irvine, et al., 2011; Zuccato, et al., 2011; Repice, et al., 2013).   The 
demographics of each city and/or country also plays a role in the types and quantities 
of drugs detected (i.e. pensioners, students, tourist town). Vuori (2014) observed a 
higher usage of AMP in larger cities and university cities such as Helsinki and Turku 
due to a prevalence of night clubs where such drugs are consumed. Lai (2012) found a 
higher usage of COC and MDMA in an urban area and a popular holiday resort versus 
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a rural area during a busy holiday period in Australia.  The increase in drug usage in 
the area frequented by holiday makers was attributed to the increase in seasonal 
visitor numbers to the area (ibid).In a separate study, the consumption of MDMA was 
higher for attendees of a music festival than for a nearby city (Lai, et al., 2013). 
 
Irvine (2011) demonstrated higher COC and MAMP consumption in larger urban cities 
(150,000 to 800,000 people) than in smaller towns (< 23, 000 people) in Australia but 
the reverse was true for MDMA consumption. In comparison with results from other 
cities, the same study found that there was up to 30 times greater use of COC in 
Milan, Italy and London, UK, than in Adelaide but the latter had a 10 times higher 
usage of MDMA. Greater drug use in metropolitan versus rural settings within Oregon 
(USA) has also been reported (Banta-Green, et al., 2009). Thomas (2012) showed 
higher COC use in European cities located in the west and central than those in the 
north and east. 
 
The sewage epidemiological approach has also been used to describe temporal trends 
in drug use. There are several studies that observed higher drug use on weekends 
than weekdays for most illicit drugs (Reid, et al., 2011; Irvine, et al., 2011; Thomas, et 
al., 2012; Nefau, et al., 2013; Baker, et al., 2014; Vuori, et al., 2014), with up to a 5-
fold increase (Irvine et al, 2011). However, this intra-week variation in drug use was 
not observed in Hong Kong suggesting more regular than infrequent use of drugs (Lai, 
et al., 2013b).  This is supported by a lack of intra-week variation in methadone use in 
Finland and Belgium, which is used as an opiate maintenance treatment and for pain 
management requiring regular use (van Nuijs, et al., 2011a; Kankaanpää, et al., 2014). 
Similarly, higher drug loads have been detected in urban waste water samples 
between December and January, due to the Christmas/New Year holiday season when 
substance use becomes more common (van Nuijs, et al., 2011b; Lai, et al., 2013a).  
Higher COC use was also observed in the evening than during the day (Reid, et al., 
2011) further showing the temporal trend in drug usage and the advantage of time-
weighted average sampling (composite and passive) over grab sampling.  The latter 
may show a much lower concentration than the former if the sample was taken only 
during the day. 
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Estimations on AMP and MAMP in waste water samples from two cities in Finland 
differed considerably in two separate studies by different research groups i.e. Thomas 
(2012) and Kankaanpää (2014). While AMP was not detected in Thomas’s (2012) 
study, it was detected in Kankaanpää’s (2014) study. A possible reason for non-
detection of AMP was the higher lower limit of quantification (LLOQ) (0.025 μg/mL) 
used by the former (Kankaanpää, et al., 2014). A similar observation was made when 
comparing MOR results from two separate areas in England. While MOR was not 
detected in Baker’s (2013) study covering a population of 3.5 million, it was detected 
in results from this thesis covering a population of 145, 310 people (section 5.4.1.5).  
This is similar to a study conducted in France where higher BZE and COC 
concentrations were observed in a WWTP serving a smaller population (40, 000 
people) than those serving larger cities (160,000 to 650, 000 people). This further 
highlights differences in results, not only from different cities/areas within the same 
country but even from similar areas with studies conducted by different research 
groups since no two waste water samples (even from the same source) are alike. In a 
study conducted in ten main cities in Finland (58,000 to 800, 000 people), illicit drug 
use was higher and more frequent in cities located in the South of Finland while 
overall COC consumption was observed to be lower in Finland in comparison to other 
European countries (van Nuijs, et al., 2011b; Thomas, et al., 2012; Kankaanpää, et al., 
2014).  In another study conducted in 25 WWTP in different towns and cities across 
France (13, 250 to 650, 000 people), significant geographical differences were 
observed especially for COC and AMP which occurred in higher frequency and 
concentration in larger cities than medium or smaller ones (Nefau, et al., 2013).  This 
was attributed to the larger consumer market and access to entertainment venues 
and events in larger cities (ibid). This further indicates the temporal and spatial 
fluctuation in the consumption of drugs of abuse within the same city or country. 
 
In a study conducted across 19 European cities (including London, UK), different usage 
patterns of illicit drugs were observed between Western and Central Europe 
compared with Northern and Eastern Europe (Thomas, et al., 2012).  For instance COC 
use was highest in Antwerp, Belgium and much lower in Finnish cities.  Highest levels 
for MAMP and AMP were detected in Finnish cities and The Netherlands, respectively.  
High usage of MDMA was also reported for The Netherlands and elsewhere in 
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England than for other European cities.  Vast spatial differences in drug usage 
patterns across Europe was further confirmed in a recently published study covering 
42 cities in 21 European countries (EMCDDA, 2014b; Ort, et al., 2014). For instance, in 
Ort’s (2014) study, COC use was highest in Amsterdam, Antwerp, London and Zurich 
but lowest in cities located in northern, eastern and southern Europe. Geographical 
differences in drug usage habits have also been demonstrated in other studies 
conducted in various cities in China and Sweden (Khan, et al., 2014; Ostman, et al., 
2014). Overall, drug usage was higher in larger, more populated urban cities than 
smaller towns (Ort, et al., 2014). 
 
Such comparisons indicate that normalization of drug consumption results from 
studies conducted in different countries and/or cities provides a standardised 
platform to equally gauge international drug use levels (Lai, et al., 2013 a&b). This is 
another advantage of the sewage epidemiological method versus conventional 
epidemiological methods as it can be used by law enforcement to estimate the rate of 
growth of drug markets among various types of communities within a country or 
around the world (Lai, et al., 2013 a&b).  However, inter-city and inter-country drug 
consumption comparisons based on daily or weekly assessments provide only a 
snapshot of drug usage trends and cannot be used to generalize for the rest of the 
year (Thomas, et al., 2013). Any results only represent the period over which samples 
were collected. 
 
5.5.2. Concentration of Pharmaceutical and Personal Care Products (PPCPs) in  
Waste Water  
In their review of PPCPs in WWTP influent and effluent from several recent studies, 
Luo (2014) reports significant spatial and temporal variations due to a number of 
factors, such rate of production, sales and usage, urinary excretion rate, size of 
WWTPs, environmental persistence and removal rate during waste water treatment 
processes.  Additionally, PPCP concentrations in waste water correlated well with 
their production amounts and consumption patterns. For instance, in Wales, UK, high 
concentrations (0.010 μg/mL) of paracetamol, codeine, and atenolol were detected in 
waste water influent which correlates with their high levels of their dispensal 
(Kasprzyk-Hordern, et al., 2009b&c). Table 5.11 list some PhACs as detected in waste 
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water influent.  Therapeutic drugs, such as paracetamol, tend to have higher 
detection frequencies and concentrations in raw waste water than illicit drugs, such as 
AMP, due to their high levels of consumption (Östman, et al., 2014). 
 
Table 5.11: Concentration of pharmaceutically active compounds found  
in waste water influent. 
 
 
For instance paracetamol and ibuprofen have been detected in waste water influent 
at levels of up to 0.482 µg/mL and 0.603 μg/mL, respectively, while AMP has been 
detected at levels of up to 0.003 µg/mL.  The higher concentration levels of 
therapeutic drugs are due to their high consumption and ease of accessibility as over-
the-counter medication. Caffeine has also been detected at levels of up to 0.05 μg/mL 
in waste water influent (Zhou, et al., 2010) due to the high consumption of caffeine 
containing compounds such as coffee, tea, energy and soft drinks (Luo, et al., 2014).  
Although official figures of the rate of production, sales and usage do not exist for 
illicit drugs, it can also be postulated that levels found in waste water correlate with 
their production and consumption patterns i.e. higher concentration levels indicate 
higher consumption of that drug (Luo, et al., 2014). Therefore, levels of drugs as 
determined in this research ranging from 0.004 ± 0.002 μg/mL to 0.549 ± 0.046 μg/mL 
(Table 5.1) are within the concentration range of PhACs as found in untreated waste 
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water. As mentioned earlier, the sample was collected over 72 h which would allow 
more time for accumulation of the target analyte, if present, as compared with a 12 or 
24 h composite sample collected during the same period and in the same source. An 
earlier indication of the concentration levels of various PPCPS as found in waste water 
influent was made in Table 1.2, page 9. 
 
However, as noted in section 5.3.1, a more appropriate way of comparing drug 
consumption in different cities and countries is to normalize it against the population.  
Therefore, Table 5.11 provides only an indication of concentration levels of PhACs 
that are found in untreated waste water with no inference to per capita usage 
(relative to population). 
 
As discussed in sections 3.4.3 & 5.2.1, due to the nature of waste water, several other 
unknown and undesired matrix components were present in the samples as indicated 
by peaks of high relative abundance in the chromatograms. Therapeutic drugs tend to 
have higher detection frequencies and concentrations in untreated waste water due 
to their high levels of consumption (Östman, et al., 2014). Although not a target drug 
and not quantified, Figure 5.5 depicts the presence of caffeine in the 72 h composite 
waste water sample. In relation to MOR and KET, caffeine appears to occur at high 
concentration levels in line with published reports (Zhou et al., 2010).  
 
 
Figure 5.5: TIC of a 72 h composite waste water sample depicting caffeine, ketamine 
and morphine. 
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Identification of caffeine in the waste water sample was confirmed by comparison 
with the NIST database and an analytical standard (Appendix XV). 
 
In spite of the higher concentration of unwanted matrix components, the target 
analytes could still be reliably detected and confirmed using the GC-MS method with 
PFPA derivatization developed during this research. In addition, although the matrix 
components of high intensity were not target drugs, they can provide future insight 
into the composition of waste water at the time of sampling.  Hence, another 
advantage of using GC-MS in full-scan mode is the ability to do retrospective 
identification (Farré, M., et al., 2014). 
 
5.5.3   Factors Contributing to Drug Concentrations in Cambridge, UK 
Calculated drug consumption levels from data obtained during this research correlate 
with consumption levels of similar target analytes reported in published literature 
(sections 5.4.1 to 5.4.4).   For drugs where back-calculations to drug consumption 
could not be conducted i.e. MCAT and MEPH, calculated daily loads (Table 5.4 and 
section 5.4.2.1) appear to be much higher in Cambridge than reported elsewhere.  
However, as mentioned in section 5.4.2.1, there is very limited published literature 
with which to adequately compare results for MCAT and MEPH. In addition, the 
historic city of Cambridge, UK is an urban city with two main universities, various 
colleges, hospitals and health centres, drug-rehabilitation and treatment centres, and 
has an active legal and clandestine night-club and rave scene.  These are all enabling 
variables for illegal and legal drug consumption. Its relatively close proximity to the 
city of London, UK, also provides seasonal and regular inhabitants of Cambridge 
access to further entertainment venues.  It has been reported in published literature 
that drugs consumed in one area will inevitably end up in the waste water in the 
residential areas of the users (Vuori, et al., 2014).  In addition, Anglia Ruskin University 
Forensic Science & Chemistry Unit is working in partnership with Cambridgeshire 
Constabulary and hence some insight has been gained on the types of drugs being 
seized in Cambridge. Based on 2009 - 2011 drug seizure data supplied by Parkside 
Police Station, Cambridge, both KET and MEPH were found in 11 - 29 % and 3 - 24 % of 
cases, respectively. In 2010, MEPH and piperazines were highest in terms of seizures 
while in 2011, KET and MEPH were the 3rd and 4th most seized and confirmed drug, 
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respectively, excluding cannabis.  Therefore, the presence of detected illicit drugs 
(including the NPS, KET and MEPH) in waste water from Cambridge, collected 
between 2011 and 2012 (section 2.2), is not surprising. 
 
With a huge referral and research hospital in the city, i.e. Addenbrooke’s Hospital, 
that administers and dispenses various pain relief medication, it is not unusual that 
high levels of MOR and KET were detected in waste water samples from Cambridge 
throughout the method development (Figures 3.27, 5.2, 5.3 and 5.4; Appendix IX). 
 
Cambridge is also a research and development hub with many science-based 
companies (including pharmaceutical companies) operating in the city and 
surrounding villages.  Therefore, the contribution of drugs directly disposed into the 
sewer from research laboratories (universities and companies) cannot be ignored.  In 
addition, the 72 h composite sample was collected from Sunday to Tuesday, 
incorporating any drugs excreted over the weekend.  It has been established in 
section 5.5.1 above that in many cities globally, higher levels of stimulant drugs were 
consumed over weekends than weekdays and that certain cities experienced 
increased drug consumption during holiday periods (i.e. increased tourism) or music 
festivals.  During the Saturday and Sunday of the collection period, there were several 
events happening in and around Cambridge that brought extra visitors to the city i.e. 
Bridge the Gap fun walk, Grantchester Fair, Stourbridge Fair.  It was also the popular 
‘Open Weekend’ where visitors have a chance to visit the various colleges of the 
University of Cambridge for free and hence many people take advantage of this 
opportunity. The Open Weekend also coincides with the beginning of the new 
university term when many ‘fresher’s parties’ and ‘clubbing’ occurs. The sample was 
also collected during the time the Paralympic games were being conducted in London. 
Cambridge, being a world famous tourist city in relatively close proximity to London, 
would no doubt have experienced an increase in national and international visitors 
from those who came to watch the games. 
 
In order to address any uncertainties related to the characteristics of the relevant 
catchment area, it has been recommended that any known observations, whether 
speculative or not, be reported with any data as these can result in unusual drug 
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concentrations in waste water (Castiglioni, et al., 2013). Hence, all the above factors 
could have contributed to the types and levels of drugs detected in Cambridge, UK.  
Therefore, the detection of BUTY, MCAT, 4-MEOPP, MEPH, in Cambridge, UK, than 
other parts of England could indicate a difference in drug usage habits across England 
and assist law enforcement in determining local hotspots for the emergence of NPS 
(Kankaanpää, et al., 2014). 
 
Whether the difference in drug consumption is due to the number of people 
consuming the drug or the daily dosage is difficult to determine without more 
comprehensive socio-epidemiological and toxicological data. Nonetheless, the ability 
to assess drug use within a day, during the week or holiday periods across regions is of 
potential use in allowing law enforcement, social and health agencies to tailor-make 
drug intervention policies and action plans (Lai, et al., 2013a).  In comprehensive 
published research studies covering 19 to 42 European cities, the results from sewage 
epidemiological studies largely correlated with data from alternative drug monitoring 
methods, thereby indicating the reliability of the method (Thomas, et al., 2012; Ort, et 
al., 2014). Relatively good correlations between estimating drug consumption using 
the sewage epidemiological approach and comparison with National Health Service 
(NHS) prescription statistics in England have also been reported for certain drugs such 
as methadone and dihydrocodeine (Baker, et al., 2014).  However, for other drugs 
such as amitriptyline and codeine, results differed significantly between the two 
methods (ibid). A recent report by the EMCDDA (2014b) acknowledges that although 
results from the sewage epidemiological approach and conventional drug monitoring 
studies correlate to a large extent, some differences can still be found with regard to 
certain drugs in some cities.  For instance, while cannabis use is amongst the highest 
levels in Italy and the Czech Republic, results from sewage epidemiology did not 
reflect this (EMCDDA, 2014b).  Hence, the sewage epidemiological approach is a 
complementary, rather than alternative, method for drug monitoring. Comparisons 
between the sewage epidemiological approach and conventional drug monitoring 
methods are discussed in the next section. 
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5.6 THE COMPLEMENTARY ASPECTS OF SEWAGE EPIDEMIOLOGY AND 
CONVENTIONAL DRUG MONITORING METHODS 
Tables 5.12 and 5.13 list some of the main advantages and disadvantages of the 
sewage epidemiological approach and conventional drug monitoring, respectively. 
The sewage epidemiological approach is not aiming to become a replacement for 
conventional drug monitoring methods such as hospital and police records, and 
population surveys (Castiglioni, et al., 2013). Instead, the various approaches to drug 
monitoring complement and enhance each other since all have strengths and 
weaknesses with respect to the data obtained from them (EMCDDA, 2008 & 2014b; 
Ort, et al., 2014).   In a published study, three complementary drug monitoring 
methods, i.e. waste water analysis, questionnaire survey, and oral-fluid samples from 
drivers, were used for the estimation of community COC consumption (Reid, et al., 
2012).  While each method had significant limitations when used alone, the 
complementary data obtained from an evaluation of all three methods together was 
useful in providing a balanced overview of COC usage within a given community in 
Norway (ibid). 
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     Table 5.12: Advantages and disadvantages of the sewage epidemiological approach. 
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          Table 5.13: Advantages and disadvantages of conventional drug monitoring. 
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CHAPTER 6 
SUMMARY, CONCLUSION AND FURTHER WORK 
This chapter provides an overall summary of the conclusions arising from the various 
studies conducted in chapters 3 (preliminary), 4 (method validation) and 5 
(application of the method). 
 
6.1   SUMMARY AND CONCLUSION 
The presence of chemical pollutants in water has led to increasing public awareness 
and concern, as well as scientific interest regarding their effects on the environment. 
In recent years scientific interest in pharmaceutical products and drugs of abuse as 
emerging pollutants has steadily increased. These pollutants enter the aquatic 
environment mainly through the discharge of treated and untreated waste water. 
Understanding the chemical behaviour and fate of emerging pollutants in surface 
water mainly relies on the development of analytical methods for their extraction and 
detection from which particular epidemiological information can be obtained.  In 
addition, drugs of abuse detected in waste water can be used to determine the drugs 
prevalent in a given geographical area as well as estimate drug consumption patterns.  
Thus, sewage epidemiology has gained momentum globally owing to the non-
intrusive nature of the method as well as the near real-time information obtained. 
With the constant emergence of NPS such as cathinones and piperazines, quick, 
reliable, specific and sensitive analytical methods are needed for their detection in 
complex matrices such as waste water. 
 
This research, therefore, set out to develop and validate an analytical method based 
on gas chromatography-mass spectrometry (GC-MS) for the simultaneous detection 
of drugs of abuse in waste water samples from Cambridge, UK.  Aside from knowing 
what drugs are present in the sewer system, the detected and quantified drugs 
would then be used to estimate drug consumption levels. 
 
A series of preliminary methods were conducted in order to understand the chemical 
behaviour of the drugs under investigation. These included chemical derivatization, 
stability studies as well as extraction and recovery studies.  In addition, an in-house 
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database of chromatographic and mass spectral information was developed during 
preliminary studies, which would be later used to reliably quantify the target drugs in 
waste water samples. 
 
During chemical derivatization studies, 5 derivatizing reagents based on silylation and 
acylation were compared on a mixed drug standard (BSTFA, MSTFA, PFPA, HFBA and 
AcAn:Pyr).  Ultimately, derivatization with PFPA: ethyl acetate (2:1, v/v), was selected 
based on higher peak areas obtained, a cleaner chromatogram (one derivative per 
added drug), and distinctive mass spectral patterns with ions of high m/z values and 
abundances greater than 50 %.  The last point was critical because in order to reliably 
detect, identify and quantify the target drugs in a complex waste water sample, the 
mass spectral patterns needed to be distinctive enough to enable adequate 
selectivity and sensitivity. 
 
The derivatization process also brought to light possible acetylation and hydrolysis 
reactions of opioids which highlighted the presence of underivatized 6-MAM and 
partially derivatized MOR occurring with the fully derivatized analogues.  These 
reactions were thought to be responsible for the low stability and low to no recovery 
of heroin and 6-MAM during recovery studies. However, the level of derivatized MOR 
was much higher than that of the partially derivatized analogue confirming that the 
reaction favours the fully derivatized product. 
 
Various stability studies were conducted to determine adequate sample pre-
treatment and storage conditions of the target drugs.  Autosampler stability (27 h) 
was conducted on a derivatized mixed drug standard in ethyl acetate, while 4 week 
storage stability studies, at 5 and -20 °C, were conducted on both derivatized and 
underivatized mixed drug standards in ethyl acetate and methanol, respectively. The 
latter was derivatized on the day of analysis. The majority of drugs were found to be 
stable to moderately stable in all stability tests especially when stored at -20 °C.  The 
exceptions were EME, 6-MAM, heroin and 3-FMC which were generally unstable. As 
a result of stability tests, it was recommended to store derivatized mixed standards in 
ethyl acetate for no more than two weeks and to store the underivatized mixed drug 
standard in methanol for no more than 4 weeks. 
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In order to determine which sample isolation and concentration method would be 
most appropriate for extracting trace levels of drugs from a complex waste water 
matrix, LLE and SPE were compared.  SPE was selected based on higher recoveries 
and ease of conducting multiple analyses at the same time.  Oasis MCX and HLB 
sorbents were further compared at different sample pH values.  Based on higher 
recovery values, the optimised method resulted in the use of the MCX (mixed mode 
cation exchange) cartridge at a sample pH of 2. 
 
The challenges associated with multianalyte methods containing drugs with different 
pKa and functional groups were highlighted by the different stability and recovery 
results. Compromises were made to find the most suitable conditions for 29 drugs 
and metabolites and hence the conditions favoured certain drugs over others. 
 
A number of instrumental parameters such as the GC oven program, SIM analysis, 
photomultiplier voltage were also optimised during preliminary studies.  Ultimately, a 
PMT voltage of 600 V, SIM analysis with 87 diagnostic ions in 14 RT windows and 
splitless injection mode were used during method validation and standard addition. 
 
Following on from preliminary studies, method validation was conducted with mixed 
drug standards and waste water samples.  The method had good linearity for all 
target drugs at R2 > 0.9900.  LODs and LOQs for some drugs were lower than with GC-
MS/MS and LC-MS/MS and recoveries were > 70 % for the majority of drugs. 
 
As a result of preliminary and validation studies, the method was successfully applied 
to waste water samples using standard addition to compensate for any matrix 
interference. 
 
Eleven drugs were detected above their LOQ and within their linear range i.e. 
amphetamine, methamphetamine, 4-fluoromethamphetamine, methcathinone,             
4-methoxyphenylpiperazine, cocaine, ephedrone, 3-trifluoromethylphenylpiperazine, 
butylone, ketamine and morphine. Two other drugs, benzylpiperazine and 
methylbenzylpiperazine were detected outwith their linear range, while, 
amitriptyline and 6-monoacetylmorphine were detected below their LOQ.  As far as 
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the author is aware, this is the first time that butylone and 4-fluorometh- 
amphetamine has been detected in waste water samples. 
 
In addition, for 4-fluoromethamphetamine, cathinone, 3-fluoromethcathinone,               
2- and 4-fluorophenylpiperazine, 4-trifluoromethylphenylpiperazine, butylone, 
methylbenzodioxolylbutanamine, 4-methylphenylpiperazine, methylbenzyl- 
piperazine, 2- and 4- methoxyphenylpiperazine, and 3-chlorophenylpiperazine, this is 
the first reported analytical method in sewage epidemiology and the first time PFPA 
mass spectra and diagnostic ions have been reported for the aforementioned drugs 
including methcathinone, mephedrone and ketamine. 
 
Out of the eleven detected and quantifiable drugs and metabolites, five could be 
used to estimate drug consumption levels in Cambridge, UK, which were found to be 
heroin (399.4 ± 90.8), ketamine (2463.5 ± 182.5), cocaine (195.7 ± 95.4), 
methamphetamine (84.3 ± 59.1) and amphetamine (38.9 ± 24.8), all in mg/day per 
1000 people. These estimated values correlate with published socio epidemiological 
surveys on the prevalent use of the respective drugs but incorporate both illicit and 
therapeutic use.  This highlights the ability of sewage epidemiology to monitor drug 
use patterns and corroborate findings from other methods. 
 
However, the capability of utilising GC-MS, with derivatization, as a cheaper and 
effective alternative to GC-MS/MS, LC-MS and LC-MS/MS in the analysis of trace 
analytes from complex matrices such as waste water has been demonstrated through 
comparable and lower LODs and LOQs, good selectivity and sensitivity for target 
analytes in the presence of other undesired matrix components, and high sample 
throughput. As the first reported sewage epidemiological method to use 
derivatization with PFPA, it is hoped that this method will gain widespread use 
especially with laboratories that do not have LC-MS but would still like to conduct 
similar research. 
 
In addition, the developed method, based on matrix-matched standard addition 
quantification, use of isotopically-labelled internal standards and dilution of the 
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sample matrix, as well as carefully monitored quality control parameters (section 2.6), 
was suitable and effective in quantifying the detected target drugs in waste water. 
 
6.2.   SUGGESTIONS FOR FURTHER WORK 
The degradation reactions observed for opioids, especially 6-MAM and heroin, are 
thought to have contributed to their lack of detection in waste water.  For further 
investigations into methods involving these drugs, the use of an alternative solvent to 
ethyl acetate (e.g. acetonitrile and dichloromethane) for reconstitution and stability 
studies would be worth investigating. In addition, alternative derivatization methods 
(e.g. silylation) to avoid degradation reactions of opioids will be worth investigating in 
future (Guillot, et al., 1997). 
 
During recovery studies, the lower peak areas of the unextracted or post-extracted 
drug standard compared with the extracted standard was an enigma and worth 
exploring further. The effect of various evaporation methods (vacuum concentrator 
and nitrogen gas) on analyte loss or preservation also warrants further investigation. 
 
Although the extraction method was reproducible for the majority of drugs, further 
work will be needed to improve the reproducibility in recovery for some of the drugs 
that had high RSDs such as 2- and 4-MEOPP, MCAT and 3-FMC.  Coupled to this would 
be incorporating ‘green chemistry’ into the research by investigating the possible use 
of SPME (Mills & Walker, 2000; Östman, et al., 2014) and supercritical fluid extraction 
(Scott & Oliver, 2001; Kalikova, et al., 2014) to enhance the sensitivity of the method 
while restricting the amount of sample, solvents and steps needed during sample 
extraction (Sheldon, 2005). 
 
In addition, alternative longer-term sampling techniques using passive samplers, such 
as POCIS or Chemcatcher®, can be investigated to facilitate the detection of some of 
the drugs such as BZP, MBZP, 6-MAM and AMIT (Mills, et al., 2007; Wille, et al., 2012; 
Boles & Wells, 2014). 
 
Since the majority of PhACs investigated have one or more chiral centres, it could be 
worth investigating the presence of the relevant potent enatiomers found in 
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recreatonal drugs to more accurately differentiate between illicit and therapeutic 
drug consumption (Emke, et al., 2014; Kalikova, et al., 2014). 
 
The developed method was applied on a sample collected during one period in 
Cambridge, UK, but longer term sampling campaigns to determine weekly, monthly or 
seasonal variations in drug consumption can further enhance the research outcomes.  
In addition, sampling in other cities within the UK or being involved in inter-laboratory 
studies will also enhance the reliability of normalized spatial and temporal 
comparisons. 
 
Although GC-MS was used as an alternative to LC-MS, it would still be worth 
conducting comparative studies with LC-MS to determine if in-house results would 
mirror those made when comparing with other research groups i.e. lower LODs and 
LOQs with GC-MS. 
 
Therefore, although detection of drugs of abuse in waste water can be linked to 
consumption levels, there are still many uncertainties and factors that need to be 
taken into account before sewage epidemiology can become a routine, universal 
method for drug monitoring (Lai, et al., 2011; van Nuijs, et al., 2011a; Castiglioni, et 
al., 2013). As this is a relatively new area of research (since 2005), it is expected that 
the method will continue to be refined as sample collection, preparation and 
preservation, as well as analytical methods and protocols continue to improve.  
However, in spite of this, the sewage epidemiological approach has even been 
adopted by the EMCDDA as a new and complementary method for estimating 
community drug consumption and has even been included in the 2014 European Drug 
Report (EMCDDA, 2014a&b).  In this regard, research studies have been conducted 
with the aim of standardizing the approach, from sampling to analysis (Thomas, et al., 
2012; Castiglioni, et al., 2014; Ort, et al., 2014). 
 
The analytical method based on GC-MS and derivatization with PFPA, as documented 
in this thesis, can be applied to almost any polar, derivatizable compound from any 
water source and as GC-MS is widely known to be more cost-effective than LC-
MS/MS, it could have much wider usage especially in developing nations where more 
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cost-effective yet sensitive methods still need to be available for these studies.  With 
further optimisation, it could also be included as an alternative method for sewage 
epidemiology thereby becoming an excellent tool for identifying and quantifying 
PhACs in various environmental matrices.  Therefore, it is the hope of the author that 
GC-MS methods will continue to be optimized for sewage epidemiological studies just 
as much as LC-MS methods have been. 
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APPENDIX II: Background to drug classes/groups investigated in this thesis. 
 
1. Cocainics 
Cocaine is a naturally occurring alkaloid extracted mostly from the leaves of the 
Erythroxylon coca bush found mainly in South America (Julien, 2005; King, et al., 2013).  
Although less harmful derivatives of cocaine, such as procaine and lidocaine, are 
therapeutically used as anaesthetics, cocaine is more popularly used as an illicit drug 
(Moffat, et al., 2011b; King, et al., 2013). Figure 2.3 shows the structures of cocaine and 
one of its main metabolites, ecgonine methyl ester. 
 
Main metabolites of cocaine 
The main metabolites of cocaine excreted in urine are benzoylecgonine and ecgonine 
methyl ester (Ambre, et al., 1982). They account for 35-55 % and 30-60 %, respectively, of 
the administered cocaine dose in urine (Moffat, et al., 2011b).  A small percentage of 
cocaine (1-9 %) is excreted as the unchanged drug in urine (Julien, 2005; Melis, et al., 
2011).  Therefore cocaine and ecgonine methyl ester were chosen as target analytes for 
the estimation of cocaine consumption in waste water for this research (van Nuijs, et al., 
2009c). 
 
2. Phenylethylamines 
Phenylethylamines comprise the amphetamine-group substances, such as amphetamine, 
methamphetamine and 4-fluoromethamphetamine (4-FMA) as well as their ring-
substituted analogues, such as methylbenzodioxolylbutanamine (MBDB) and 
methylenedioxymethamphetamine (MDMA) (Melis, et al., 2011; UNODC, 2013).  These 
are depicted in Figure 2.4. 
 
Phenylethylamines are among the most widely abused classes of psychotropic drugs 
globally. They are mainly excreted as the parent drug in urine i.e. 30 - 90 % of a dosage for 
amphetamine, 40 - 50 % for methamphetamine and 65 % for MDMA (Moffat, et al., 
2011b).  In addition, methamphetamine is also eliminated as amphetamine (4 - 7 %) 
(Levine, 2006; Moffat, et al., 2011b). Since they are emerging drugs of abuse and as far as 
the author is aware, the toxicological profiles of 4-FMA and MBDB were not available at 
the time of writing of this thesis. 
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Since the majority of the phenylethylamines are excreted in a relatively large percentage 
as the unchanged drug (in comparison with their other metabolites), the parent drugs 
were used as target analytes for waste water analysis (Melis, et al., 2011). 
 
3. Piperazines and Cathinones 
As mentioned in section 2.1.2, piperazines and cathinones are NPS that have become 
prevalent over the last few years.  Most of the commonly abused piperazines are aryl 
substituted derivatives of piperazine such as benzylpiperazine (BZP) and 3-trifluoromethyl 
phenylpiperazine (3-TFMPP). Figure 2.5 shows the piperazines targeted in this research. 
 
Cathinones are semi-synthetic or wholly synthetic derivatives of the extract from the 
Catha edulis plant found mainly in East Africa and the Arabian Peninsula (Gautam, et al., 
2013). The leaves and fresh shoots are referred to as ‘khat’ and can be chewed or brewed 
as a tea (King, et al., 2013).  The main psychotropic and regulated components of khat are 
cathinone and cathine (Cole, 2003). Both are chemically and pharmacologically similar to 
synthetically manufactured amphetamine and methcathinone (King, et al., 2013). 
 
Semi-synthetic analogues of cathinone, referred to as beta-keto amphetamines, have 
recently gained popularity among the same demographic population that uses ATS and 
piperazines (Measham, et al., 2010). These include mephedrone, methylone and butylone 
(Meyer, et al., 2010; Gautam, et al., 2013). Figure 2.6 depicts structures of cathinones 
relevant to this research. 
 
In contrast to the traditional drugs of abuse, the metabolic pathways of piperazines and 
cathinones in humans have not been as extensively studied.  However, both groups are 
known to mainly form hydroxyl- and 4-hydroxy-3-methoxy- metabolites in rat and/or 
human urine (Staack, et al., 2002; Staack & Maurer, 2004; Gautam, et al., 2013). Data on 
the urinary excretion profile in humans for piperazines and cathinones was not readily 
available at the time of writing of this thesis (Castiglioni, et al., 2014).  However, the main 
metabolites of mephedrone as determined in rat urine were normephedrone                    
4-(hydroxymethyl) methcathinone and 4-(carboxy)methcathinone (Khreit, et al., 2013). 
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4. Opiates and Opioids 
Opiates are a group of more than 20 active alkaloids extracted from the juice of the 
opium poppy, Papaver somniferum (Levine, 2006).  Morphine, a principal alkaloid, is used 
to make synthetic (e.g. methadone) and semi-synthetic (e.g. heroin) opioids (Cole, 2003; 
Melis, et al., 2011).  The term ‘opioid’ therefore refers to natural and semisynthetic 
alkaloids derived from opium as well as synthetic analogues with similar pharmacological 
activity to morphine (Levine, 2006). Opioids targeted in this research are depicted in 
Figure 2.7. 
 
Main metabolites of opioids 
The main metabolites of morphine are morphine-3-glucuronide and morphine-6-
glucuronide, excreted as 65-70 % of a dosage (Moffat, et al., 2011b).  However, these are 
quickly hydrolysed to morphine in waste water (section 2.3.2). In addition, around 3-10 % 
of a dosage of morphine is excreted as the parent drug in urine (Moffat, et al., 2011b). In 
aqueous solution, heroin is known to hydrolyse to 3- and 6-monoacetylmorphine and 
morphine (Moffat, et al., 2011b). Therefore, morphine, 6-monoacetylmorphine and 
heroin were targeted for analysis (Boleda, et al., 2009; Melis, et al., 2011). 
 
5. Benzodiazepines, Tricyclic Antidepressants and Dissociatives 
These drugs are legally manufactured for psychotherapeutic use but are increasingly 
being abused due to their relaxant properties (Figure 2.8).  In contrast to ATS, illicit 
manufacture of benzodiazepines, tricyclic antidepressants and sedatives is rare.  
Commonly abused members of these groups are obtained through legitimate 
(prescription) or illegal (forged prescriptions, stolen from pharmaceutical supplies) means 
(King, et al., 2013). 
 
Benzodiazepines are among the most widely prescribed groups of drugs (Julien, 2005; 
Drummer & Wong, 2013). Structurally, they all have a common tricyclic nucleus differing 
only in the functional groups attached at different positions (Julien, 2005; Levine, 2006). 
Commonly used members of this group include diazepam (Valium) and lorazepam (King, 
et al., 2013). Although mainly used in the management of depression, anxiety, insomnia 
and related conditions (Julien, 2005; Östman, et al., 2014), they are also used in 
combination with some illicit drugs, such as heroin, to enhance the effects (Scott & Oliver, 
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2001; UNODC, 2013). Benzodiazepines are extensively metabolised, often with very little 
of the parent drug present in urine (Drummer & Wong, 2013). Only diazepam was 
targeted in this research and its key metabolites excreted in urine are 
desmethyldiazepam, oxazepam and temazepam conjugates, collectively excreted as 70 % 
of a dose (Scott & Oliver, 2001; Moffat, et al., 2011b). 
Tricyclic antidepressants share a three-ring molecular core with different functional 
groups. A common member of this group is amitriptyline used to treat depression, 
migraines and pain (Julien, 2005). The main metabolites of amitriptyline in urine are 
nortriptyline and free and conjugated 10-hydroxynortriptyline and 10-
hydroxyamitriptyline, excreted as 35 % of a dose (Julien, 2005; Moffat, et al., 2011b; 
Drummer & Wong, 2013). The parent drug is excreted at less than 5 % in urine and 8 % in 
faeces (Moffat, et al., 2011b). 
As a tranquiliser, ketamine is mainly used as an anaesthetic for human and veterinary 
procedures (Levine, 2006; UNODC, 2013).  Ketamine is not completely metabolized in 
humans and other organisms. Ketamine is metabolized primarily as conjugates of 
hydroxylated metabolites (80 %), norketamine (2 %) and unchanged drug (2 %) (Levine, 
2006; Moffat, et al., 2011b; Lin, et al., 2014). 
According to the World Drug Report (UNODC, 2013), sedatives and tranquilisers, such as 
benzodiazepines and barbiturates, were reported as the top three misused substances by 
more than 60 % of the countries assessed. 
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APPENDIX III: Acid-base equilibria. 
 
In order to understand how drugs of abuse are isolated from complex sample matrices 
such as waste water by SPE and LLE, the relationship between pH and dissociation 
constants Ka needs to be explored. 
Most drugs will ionise in solution based on their pKa and the pH of the solution in which 
they are dissolved. The relationship between the pKa and the pH is represented by the 
Henderson-Hasselbalch Equation (Harris, 2010) which for acids is; 
 
Equation A-1 
Where [A- ] is conjugate base and [HA] is the acid, 
 
and for bases is; 
       Equation A-2 
Where [B] is base and [BH+] is the conjugate acid. 
 
The pKa expresses the pH at which 50 % of the analyte molecules in solution are ionised 
(Levine, 2006; Stimpfl, 2011). 
During solid or liquid phase extractions, the aim is to get 100 % of ions either in an ionised 
or unionised state.  This is achieved by either lowering or increasing the pH with respect 
to the pKa of the ionisable group in solution (Hendriks, et al., 2007). A rule of thumb when 
adjusting pH for SPE and LLE is to modify it at least 2 pH units below or above the pKa of 
the target analytes (Telepchak, et al., 2004; Flanagan, et al., 2007).  This has been referred 
to as the pKa ± 2 rule and enables the analytes to either be in an ionised or unionised 
state depending on the pH adjustment (Hendriks, et al., 2007).  Neutral drugs, on the 
other hand, do not contain ionisable functional groups and hence can be extracted at all 
pH values between 0 and 14 (Levine, 2006).  By taking advantage of the physico-chemical 
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properties of the analytes (e.g. pKa) a suitable sample extraction procedure can be 
developed. 
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APPENDIX IV: Selection of internal standards used in this thesis. 
 
During method development, internal standards are recommended additions to analytical 
processes as they help compensate for variability during sample preparation and 
instrumental analysis (e.g. injection volume, flow rate, operating pressure) (Furey, et al., 
2013). 
 
Although various internal standards can be used, stable isotope-labelled internal 
standards (deuterated, 13C, 15N or 17O) with similar chemical properties to the compound 
under analysis are more commonly used (Flanagan, et al., 2007; Cooper, et al., 2010).  In 
this research, deuterated internal standards were used. Since many of the NPS under 
investigation did not have commercially available deuterated analogues, 4 internal 
standards were used to represent the 29 drugs under investigation. These were AMP-d6, 
MDMA-d5, COC-d3 and MOR-d3. However, MOR-d3 was eliminated as an internal standard 
during preliminary investigations due to its instability (section 3.3.1, pages 108-109, 
Figure 3.22).  Assigning of the internal standard was based on one or more of the 
following criteria: similarity in structure to the target drugs, the one closest in retention 
time (RT) to the analyte and the most stable internal standard for the method (Pedrouzo, 
et al., 2011; Gago-Ferrero, et al., 2013).  The drug standards and corresponding internal 
standards are listed in Table 3.3 on page 102. Using a few representative internal 
standards during multianalyte methods is acceptable practice especially when 
investigating newer drugs with no commercially available deuterated analogues or when 
the cost of obtaining a deuterated analogue for each drug under analysis becomes too 
high (Couchman & Morgan, 2011; Pedrouzo, et al., 2011). 
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APPENDIX V: Kovat’s retention index (RI) formula for linear temperature programing. 
    
Where RI is the retention index, RT is the retention time, n and n+1 are the smaller and 
larger n-alkanes, respectively, which bracket the drug (Newton & Foery, 1984). n-alkanes 
used ranged from n=10 to n=28 as listed in Table 2.2. 
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APPENDIX VI-a: Mass spectra, molar mass and proposed fragmentation patterns for PFPA derivatized target drugs. 
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         APPENDIX VI-b: Mass spectra, molar mass and proposed fragmentation patterns for PFPA derivatized target drugs. 
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       APPENDIX VI-c: Mass spectra, molar mass and proposed fragmentation patterns for PFPA derivatized target drugs. 
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APPENDIX VI-d: Mass spectra, molar mass and proposed fragmentation patterns for PFPA derivatized target drugs. 
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         APPENDIX VI-e: Mass spectra, molar mass and proposed fragmentation patterns for PFPA derivatized target drugs. 
 
 
253 
 
            APPENDIX VI-f: Mass spectra, molar mass and proposed fragmentation patterns for PFPA derivatized target drugs. 
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APPENDIX VII-a: Graphs of PAR versus injection time for 27 h autosampler stability study, including R2 and regression equation, n=24. 
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APPENDIX VII-b: Graphs of PAR versus injection time for 27 h autosampler stability study, including R2 and regression equation, n=24. 
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APPENDIX VII-c: Graphs of PAR versus injection time for 27 h autosampler stability study, including R2 and regression equation=24. 
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APPENDIX VII-d: Graphs of PAR versus injection time for 27 h autosampler stability study, including R2 and regression equation, n=24. 
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APPENDIX VII-e: Graphs of PAR versus injection time for 27 h autosampler stability study, including R2 and regression equation, n=24. 
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APPENDIX VII-f: Graphs of PAR versus injection time for 27 h autosampler stability study, including R2 and regression equation, n=24. 
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APPENDIX VII-g: Graphs of PAR versus injection time for 27 h autosampler stability study, including R2 and regression equation, n=24. 
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       APPENDIX VIII: Comparison of chromatograms of a mixed drug standard and untreated waste water sample. 
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APPENDIX IX-a: Detection of morphine in different untreated waste water samples. 
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APPENDIX IX-b: Ion ratios for confirmation of morphine in different untreated waste water samples. 
 
1Based on the commonly used acceptance criteria for ion ratios of ± 20 % relative to that of the corresponding drug standard  
(Cooper, et al., 2010).
264 
 
APPENDIX X-a: SIM spectra of the quantifier ions for the target drugs. 
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        APPENDIX X-b: SIM spectra of the quantifier ions for the target drugs. 
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APPENDIX X-c: SIM spectra of the quantifier ions for the target drugs. 
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         APPENDIX X-d: SIM spectra of the quantifier ions for the target drugs. 
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          APPENDIX XI-a: Linear regression plots for determination of linear range, n = 3. 
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      APPENDIX XI-b: Linear regression plots for determination of linear range, n = 3. 
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    APPENDIX XI-c: Linear regression plots for determination of linear range, n = 3. 
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APPENDIX XI-d: Linear regression plots for determination of linear range, n = 3. 
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      APPENDIX XI-e: Linear regression plots for determination of linear range, n = 3. 
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APPENDIX XII: Establishment of linearity for amphetamine 
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   APPENDIX XIII-a: Standard addition plots of detected drugs, n = 3. 
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APPENDIX XIII-b: Standard addition plots of detected drugs, n = 3. 
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         APPENDIX XIV-a: Calculation of the concentration of cocaine using standard addition. 
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APPENDIX XIV-b: Calculation of the concentration of cocaine (COC) using standard addition. 
 
 
 
 
 
 
 
 
The concentration of cocaine in waste water was calculated using the linear equation for standard addition, 
y = mx + c, where:   
y = 0; m = gradient; c = intercept; x = Conc of COC in waste water 
For standard addition, when y = 0 (i.e. no drug standard added) the positive intercept is due to the response 
of the analytes already present in the sample.  
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    APPENDIX XV: Mass spectra of caffeine in drug standard, waste water sample and NIST [Version 2.0(2)] database. 
 
 
 
 
 
